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Maximum levels of a-bungarotoxin binding to human foetal 
brain membranes remained constant between gestational ages of 
10-24 weeks at 30-50 gmol/mg protein (1.1-1.5 p mol/g wet weight 
in whole brain).
Subcellular fractionation of whole brain homogenate showed 
an enrichment of a-bungarotoxin binding in the crude mitochondrial 
fraction and the subsequent nerve ending sub-fraction. The high 
proportion of occluded LDH in the nerve ending fraction was indicative 
of the presence of synaptosomes. Analysis of the fraction at the 
electron microscope level revealed the existence of synaptosome-like 
profiles containing mitochondria and very few synaptic vesicles.
The specific binding of a-bungarotoxin to membranes and
crude detergent extracts was shown to be saturable with ^ j
-9 -93.5 X 10 M and 2.4 x 10 M respectively. Scatchard and Hill
of
analysis revealed the presence of a single class of sites exhibiting 
no cooperativity. Association rate constants, determined by measuring
the binding of a-bungarotoxin with time to membranes and crude detergent
5 - 1 - 1  5 -1 -1extracts were 2.3 x 10 M sec and 2.6 x 10 M sec respectively.
Dissociation of a-bungarotoxin from membranes and crude detergent
extract was rapid with a T, in the order of 12 min. and off rate
2
— Zj. “1 “A “1 «
constants of 9.2 x 10 sec and 9.8 x 10 sec respectively. The
intrinsic dissociation constant (K^) was calculated from the on and off
-9 -9rate constants to be 4.0 x 10 M and 3.3 x 10 M for membranes and
crude detergent extracts respectively.
(x)
Competition studies with several cholinergic ligands 
indicated that the a-bungarotoxin binding sites displayed a predom­
inantly nicotinic pharmacology. Unlabelled a-BgTx, nicotine and
d-tubocurarine were found to be the most effective inhibitors of 
-125-1
|_ I J-a-bungarotoxin binding.
A histological study employing autoradiographic techniques 
showed that -a-bungarotoxin binding was concentrated primarily
in the dorsal horn of the spinal cord of a 14 weekold foetus. Clusters 
of silver grains above the background density were also observed in the 
ventral horn. Silver grain densities above background were abolished 
by pre-treatment of the sections with unlabelled a-bungarotoxin.
A sample of myasthenic plasma and the subsequently prepared 
immunoglobulin fraction containing antibodies directed against the 
nAChR from human skeletal muscle were able to precipitate a low but 
measurable amount of the a-bungarotoxin binding sites in human foetal 
brain. Samples of serum in which an anti-(muscle nAChR) titre was 
absent failed to precipitate the brain component.
(xi)
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CHOLINERGIC TRANSMISSION IN THE NERVOUS SYSTEM
Acetylcholine (ACh), historically pre-eminent among neuro­
transmitters is a messenger at both peripheral and central synapses 
(Krenjevic, 1974).
In the central nervous system (CNS) evidence that ACh is a 
transmitter was originally based on the distribution of the synthesizing 
enzyme choline acetyltransferase (CAT) and of its hydrolysing enzyme 
acetylcholinesterase (AChE), together with the central effects of 
systemically applied ACh (Phillis, 1974). From the early observations 
of Dale (1914) it became apparent that ACh elicits two pharmacologically 
distinct responses in excitable tissue. The nicotinic responses, mimicked 
by the application of nicotine, are rapid in onset, of short duration and 
can be blocked by d-tubocurarine. This type of response is found, for 
example, in skeletal muscles. The muscarinic responses, mimicked by the 
application of muscarine, are slower in onset,of longer duration and can 
be blocked by atropine (Krenjevic, 1974). Smooth muscles exhibit a 
characteristic muscarinic response (Harry, 1962).
The pharmacological activity of a number of drugs has been used 
to distinguish between the receptors responsible for mediating muscarinic 
and nicotinic responses (Phillis, 1974).
The drugs are classified according to their ability to either 
mimic or block the action of ACh and subsequently three main categories 
have emerged. Compounds which have the ability to mimic the action of 
ACh are referred to as agonists, for example, carbachol, methacholine 
and bethanachol. Compounds such as nicotine and muscarine have the 
ability to distinguish between nicotinic and muscarinic receptors. The
2.
structures of some cholinergic agonists are shown on page 3 .
Compounds which block the action of ACh are referred to as 
antagonists and they can be classified further according to their 
selectivity towards nictonic and muscarinic receptors. The nicotinic 
response is selectively inhibited by compounds such as d-tubocurarine 
gallamine, flexadil, g-erythroidine and hexaméthonium (see page U ) 
while atropine,3-quinuclidinyl benzilate and scopolamine (see page 5 ) 
are more effective at muscarinic receptors (Triggle and Triggle, 1976).
The third group of compounds classified as depolarizing antag­
onists evoke a response mediated through nicotinic receptors initially 
causing depolarization of the post synaptic membrane but later, synaptic 
transmission is blocked irreversibly (Zaimis and Head, 1976).
The ability of these compounds to block the ACh induced depolarization 
at the skeletal neuromuscular junction and at autonomic ganglia has 
revealed quantitative differences in potency (Michelson and ZeimaH, 1973) 
indicative of two types of nicotinic receptor. Of the various homologues 
of the polymethylene bismethonium compound series ((CHg)gN^ ”^^^2^n 
-N (CHg)^), décaméthonium (n = 10) was found to be the most effective 
at the neuromuscular junction while hexaméthonium (n = 6) was found to be 
the most effective at ganglionic synapses. Nicotinic receptors at skele­
tal muscles and autonomic ganglia are classified as receptors and 
receptors respectively. The'receptor has also been distinguished in 
the spinal cord (Curtis and Ryall, 1966a) and in the brain (Phillis, 1974)
In the central nervous system the predominant excitatory action 
of ACh is of a muscarinic nature (Henderson and Wilson, 1936) although 
nicotinic excitation (Katz and Thesleff, 1957) and muscarinic inhibition 
(Jordan and Phillis, 1972) have also been demonstrated. A schematic
3.
Fig. 1.1. The Structure of Some Cholinergic Agonists
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Fig. 1.3. The Structure of Some Muscarinic Antagonists
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representation of a cholinergic synapse is shown in Fig. 1.4 on
page 7). The (+) and (-) signs denote the action of ACh presynaptically
upon the release of neurotransmitter.
Unlike cholinergic transmission at the neuromuscular junction, 
which is exclusively nicotinic, several groups of neurones in the 
mammalian CNS appear to display a mixed nicotinic-muscarinic pharmacology 
(Krenjevic, 1974). Muscarinic excitation, inhibition and nicotinic 
excitation have all been identified on Renshaw cells of the spinal cord 
(Curtis and Ryall, 1966a,b) and the excitatory responses were shown to be 
mediated through separate muscarinic and nicotinic receptors (Curtis and 
Ryall, 1966a). Cholinergic receptors of intermediate nicotinic-muscarinic 
character in the CNS have also been implicated since in some groups of 
neurones, the response elicited by nicotinic and muscarinic agonists was 
shown to be blocked by both types of antagonists (Phillis, 1974). Recently, 
Saji and Miura (1982) have shown that the facilitatory response of nico­
tine and muscarine on cultured neurones could be antagonized by the 
application of hexaméthonium or atropine. These observations are con­
sistent with findings in hippocampal pyramidal cells in which nicotinic 
antagonists were found to block the response evoked by muscarine (Bird 
and Aghajanian, 1976).
7.
Fig. 1.4. A Diagrammatic Representation of the Cholinergic Synapse













CHARACTERIZATION OF THE NICOTINIC ACETYLCHOLINE RECEPTOR
The purification and characterization of nicotinic acetylcholine 
receptors (nAChRs) are greatly facilitated by the application of neuro­
toxic proteins found in snake venom. The venoms of the Elapidae and 
Hydrophiida snakes contain basic polypeptide neurotoxins which bave been 
shown to bind to nAChRs at the neuromuscular junction thereby producing 
an anti-depolarizing block in neurotransmission characteristic of the 
curare alkaloids, (Lee et al., 1972). Such neurotoxins (Tu, 1977) are 
classified as either short (60-62 amino acids) or long (71-74 amino acids) 
and cause neuromuscular blockade that is reversible or irreversible 
respectively. a-Bungarotoxin (a-BgTx) is a post-synaptic neurotoxin 
purified from the venom of Bungaris multicinctus and fulfills the require­
ments of a highly specific irreversible probe for the nAChR (Chang and Lee, 
1963). At the neuromuscular junction, a-BgTx evokes an irreversible 
blockade of ACh induced depolarization which can be delayed by nicotinic 
but not muscarinic compounds.
Many applications of the a-toxins require that they be labelled,
most commonly by the incorporation of radioactivity. Radiolabelling
permits the detection of very small quantities of toxin in biochemical
assays and permits their use in autoradiographic studies (Fertuck and Salpeter,
3
1974). ot-BgTx has been labelled with H (Eterovic et al., 1975; Jones
125
and Thomson, 1980; Dolly et al., 1981) and I (rev. Fulpius, 1976;
James et al., 1980) with little loss of biological activity. Although
125
much higher specific activities are achieved using I, the iodination 
procedure yields a heterogeneous product (Vogel et al., 1972) of mono­
an d di- iodo toxins, both of which arise from the modification of a 
single tyrosine residue. The binding characteristics of the di-iodinated
9.
form to solubilized Torpedo electroplax, chick muscle (Wang and Schmidt, 
1980) and rat brain (Lukas et al., 1981) has been shown to deviate 
sufficiently from that of the native, tritiated and mono-iodinated 
species to necessitate the separation of the derivatives for kinetic 
studies (Lukas et al., 1978).
The nAChR from peripheral tissues in vertebrates is now a 
well characterized molecular entity. The nAChR from fish electric organ 
(revs. Heideman and Changeux; Changeux, 1981; Conti-Tronconi and 
Raftery, 1982) and skeletal muscles (revs. Dolly, 1979; Barnard et al., 
1980; Barrantes, 1983) have been studied extensively in both their mem­
brane bound and purified forms.
The nAChR from either source can be extracted into a non-ionic 
detergent with full retention of specific a-toxin binding properties. 
Purification of the receptor from the detergent extract is achieved by 
affinity chromatography using an adsorbent of a-toxin covalently linked 
to an agarose support (see Lindstrom, 1978). The a-neurotoxin from 
Naja naja siamensis (Lee, 1972) is frequently employed as an affinity 
ligand for the purification of nAChRs from electroplax and muscle tissue 
since a-bungarotoxin binds with high affinity to the nAChR from these 
tissues, forming complexes which are essentially irreversible. Naja 
Naja toxin binds less tightly thus later permitting the removal of 
receptor from the affinity column.
The nAChR purified from Torpedo species has been shown to occur 
in monomeric and dimeric forms with sedimentation coefficients of 9S and 
13S respectively (see Conti-Tronconi and Raftery,1982). By SDS electro­
phoresis, the monomer was found to be composed of 40K, 5OK, 6OK and 65K 
subunits in the ratio of 2:1:ItKa^Byd) and the dimer is held together by
10.
disulphide bridge(s) between the 65K subunits. In Torpédo californica, 
the dimer is the predominant form in the membrane bound state. Previous 
attempts to determine the molecular weight of each of the subunits pro­
duced variable results which was attributed to the simplification of 
subunits through mild proteolytic attack (see Changeux, 1981). For the 
nAChR from Electrophorous, most reports describe a 9S species (see 
Conti-Tronconi and Raftery, 1982) composed of 41K, 50K, 55K and 64K 
subunits (Lindstrom et al., 1980).
Purification of the nAChR from mammalian muscle posed diffi­
culties in comparison to electroplax tissue because of the very low con­
tent of receptor in muscle (Wallis et al., 1980) although in denervated 
or foetal muscle (Borg et al., 1972) and in cultured cells (Boulter and 
Patrick, 1977), the content is considerably higher. The subunit pattern 
obtained for the nAChR from mammalian muscle varies with species although 
a polypeptide of approximately 42K was present in all preparations (see 
Conti-Tronconi and Raftery, 1982).
To determine which of the polypeptides carry the ACh binding 
site, radiolabelled affinity reagents which have been designed to react 
with a sulfhydryl group near the binding site in purified nAChR pre­
parations reduced by dithiothreitol. Of the radiolabelled quaternary 
ammonium derivatives available (see revs. Heidemann and Changeux, 1978; 
Conti-Tronconi and Raftery, 1982), [% J-MBTA has been frequently employed 
in such studies. This reagent binds to the 4OK polypeptide in both 
Electrophorous and Torpedo thus identifying these subunits in
bearing the ACh binding site. In Torpedo it was concluded that the nAChR 
contains two binding sites for ACh, each located on the a-subunits.
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Purification of the nAChR from cat and rat denervated muscles 
(rev. Dolly, 1979) and human muscle (Stephenson et al., 1981;
Turnbull et al., 198 5) has shown that they have in common an a-subunit whicn 
varies between 40K-46K (see also Barnard et al., 1980) and this polypeptide 
is able to bind affinity reagents following the modification of the 
thiol groups. It was concluded that in cat muscle the nAChR contains 
two binding sites for ACh, each located on the a-subunit (see Barnard 
et al., 1980). In rat muscle, MBTA labelled a 45K and a 49K polypeptide 
(Froehner et al., 1977) which must be closely related since they give 
identical peptide maps (Natheson and Hall, 1979). In human muscle,
[^ifl-MBTA labels a single polypeptide of approximately 43K 
(Stephenson et al., 1981; Turnbull et al., 1985).
The purified nAChR from electroplax and muscle is an acidic 
glycoprotein with an isoelectric point of about 5.0 (see Conti-Tronconi 
and Raftery, 1982). The reconstitution of the nAChR into both lipid 
vesicles and planar lipid bilayers (revs. Anholt, 1981; McNamee and 
Ochoa, 1982) has demonstrated that the macromolecule retains the 
property of agonist controlled cation flux although previous attempts 
were either unsuccessful or not readily reproducible. These experiments 
have facilitated studies of the contribution of the membrane environment 
on receptor function and the role of the subunits in the agonist induced 
response.
12.
NICOTINIC ACETYLCHOLINE RECEPTORS IN THE CENTRAL NERVOUS SYSTEM.
ARE g-NEUROTOXINS SUITABLE AS PROBES? .
Radiolabelled a-BgTx has been shown to bind specifically to 
vertebrate and invertebrate brain, autonomic ganglia and chromaffin 
cells in the adrenal medulla (revs. Schmidt et al., 1980; Morley et al., 
1979; Oswald and Freeman, 1981; Morley and Kemp, 1981). The significance 
of toxin binding to neuronal preparations was viewed with caution since 
attempts to block synaptic transmission in sympathetic ganglia (Brown 
and Fumagalli, 1977) or spinal cord (Miledi and Szczepaniak, 1975;
Duggan et al., 1976) have not been successful. It has been shown that 
the lack of inhibition of a-BgTx at these synapses is not attributable 
to a diffusion barrier since the binding of radiolabelled toxin vivo 
has been demonstrated autoradiographically (Fumagalli et al., 1976) and 
ganglionic synapses have been shown to be permeable to cations with a 
Stokes radius similar to that of a-BgTx (Bursztajan and Gershon, 1977).
Evidence that the a-BgTx binding component and the nAChR may be
separate entities was presented by Patrick and Stallcup (1977a,b).
The binding of radiolabelled a-BgTx to cultured sympathetic neurones
was competitively inhibited by d-tubocurarine but although the latter
22
blocked agonist induced Na flux, a-BgTx was found to be ineffective
(Patrick and Stallcup, 1977a). Furthermore, anti- (eel electroplax
22
nAChR) antisera which also inhibited the agonist induced Na flux, 
failed to recognise the detergent solubilized a-BgTx binding component 
from these cells.
In contrast to the reports cited above, the ability of a-BgTx 
to elicit a blockade of neurotransmission has been demonstrated in 
neurones from frog sympathetic ganglia (Marshall, 1979) and in Pigeon
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cilliary ganglion (Chiapinelli et al., 1981). It was shown, however, 
that the blockade observed in the chicken ciliary ganglion could only 
be achieved by using certain commercially available lots of a-bungaro­
toxin (Chiapinelli et al., 1981). It was suggested that the presence 
of one or more a-neurotoxins other than a-bungarotoxin in the crude 
venom may be responsible for eliciting a blockade in transmission, a con­
clusion which was supported by the appearance of an additional band in 
the electrophoretic gels of only those lots which blocked transmission. 
Toldi et al. (1983) found that a blockade of transmission could be achieved 
if a-BgTx was administered by an intercarotid route. In contrast to 
previous reports (Bursztajan and Gershon, 1977; Fumagalli et al., 1976, 
page 12 ) the authors suggest that the failure to elicit a blockade
in transmission by local application is caused by a diffusion barrier.
In the central nervous system, a blockade of transmission has been demon­
strated at the retinotectal synapses of lower vertebrates. a-BgTx was 
found to block transmission in toad (Freeman et al., 1980), goldfish 
(Schmidt and Freeman, 1980), turtle and pigeon (Schmidt and Freeman,
1979) and additionally. Freeman (1979) found that the toxin was effective 
in blocking both intracellular and extracellular responses of goldfish 
tectal neurones to the iontophoretic application of ACh.
The reasons for the regional and phylogenetic variation in the 
ability of a-BgTx to block synaptic transmission in ganglia and the 
CNS have not been resolved. Since the observation that the off rate of 
radiolabelled a-BgTx is slower in tissues which are sensitive rather than 
insensitive to blockade by a-BgTx it has been suggested that the ability 
of a-BgTx to inhibit synaptic transmission in the CNS may be related to 
its affinity for the receptor (Oswald and Freeman, 1979). A rapid rate
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of dissociation of the a-BgTx-receptor complex is characteristic of the 
binding sites found in the CNS of several species (see pages 16-18) 
compared to peripheral nAChR (pages,8,24) . The binding in goldfish brain 
has been found to exhibit properties which are similar to the peripheral 
receptor (Oswald and Freeman, 1979) thus, when viewed in the light of 
pharmacological evidence it seems that the brain may possess 
subclasses of nicotinic receptor.
15.
PROPERTIES OF THE CENTRAL NICOTINIC ACETYLCHOLINE RECEPTOR
Although electrophysiological evidence has shown that few 
a-BgTx sensitive sites appear to exist in the central nervous system, 
several other lines of investigation have strongly suggested that the 
central a-BgTx binding component is a nAChR. The pharmacological 
specificity of the a-BgTx sites has been evaluated by measuring the 
ability of several cholinergic and non-cholinergic drugs to inhibit 
the binding of radiolabelled a-BgTx to membrane bound, detergent 
solubilized and affinity purified preparations (for refs, see pages 19 
and 2 0). Central a-BgTx receptors from several species display a 
distinctly nicotinic profile which is reminiscent of peripheral nAChRs 
(see Barnard et al., 1980). The most potent inhibitors of a-BgTx binding 
to the central sites are nicotine and d-tubocurarine although in muscle, 
nicotine was shown to be a weaker inhibitor of a-BgTx binding. 
Décaméthonium, a potent inhibitor of a-BgTx binding in muscle (Barnard 
et al., 1980; Dolly, 1979) is a poor inhibitor of a-BgTx binding
in rat brain (refs, page 19 ) and chick brain (Kouvelas and Green, 1976) but 
is significantly more effective at the chick optic tectum (Barnard et al. , 
1979). Morley et al. (1977) have also reported the differing affinities 
of décaméthonium for a-BgTx binding sites in discrete areas in rat brain. 
Hexaméthonium, a potent inhibitor of ganglionic transmission is a poor 
inhibitor of a-BgTx binding in the CNS which suggests that the central 
receptor bears a closer similarity to the nAChR at the neuromuscular 
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References and Legend, Table 1.1
1 Davis and Feisullin (1981)
2 Schmidt (1977)
3 Ben-Barak and Dudai (1979)
4 Lukas et al. (1981)
5 Salvaterra and Mahler (1976)
6 Lowy et al. (1976)
7 Moore and Brady (1977)
8 MacQuarrie et al. (1978)
9 Wang and Schmidt (1980)
10 Norman et al. (1982)
11 Barnard et al. (1979)
12 Oswald and Freeman (1981)




17 Patrick and Stallcup (1977)
M Membrane bound
D Detergent extract 
P Purified 
C Culture
R Determined by rate constants 
E Determined at equilibrium 
I Inhibition of toxin binding 
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References and Legend, Table 1.2
1 Schmidt (1977)
2 Ben-Barak and Dudai (1979)
3 McQuarrie et al. (1978)
4 Speth et al. (1977)
5 Wang et al. (1978)
6 Barnard et al. (1979)
7 Patrick and Stallcup (1977a)
8 Oswald and Freeman (1979)
9 Filbin (1981)
a -a- Naja Naja toxin binding
= The concentration of ligand at which a-toxin binding is
reduced by 50% irrespective of conditions (initial rate 
Kp, equilibrium, K^) used (see page 60).
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Further evidence that the a-BgTx binds to nAChRs in the CNS 
was supported by observations which showed that pre-incubation of 
receptor with agonist altered the ability of the agonist to block a-BgTx 
binding. In rat brain, Lukas and Bennet (1979a) found that the ability 
of cholinergic agonists to block the specific interaction of radio­
labelled a-BgTx to membrane bound receptor was enhanced when the membranes 
were preincubated rather than co-incubated with agonist. Thus toxin 
binding sites in rat brain appear to exhibit a time dependent alteration 
in sensitivity towards cholinergic agonists (Lukas (iewicz) and Bennet, 
1978) in a manner analogous to that observed in peripheral systems 
(Katz and Thesleff, 1957) and consistent with the observed desensitization 
of the CNS nAChR (Curtis and Ryall, 1 966a) . Furthermore, Lukas and 
Bennet (1979b) have shown that local anaesthetics accelerate the trans­
formation of the aBgTx component into the high affinity form which is 
analagous to the effect observed in the electric organ (rev. Heidemann 
and Changeux, 1978).
The presence of thiol groups associated with the neuronal a-BgTx
binding component has been utilized to provide further evidence that
a-BgTx binds to the nAChR. Following reduction of the thiol groups in
rat brain (Lukas and Bennet, 1980) and chick brain (Barnard et al., 1979)
a-BgTx binding components by dithiothreitol, subsequent alkylation with 
<"3-1 . r3 -iL Hj-bromoacetylcholine (BrACh) or |_l^|-MBTA (rat brain only) resulted 
in an irreversible blockade of a-BgTx binding.
Further similarities between peripheral (see page 10 ) and 
central a-BgTx binding components have become apparent following an 
examination of the molecular properties of detergent solubilized and 
purified preparations from control sources (rev. Oswald and Freeman, 1981;
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Betz et al., 1982; Norman et al., 1982). Like muscle (Barnard et al., 1980) 
and electroplaque (rev. Heidemann and Changeux, 1981) the central a-BgTx 
binding component was found to be an acidic glycoprotein with an iso­
electric point of about 5.0 (rev. Oswald and Freeman, 1981; Norman et al., 
1982). The glycoprotein nature of the central receptor has been exploited 
as a means of purifying the a-BgTx binding component in addition to 
affinity chromatography using immobilized a-toxins (see page 9 ). The
interaction of concanavalin A with the central a-BgTx component has been
confirmed in rat (Moore and Brady, 1977), in chick (Barnard et al., 1980), 
mouse (Seto et al., 1977) and in goldfish (Oswald and Freeman, 1980).
In chick optic tectum. Lens culinaris lectin has been employed as an 
affinity agent for the a-BgTx binding component (Barnard et al.,1980) 
as for muscle (Shorr et al., 1978).
The central a-BgTx binding components appear to differ in sub­
unit composition from their peripheral counterparts although the puri­
fication of sufficient amounts of the central component to fully 
characterize the protein has been severely hampered since mammalian brain 
has such low concentrations of a-BgTx binding sites (Schmidt et al., 1980).
In mouse brain, Seto et al. (1981) demonstrated the presence of a
51K-52K subunit although in chick retina, Betz et al. (1982)
detected three polypeptides, the heaviest being of an apparent molecular 
weight of 63K. In chick optic lobe, the presence of' three subunits has also 
been reported, of apparent molecular weights 53K,
60K and about 7OK (Barnard et al., 1983). The 53 K subunit 
can be labelled specifically with [|^H|-bromoacety 1 choline after disulphide 
reduction (Norman et al., 1982) which suggests that it may be the equiva­
lent of the muscle a-subunit.
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In an alternative approach to affinity purification,
Abood et al. (1983) employed nicotine as the immobilized affinity ligand
and succeeded in isolating a major protein of 56K from a detergent
extract of rat brain. Drug competition studies subsequently showed that
aBgTx was a poor inhibitor of -nicotine binding which was similar to
earlier findings utilizing rat brain membranes as a source of receptor
(Abood et al., 1980). It is noteworthy that although a-BgTx was found
r3 -ito be a poor inhibitor of |_l^ |-ACh binding in rat brain (Schwartz et al., 
1982), nicotine is a potent inhibitor of both radiolabelled a-BgTx 
(refs., page 20) and -nicotine (Abood et al., 1980) binding. The 
central actions of nicotine have raised doubts as to whether the effects 
of the drugs are mediated exclusively through nicotinic receptors 
(Schwab and Kritzer, 1982). The results of Caulf ield and Higgins (198 3) 
have suggested that the convulsions have a pharmacological profile con­
sistent with the ganglionic or type of receptor (see page 2 ).
Isolation of a putative nAChR using alternative affinity ligands may 
thus further resolve the question as to whether all nicotinic drugs bind 
to a common macromolecule.
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PROPERTIES OF a-BUNGAROTOXIN BINDING IN THE CENTRAL NERVOUS SYSTEM
Radiolabelled a-BgTx binds saturably and specifically to 
membrane bound and detergent extracted preparations and unlike electro­
plax (Changeux, 1981) and skeletal muscle (Lo et al., 1981) the binding 
is readily reversible. Intrinsic dissociation constants for most brain 
preparations have been calculated to be in the nM range (refs., pages 16-171 
although notable differences are apparent in the dissociation kinetics.
The dissociation of a-BgTx from toad and goldfish brain is biphasic and 
has been shown to arise from the presence of two interconvertible a-BgTx 
binding sites (Oswald and Freeman, 1980). In mammalian brain however, 
existing reports suggest that kinetically, there is only one site 
(refs., pages 16-17)
The concentration of a-BgTx binding sites in vertebrate CNS 
is very low compared to electroplax tissue (Miledi et al., 1971) but it 
is comparable to that of skeletal muscles (Colquhoun et al., 1974;
Dolly and Barnard, 1977). The levels reported for vertebrate brain 
vary between Ipmol/g to lOpmol/g wet weight of tissue (rev. Oswald and 
Freeman, 1981). The presence of a-BgTx binding sites in human brain 
has been reported (Volpe et al., 1979; Davis and Fiesullin, 1981; Lang 
and Henke, 1983) although the receptor sites have not been characterised 
in any detail. Binding studies have indicated that the density of sites 
(expressed as f moles of toxin bound per mg protein) in frontal cortex 
(Davis and Fiesullin, 1981) and a number of other brain areas (Volpe 
et al. , 19 79) is significantly lower than the concentration in rodent 
brain (Segal et al., 1978; Salvaterra and Foders, 19 79). Exceptionally, 
the mamilliary nucleus of human brain binds 17 fmol of a-BgTx per mg 
protein (Volpe et al., 1979) which is comparable to whole rat brain 
(Salvaterra and Foders, 1979). Despite the low concentrations of receptor
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present in human brain, the large quantities of tissue postmortem offers 
the possibility of purifying the quantities of receptor required for an 
extensive characterization. There are however obvious problems associated 
with the choice of adult tissue. Firstly, the source of tissue may be 
unpredictable and secondly, the postmortem delays could vary considerably. 
Although Davis and Fiesullin (1981) have demonstrated that toxin 
binding levels do not change in mouse brain for up to 24h after death, 
ultrastructural studies have shown that in guinea pig (Stahl and Swanson,
1975) and human (Garey et al., 1974) brain, notable morphological changes 
occur in subcellular organelles with increased postmortem delay. Addition­
ally, it is not known if the structural integrity of the receptor protein 
is retained 24h after death even if a-BgTx binding is still demonstrable. 
Thirdly, the use of adult tissue from a wide age range may give rise to 
variability in the course of a regional distribution study since some 
brain areas may show signs of neuronal degeneration and metabolic changes 
as a result of either ogiçing, disease or damage (McGeer and McGeer, 1981; 
Selkoe, 1982; Hardy et al., 1982). Fewer problems of this type however, 
are encountered when considering human foetal brain tissue as a potential 
source of a-BgTx receptor.
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REGIONAL DISTRIBUTION OF a-BUNGAROTOXIN BINDING SITES
The binding of radiolabelled a-BgTx to various brain regions 
has been evaluated by biochemical assay following dissection (rev. 
Oswald and Freeman, 1981; Morley and Kemp, 1981) and autoradio­
graphic techniques (rev. Murrin, 1981). In rat brain the highest 
binding levels are found in the colliculi, hippocampus and hypothal­
amus and in chick brain, the optic lobes. Particularly high levels 
are present in goldfish optic tectum (Salvaterra and Foders, 1979).
In the regions of human brain investigated (Volpe et al., 1979) the 
highest levels were found to be associated with the mammiliary 
bodies although appreciable levels were also observed in the colli­
culi. All studies show that very low amounts of toxin are bound by 
the cerebellum.
The distribution of a-BgTx binding sites correlates reason­
ably well with the distribution of CAT, choline uptake and AChE 
(rev. Morley et al., 1979) although employing the latter as a marker 
for cholinergic neurones has been viewed tentatively since the 
enzyme has been found within both cholinergic and non-cholinergic 
neurones (Butcher et al., 1975). In certain areas, the lack of 
correlation observed between a-BgTx binding and cholinergic markers 
has been attributed to the predominance of muscarinic receptors 
(Kuhar and Yamamura, 1976) . Autoradiographic techniques have been 
employed by several investigators to study the distribution of
-a-BgTx binding in brain. Analysis of the rat CNS following 
intraventricular injections of -a-BgTx or incubation of fresh
cryostat sections with labelled toxin have indicated that receptors 
are present in most brain areas but are found predominantly within
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the cortical and limbic structures and areas which are in direct 
receipt of sensory input (Hunt and Schmidt, 1978a). Similar findings 
have been reported in mouse brain although it is clear that species 
differences do exist. In mouse brain the striatum is quite heavily 
labelled (Arimatsu et al., 1978; Marchand et al., 1979) but in rat 
brain, label is virtually absent (Marchand et al., 1979); indeed 
biochemical assays have shown that toxin binding in rat striatum is 
very low (Morley et al., 1977; Schechter et al., 1978). Species 
differences are also apparent in the retina. a-BgTx binding is seen 
in both the inner and outer plexiform layer of chick (Vogel and 
Nirenberg, 1976) goldfish and turtle (Yazulla and Schmidt, 1976) and 
in pigeon (Yazulla and Schmidt, 1977). In rat however, binding is 
continued to the inner plexiform layer (Vogel and Nirenberg (1976) .
Morphological studies have indicated that considerable a- 
toxin binding can occur in regions which do not have a known cholin­
ergic innervation. Hunt and Schmidt (1978a) for example have reported 
that parts of the hippocampal dentate gyrus (see page 156 ) that do 
not receive any known cholinergic afferents nevertheless contain 
heavy patches of toxin binding. Attempts to label neurones at the 
motoneurone collateral-Renshaw cell junctions, an area where cholin­
ergic synapses are known to exist (Curtis and Ryall, 1966) have failed 
in cat (Duggan, 1976b)although the labelling of small cells has been 
demonstrated in the ventral horn of rat spinal cord and these are 
thought to be Renshaw cells (Hunt and Schmidt, 1978a). From the know­
ledge available on the organization of cholinergic projections in 
vertebrate brain (rev. Fibiger, 1982) the correlation between cholin­
ergic pathways and toxin binding patterns in most areas remains un­
resolved .
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In human brain, the autoradiographic distribution of toxin 
binding is poorly documented. Attempts to label structures in the 
hippocampus have given inconclusive results (Lang and Henke, 1983 ) 
however the labelling of sensory ganglia was achieved by Ninkovic 
and Hunt (1983) which is similar to the findings in both rat and 
monkey.
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IMMUNOLOGICAL CHARACTERISTICS OF THE g-BUNGAROTOXIN BINDING COMPONENT
Several investigations employing both polyclonal and mono­
clonal antibodies have revealed that the central a-BgTx component 
shares common antigenic determinants with the peripheral counterparts. 
Precedents for shared determinants between neuronal ACh receptors and 
the nAChR of electric organ have arisen from studies with polyclonal 
sera. Patrick and Stallcup (1977b) found that a rabbit antiserum raised
against the nAChR from Electrophorous was able to block the agonist 
22 +
induced Na flux in the pheochromocytoma cell line PC12 although the 
antisera failed to precipitate the a-BgTx binding component. Marshall 
(1981) found that a rabbit antiserum raised against the nAChR from 
Torpedo cross-reacted with a synaptic component on frog sympathetic 
neurones. Anti-(eel nAChR) antibodies were found to cross-react poorly 
with the aBgTx binding component in rat brain (Morley and Kemp, 1980) 
although Schwartz et al. (1980) report a good cross-reactivity between 
an anti-(eel NAChR) antisera and a component in goldfish brain. The 
antigenic sites were detected by an indirect unlabelled antibody com- 
plexed to horseradish peroxidase and the staining pattern observed in 
the optic nerve and neurites in culture correlated with the pattern of 
a-BgTx binding.
Polyclonal antibodies to muscle have generally shown a low but 
definite cross-reactivity to their central counterpart. The receptor 
from chick optic lobe exhibits low but definite cross-reactivity with 
purified nAChR from cat muscle (Norman et al., 1982) and Wonnacott 
et al. (1982) demonstrated that the rat muscle nAChR share some anti­
genic determinants with the rat brain a-BgTx binding component and to a 
lesser extent Torpedo nAChRs.
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Hybridomas secreting monoclonal antibodies provide greater 
opportunities to find such probes and prepare them in adequate quan­
tities. Of the monoclonal antibodies raised to purified chick muscle 
nAChR (Mehraban et al., 1983), two specifically precipitated the puri­
fied receptor from chick optic lobe (Barnard et al., 1983). In con­
trast, Morley et al. (1983) did not detect a measurable interaction 
between the rat brain a-BgTx binding component and a total of 61 
monoclonal antibodies raised to rat muscle nAChR. Recent studies 
have shown that monoclonal antibodies specific for each of the four 
subunits of nAChRs from muscle and electric organ bind to specific 
neural elements in the chick midbrain (Swanson et al., 1983). Out 
of 17 monoclonal antibodies that recognised the motor-end.plates on 
chick muscle, 14 produced a similar pattern of labelling. The neuronal 
perikarya and the dendrites in the lateral spiriform nucleus were 
intensely labelled. However, this area was not labelled by a-BgTot.
The best cross-reaction was obtained with monoclonal antibodies to 
the "main immunogenic region" (MIR) that is exposed on the extra­
cellular surface of receptor a-subunits (Tzartos et al., 1981).
Jacob et al. (1984) has reported that monoclonal antibodies to the 
MIR preferentially bind to the synaptic membrane on ciliary and 
choroid neurons in embryonic,chicken ganglia. The pattern of 
labelling was different from that previously found for a horse­
radish peroxidase conjugate of a-BgTx, however the evidence suggests 
that the monoclonal antibodies may be recognizing a particular class 
of neuronal AChRs.
In man, the existence of shared antigenic determinants in the 
nAChRs firom brain and skeletal muscle is of particular interest in view 
of the role of muscle nAChRs as the auto­
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antigen in the autoimmune disease myasthenia gravis which is character­
ized by an impairment of transmission at the neuromuscular junction 
(rev. Vincent, 1980; Drachman, 1981). The sera of most patients con­
tain anti-(muscle nAChR) antibodies and there is evidence for their 
involvement in the depletion of functional nAChRs at the neuro­
muscular junction (Drachman, 1981) although there is a lack of corre­
lation between antibody titre and the severity of the disease 
(Lefvert et al., 1978). The presence of anti-(muscle nAChR) in the 
cerebrospinal fluid (Lefvert and Pirskanen, 1977; Keesey et al.,
1978) and the increased incidence of central dysfunctions in myas­
thenic patients (Hokkanen and Toivakka, 1969; Papazion, 1976) raise the 
question of whether the anti-(muscle nAChR) antibodies are able to 
recognise a central counterpart. Central disturbances have also been 
observed in the animal model of the disease (Fulpius et al., 1977) 
and following the intracerebrally administered anti-(nAChR) antisera 
(Tarrab-Hazdai and Edery, 1980; Weidenfeld et al., 1983). Demon­
strations that anti-(rat muscle nAChR) antibodies ace able to block 
agonist induced release of dopamine from striatal synaptosomes 
(Futerman et al., 1981; Mills and Wonnacott, 1984) provide further 
evidence for the presence of structural similarities in central and 
peripheral nAChRs.
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SUBCELLULAR FRACTIONATION OF BRAIN
The isolation of synaptosomes from brain has provided a means 
of examining the dynamics of nerve ending metabolism vitro. 
Synaptosomes are nerve endings or synaptic boutons that are pinched 
off by homogenization which spontaneously reseal to form small 
spheres. They consist of a plasma membrane which encapsulates mito­
chondria, vesicles and the cytosolic components. Fragments of the 
post-synaptic membrane are often attached.
Synaptosomes retain many of the properties of presynaptic 
nerve endings as indicated by their capacity to accumulate ions and 
synthesize proteins and phospholipids (Morgan and Austin, 1968; Abdel 
Latif, 1969), metabolize various substrates (Bradford and Thomas,
1969) and generate membrane potentials (Bradford, 1970). Synapto­
somes have been used to study the release of putative transmitter 
compounds (De Belleroche and Bradford, 1972a, b ; De Belleroche 
and Bradford, 1978; 1980) and have served as models of ACh synthesis, 
degradation and compartmentation and the uptake and availability of 
choline (rev. Gibson and Blass, 1982). Various aspects of cholinergic 
function have been studied using synaptosomal preparations by 
investigating the role of ions, presynaptic receptors and membrane 
potentials in the release of ACh (see Gibson and Blass, 1982).
The isolation of synaptosomes from mammalian brain by the 
application of differential centrifugation and density gradients 
was originally described by Gray and Whittaker (1960; 1962) and 
De Robertis et al. (1961) although numerous modifications have since
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been introduced (see Gibson and Blass, 1982). The purity and integ­
rity of synaptosomal preparations can be deduced morphologically and 
by the incorporation of marker enzymes,many of which are stable for 
up to several hours post mortem (see Hardy and Dodd, 1983).
SUBCELLULAR LOCALIZATION OF a-BUNGAROTOXIN BINDING SITES
Subcellular fractionation of rat brain has shown that
a-BgTx binding sites are associated mainly with the synaptosomal
fraction (rev. Schmidt et al., 1980; Oswald and Freeman, 1981)
described by Gray and Whittaker (1962) although a significant amount
of toxin binding activity has been reported to exist in the lighter
microsomal fraction (Eterovic and Bennet, 1974). Additionally, the 
r3 “I . .binding of H_| nicotine was also found to bind primarily to the 
synaptosomal fraction in rat brain (Yoshida and Imura, 1979). The 
significance of the preferential association of a-BgTx with the 
nerve ending fraction has been resolved at the ultrastructural 
level. Autoradiographic studies have indicated that the toxin is 
predominantly associated with synaptic structures (Hunt and Schmidt, 
1978b;Hunt and Schmidt, 1978c; Arimatsu et al., 1978). Employing 
horseradish peroxidase labelled a-BgTx which affords greater 
spacial resolution, the toxin was found to label post-synaptic 
sites in rat brain (Lentz and Chester, 1977) and chick optic lobe 
(Barnard et al., 1979).
Subcellular fractionation of adult human brain has utilized 
fresh biopsy material (Dodd et al., 1981) or fresh post mortem brain 
obtained within the minimal delay, often 8 hours of death (Ggrey 
et al., 19 74; Van Kempen and Vrensen, 1974; Hickey et al., 19 76;
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Hardy et al., 1982). Synaptosomes prepared from human brain raeta- 
bolically active for up to at least 25h post mortem but morphologically 
the proportion of identifiable nerve ending profiles is lower than in 
fresh derived material (Dodd et al., 1981) as has been found with 
guinea pig brain (Swanson et al., 1973). Ultrastructural changes 
were also noted by Garey et al. (1974) in brains obtained between 
six and eight hours post mortem, although no significant differences 
in the distribution of protein and marker enzymes were evident.
The ability of synaptosomes prepared from human brain to 
accumulate catecholaminergic transmitters appears to be unaffected 
by a post mortem delay of several hours. Garey and Heath (1974) 
demonstrated that synaptosomes derived from the dorsal caudate 
nucleus and the septal region retain high affinity uptake for 
accumulation of dopamine and noradrenaline for at least seven hours 
after death.
Subcellular fractions have also been prepared from frozen 
human brain tissue (Stahl and Swanson, 1975; Hardy et al., 1983) 
and investigations revealed that neither the distribution of protein 
or marker enzymes was significantly altered as a result of freezing 
(Stahl and Swanson, 1975). Hardy et al. (1983) found that the optimal 
conditions involved slow freezing and fast thawing, a procedure which 
yielded preparations with 70% of the activity and purity of fresh 
preparations as judged by electron microscopy, oxygen uptake, 
potassium content and the ability to release transmitter amino acids. 
Studies performed on adult human brain therefore indicate that synapto­
somes prepared from fresh and frozen tissue obtained several hours 
after death may prove useful in metabolic studies and of neurotrans-
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mitter release.
Information pertaining to the fractionation of immature 
human brain is currently not available although the isolation of 
synaptosomes from post natal rat brain (Jones and Revell, 1970; 
Gonatas et al., 1971) has been described. In human foetal brain, 
the marker enzymes, CAT, AChE and LDH are present at 10 weeks 
gestation (Mahajan et al., 1980). It is of interest, therefore, 
to isolate and characterize synaptosomes from human foetal brain 
with a view to studying various aspects of cholinergic transmission 
in immature brain.
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DEVELOPMENTAL ASPECTS OF a-BUNGAROTOXIN BINDING
A study of the centralnAChRduring development has been confined 
largely to rat and chick brain (rev. Oswald and Freeman, 1981;
Morley and Kemp, 1981). In rat brain the concentration of a-BgTx 
binding sites reaches adult levels at 10 days post-partinum (Salvaterra 
and Moore, 1973; Morley and Kemp, 1978) but precedes the appearance 
of adult levels of AChE (Abdel-Latif et al., 1970), CAT (Coyle and 
Yamamura, 1976) and the adult complement of synapses stained by 
ethanolic phosphatungstic acid (Aghanjanian and Bloom, 1967). In rat 
hippocampus, a-BgTx binding sites appear before the ingrowth of chol­
inergic fibres (Hunt and Schmidt, 1979) and show a marked proliferation 
around birth (Ben-Barak and Dudai, 1979 ). In chick sym­
pathetic ganglia, the proliferation of a-BgTx binding sites is corre­
lated to the maturation and development of synaptic transmission 
(Greene, 1976; Kouvelas et al., 1978). Similarly, proliferation in 
the optic lobe was observed to be especially rapid between days 12-15 
which is correlated to the period of synapse formation (Catino and 
Daneo, 1973) and reaches peak at day 15. Since -a-BgTx binding
has been localized in layers which receive retinal terminals (Hunt and 
Webster, 1975) and that some evidence is available suggesting that 
a-BgTx sites may be found at retino-tectal synapses (Brecha et al.,
1979), the time course of the formation of synapses in this region may 
be correlated with the appearance of a-BgTx binding sites.
So far, developmental studies have indicated that the appearance 
of a-BgTx binding is related to maturation and onset of synaptic trans­
mission which is a finding synonymous with embryonic muscle (Lomo, 1980).
37.
In human brain, information pertaining to the development 
of cholinergic parameters is poorly documented. Only Brooksbank et al.
(1978) have shown concurrently the development of QNB binding sites and 
AChE and CAT activity in human brain. All these cholinergic markers 
were observed to be present at 18 weeks although Mahajan et al. (1980) 
has demonstrated CAT activity at 10 weeks. Brooksbank et al. (1978) 
observed marked differences in the ontogenic patterns found in the 
cerebral cortex and cerebellum of human brain aged between 18 weeks 
gestation and adult. In cortex, adult levels of [^ lT|-QNB binding were 
attained around birth but in cerebellum, the highest concentration was 
observed at 18-20 weeks. This is in sharp contrast to the findings in 
rat brain by Coyle and Yamamura (1976) in which the binding levels at 
birth were only 10% of the adult value.
In rat brain, the findings that muscarinic receptors appear 
before presynaptic markers (Coyle and Yamamura, 1976) and before the 
completion of major synaptic events (Ben-Barak and Dudai, 1979) suggests 
that in the human nervous system, cholinergic receptors may be present 
in the first 10 weeks of gestation. In developing human brain, synaptic 
contacts have been reported in foetuses aged 8.5 weeks (Molliver and Kostovic, 





PREPARATION AND CHARACTERIZATION OF a-BUNCAROTOXIN
Materials
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Carrier free Na I (lOOraCi/ml) in dilute NaOH was obtained
from the Radiochemical Centre, Amersham, Bucks. a-Bungarotoxin was 
prepared from the crude venom of Bungaris multicinctus using the method 
of Lee et al. (1972). The venom was obtained from Miami Serpentarium, 
Florida, U.S.A. Aliquots of a-bungarotoxin (0.5mol/ml) were stored at 
-20°C in 0.05M potassium phosphate, ph 7.5, until required. Chloramine T, 
potassium iodide and sodium metabisulphite were used freshly prepared in 
0.05M potassium phosphate, pH 7.5. Purified nAChR from the electric organ 
of Torpedo marmorata was prepared as previously described (Wonnacott et al. , 
1980.
Methods
a-Bungarotoxin was labelled by a modification of the method des-
125
cribed by Hunter and Creenwood (1962). Na I (3mCi) was added to
a-bungarotoxin (6.4nmol in IBOyl) in a plastic vessel (20ml) followed by
the addition of potassium phosphate (50yl) pH 7.5. The reaction was
initiated by chloramine T (50yl, 0.5% (w/v)) and stirred for 1 min at
23°C. The reaction was stopped by the addition of sodium metabisulphite
(3.75ml, 0.016% (w/v)) followed by potassium iodide (1ml, 1% (w/v)).
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Radiolabelled a-bungarotoxin was separated from free I by passage down 
a Sephadex C25 column (25 x 1cm) equilibrated with O.OIM potassium 
phosphate containing bovine serum albumin (1%, w/v). The toxin was 
eluted with the same buffer and 30 x 1ml fractions were collected.
Samples of each fraction (lOyl) were counted in an LKB 1280 Ultragamma 
counter. Peak tubes were pooled and the concentration of toxin was cal­
culated assuming a 100% recovery of protein.
39.
Chromatographic Separation of Radiolabelled a-Bungarotoxin
a-Bungarotoxin (6.4nmol) was labelled with ] as previously
described (page 38 ). The labelled toxin was separated into the mono and 
di-iodinated derivatives by the method of Lukas et al. (1978) with some 
modifications. The pooled peak obtained by gel filtration was applied 
to a CM 52 (Whatman) cation exchange column (1 x 6cm) equilibrated with 
5mM potassium phosphate, pH 6.5 (50ml). The column was washed with the 
same buffer until no further decrease in radioactivity was observed. The 
radiolabelled toxin was eluted with a linear salt gradient (80mM sodium 
chloride in 5mM potassium phosphate pH 7.5). Fractions (80 x 1ml) were 
collected at a flow rate of 7ml/h and samples (lOyl) were counted for 
radioactivity. Peak tubes corresponding to the mono and di-iodinated 
derivatives were pooled (see Fig.3.1) and stored at 4°C for up to three 
weeks in 5mM phosphate buffer, pH 7.5, containing 1% (w/v) bovine serum 
albumin.
The g-Bungarotoxin Binding Assay
Samples of the particulate fraction or crude detergent extract 
(500yl) were incubated with -a-bungarotoxin at a final concen­
tration of lOnM for Ih at 23°C. Non-specifically bound toxin was deter­
mined in parallel by incubating samples in the presence of unlabelled
-5 -4toxin (10 M) or nicotine (10 M) for 15 min. prior to the addition of
the labelled toxin. Non-specific binding was defined as the amount of
[2^^^iJ-a-bungarotoxin which remained bound to particulate or detergent
solubilized preparations in the presence of unlabelled toxin or nicotine.
Bound and free toxins were separated by one of the following
methods:-
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(i) Centrifugation Assay: The method of Schmidt(1977) was used with 
slight modifications. The quantity of radiolabelled toxin bound to 
particulate fractions was measued by centrifuging the samples contained 
in Eppendorf tubes (1.5ml) at ll,500g for 1 min. The supernatant was 
removed with a Pasteur pipette and the pellet resuspended in ice cold 
buffer A (1ml) and centrifuged as before. Radioactivity was measured
in the pellets. Blanks contained assay buffer in place of sample.
(ii) Filtration Assay: Particulate fractions were filtered through GF/C 
glassfibre discs (Whatman) under vacuum, washed with ice cold assay buffer 
(2 X 3ml) and the retained radioactivity was determined. Discs were 
soaked in 1% (w/v) bovine serum albumin for 10 min prior to filtration. 
Blanks contained assay buffer in place of sample.
(iii) Ammonium Sulphate Precipitation Assay; The assay procedure was 
adapted from Meunier et al., (1972) and was used almost exclusively for 
the determination of toxin binding activity in crude detergent extracts 
and soluble fractions.
To each sample, a saturated solution of ammonium sulphate was 
added to achieve a final concentration of 33% (v/v) and the precipitate 
was allowed to develop at 4°C for 16h. Samples were filtered through 
GF/C filter discs as previously described and washed with 33% (v/v) 
saturated ammonium sulphate solution (2 x 3ml). Retained radioactivity 
was measured as before. Blanks contained assay buffer in place of the 
sample.
(iv) DEAE Cellulose Assay; Bound and free toxins were separated by ion 
exchangé by the method of Schmidt and Raftery (1973), with modifications 
using DEAE cellulose discs. The assay method was used for measuring the 
toxic binding activity.
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of partially purifed receptor preparations.
The incubation mixture was allowed to soak through two DE81 
discs (Whatman) mounted in a Millipore vacuum filtration apparatus.
After 2 min., the discs were washed with assay buffer (3 x 3ml) under 
vacuum and the retained radioactivity determined. Blanks contained assay 
buffer in place of sample.
Radioactivity
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Samples containing I were counted for 1 min. in an LKB 
1280 Ultrogamma counter. Filter discs were tightly rolled and trans­
ferred to plastic tubes prior to placing in the holders.
Samples containing or were transferred to scintillation
vials followed by the addition of a scintillation cocktail and counted in 
a Packard Tri-Carb Scintillation Spectrophotometer.
Competition Studies
The concentration of toxin in each of the radiolabelled pre­
parations was determined by competition with native toxin for the binding
sites on the nAChR purified from Torpedo marmorata, James et al., (1980).
Samples (5yl) of unfractionated, mono and di-iodinated toxin
were diluted with a range of known concentrations (0-8pmol) of native 
toxin and incubated with Torpedo in AChR (0.1-0.4pmol, 200yl) for 90 min. 
at 23°C. Bound and free toxin were separated by ion-exchange using DEAE 
cellulose filter discs (page 40).
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Assessment of the Biological Activity of Radiolabelled a-Bungarotoxin 
Radiolabelled toxin derivatives (0.1-lpmol, lOyl) were 
incubated with 1000 fold molar excess of Torpedo nAChR (200yl) for 3h at 
23°C. Toxin binding was assayed as previously described.
Biological activity (%) can be defined as:-
labelled toxin bound (CPM) ^
total labelled toxin added (CPM)
Immunological Activity
Preparation of Anti-a-Bungarotoxin in Antibodies.
Antisera to a-bungarotoxin were prepared by the method of 
Clarke et al., (1972).
a-Bungarotoxin (O.lmg in lOOyl water) was emulsified in lOOyl 
Freunds Adjuvant and injected weekly into two male New Zealand white 
rabbits. A preliminary injection of toxin dissolved in 0.9% saline 
(200yl) was given subcutaneously along the backs of the animals. Sub­
sequent injections were administered intramuscularly each week up to
ten weeks. The animals were bled initially each week for six weeks and
pl25 -|
the serum was assayed for anti-(a-bungarotoxin) antibodies using |_ I_|-
a-bungarotoxin as the antigen.
Radioimmunoassay
Radiolabelled toxin (O.Spmol, 20yl) was incubated with rabbit 
anti-(a-bungarotoxin) antiserum (5yl, dilutions ranging from 5 - ^500)
for 24h at 4°C. Antisera was prepared as described above. Non­
specific binding was determined by preincubating immune serum with O.lmM
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native toxin (5yl) or by substitution with rion-immune serum. Toxin- 
antibody complexes were precipitated by using sheep anti-(rabbit IgG) 
serum (50yl) in the procedure described on page 69 .
Immunological activity can be defined as:
Toxin-ab complex precipitated (CPM)-nonspecific component(CPM) x 100
total toxin added (CPM)
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SUBCELLULAR FRACTIONATION OF BRAIN
Materials
a-Bungarotoxin was prepared from crude venom and iodinated as 
previously described. 1-Quiniclidinyl [phenyl-4-^ir| benzilate 
(42 Ci./mmol) , [jL-^ C^_l-Acetyl coenzyme A (5.55mCi/mmol) and 
adenosine 3', 5'-cyclic phosphate (25Ci/mmol) were obtained from 
Amersham International, Bucks. Cyclic AMP binding protein and 
charcoal (Norit CSX) were supplied as a kit by BDH Chemicals, Poole, 
England. Glutaraldehyde (histochemical grade) was obtained from 
E M Scope and osmium tetroxide from E M Chemicals, Ely, Cambs. Em­
bedding resin was obtained from Taab Laboratories, Berks. All other 
chemicals were supplied by either Sigma or BDH.
Human foetuses (13-16 weeks) were collected from Bristol 
General Hospital within 8h of pregnancy termination by prostaglandin 
induced abortion. The brains were dissected out and placed on ice.
Methods
Fractionation of Human Foetal Brain Homogenate
The procedure was adopted from Gray and Whittaker (1962).
Brains (up to 20g of material wet weight) were homogenized in ice cold 
0.32M sucrose 20% (w/v) containing O.lmM P M S F using a glass homo- 
genizer (Aldridge, et. al., 1960) equipped with a motor driven perspex 
pestle (clearance 0.25mm). Routinely, a speed of 800 rpm was employed 
with 12 up and down strokes of the pestle. The resulting homogenate (H) 
(of which 5ml was retained) was centrifuged at lOOOg for 10 min at 4°C in 
a Sorvall RC-5B centrifuge equipped with a 8 x 50ml rotor. The super­
natant (S^) was carefully decanted from the pellet (P^) which was washed
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with two volumes of sucrose and centrifuged as before. The supernatants 
were combined and centrifuged at 17,000g for 30 min at 4°C. The super­
natant (S^) was retained and the pellet (P^) was resuspended in 0.32M 
sucrose using a Pasteur pipette to give a final volume of 10ml. The 
suspension (of which 1ml was retained) was carefully layered on top of a 
discontinuous sucrose gradient prepared from 0.8N sucrose (17ml) and 
1.2M sucrose (17ml) at 4°C. The gradients were centrifuged at 100,000g 
for Ih at 4°C in a Beckman L5-50B ultracentrifuge equipped with a SW 28 
rotor. Gradient fractions were collected using an upturned Pasteur 
pipette by the total and partial schemes shown on pages 104 and 106. The 
total scheme involved collection of the whole gradient as three separate 
fractions and the partial scheme involved collection of particulate matter 
at the gradient interfaces.
Each fraction was returned to the original molarity of 0.32M 
by the addition of the appropriate volume of O.OIM sucrose. Fractions, of 
which 500yl were retained for protein estimation were centrifuged at 
100,000g for 30 min. at 4°C and the pellets resuspended in 50mli sodium 
phosphate pH 7.4, containing ImM EDTA and O.lmM PMSF (buffer A, see page 
73). Each fraction was resuspended to approximately 5% of the volume of 
the original homogenate. Supernatants were retained for the determination 
of protein. Samples representative of each step in the procedure (see 
page 46) were stored on ice for up to 5h for the analysis of enzyme 
activity, receptor binding studies and protein estimation. Remaining 
samples were stored at -80°C for the repetition of experiments.
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Fractionation of Rat Brain
Male Wistar rats (2) weighing approximately 200g were killed 
by cervical dislocation and the brains(minus cerebellum) were dissected 
out rapidly and placed on ice. Fractionation procedures were as described 
for human foetal brain (page 44) but using 10 volumes of ice cold sucrose 
in the homogenization step.
Determination of Protein
Protein was assayed by the method of Lowry et al. (1951) . 
Standard curves were constructed using a freshly prepared solution of 
bovine serum albumin ranging in concentration between lOO-SOOyg/nl.
For assay, BSA standards (lOOyl) or unknown (lOOyl) were incubated with 
alkaline cupric tartrate (1ml). This solution was freshly prepared by 
diluting 0.5% (w/v) copper (II) sulphate (1 vol) and 1% sodium potassium 
tartrate (1 vol) with 2% (w/v) sodium carbonate (50 vol) in O.IM sodium 
hydroxide. After incubating for 10 min at room temperature, Folin- 
Ciocalteau reagent (1ml) diluted 1:1 with water was added to each sample 
and the colour was allowed to develop for 30 min. Blanks contained dis­
tilled water in place of protein. The absorbance was read at 750nm in
a Pye Unicam SP 8-100 spectrophotometer.
Choline acetyltransferase: (CAT) activity was measured by the procedure
described by Fonnum (1969a) with minor modifications.
Tissue fractions (lOOyl) were added to 5% (v/v) Triton X-100 
(lOyl) contained in Eppendorf tubes (1.5ml) and allowed to stand for 
30 min at 23°C. The suspensions were then centrifuged for 5 min in an
M.S.E. Microfuge and supernatants (20yl) were transferred to Eppendorf
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tubes (1.5ml) containing the equivalent volume of solution composed of 
50mM sodium phosphate pH 7.5, ImM EDTA, 0.2M NaCl, 0.5% (v/v) Triton 
X-100, 0.5% (w/v) BSA and 0.2mM |-Acety1-Coenzyme A. Samples were
incubated for Ih at 37°C. Controls contained extract boiled for 2 min. 
prior to the addition of substrate.
The reaction catalysed by CAT is:
(44 - CAT _
[j C_["-Acetyl-CoA + choline   [y Cj-acetyl choline + Co A
The reaction was terminated by the addition of IM formic acid 
(lOyl) and the acetylcholine was extracted from aqueous solution by 
liquid cation exchange (Fonnum, 1969b). A freshly prepared solution of 
sodium tetraphenyl boron dissolved in heptanone (0.5ml, 15mg/ml) was 
added to each sample, mixed well and centrifuged at 3000g for 1 min.
Samples of the ketone layer (0.25ml) were transferred to scintillation 
vials containing 5ml of scintillation mixture (70% toluene, 30% Triton,
0.5% PPO and 0.01% POPOP) and the radioactivity determined in a Packard 
Tricarb liquid Scintillation Spectrophotometer.
The specific activity of CAT was calculated from the relation­
ship :
ymoles/h/g protein = total CPM-control CPM
----------------------- ^ mole substrate x g protein
total CPM added
Acetylcholinesterase : activity was measured by using acetyl thiocholine
iodide as substrate (Ellman et al., 1961).
^ AChE
RCO.SCH^CH^N (CHg)^ + H^O ------- > RCOOH + KSCH^n "^(CH^)^
49.
°^2 CO^  °^2
N02-(Q>-S-S-(^N0^ + HSCH2CH2N*(CH^3'>N02-<^SH+N02-(^S-S(CH2)2n'' (CHj)^
yellow
Acetylthiocholine iodide and DTNB (see page X  ii) were freshly prepared in 
O.IM sodium phosphate buffer at pH 8.0 and 7.4 respectively. For assay,
O.IM sodium phosphate buffer, pH 8.0 was added to primary fractions 
(0.1ml) and gradient fractions, (0.3ml) in a 3ml cuvette to give a final 
volume of 2.8ml, DTNB (0.1ml, 3.96mg/ml) and acetyl thiocholine iodide 
(0.1ml, 4.3mg/ml) were added in succession to each sample, stirring 
rapidly, and the change in optical density was maintained at 412nm in a 
Pye Unicam SP 8-100 Ultraviolet Spectrophotometer. Measurements were 
also taken in the absence of substrate as a control and the specific 
activity was calculated from the relationship:
ymoles substrate hydrolysed/min/g protein =
E 10^  ^ . -1
X -------------  X g protein
e d vol in cuvette (ml)
where E = change in absorbance/min
e = molar extinction coefficient (1.36 x 10^) 
d = light path 1cm.
Lactate dehydrogenase: (LDH) is a soluble enzyme present in the cyto­
plasm. However in fractions enriched in nerve endings, it is protected 
from its substrate and co-factor by the synaptosome plasma membranes.
The occluded LDH can be rendered accessible to its substrate by treatment 
with Triton X-100, thus giving an estimate of the total activity. This 
method for the estimation of occluded LDH was derived from that of 
Marchbanks (1967). Enzyme activity was assayed by measuring the oxidation
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of NADH^ in the presence of pyruvate,
Pyruvate + NADH + Lactate + NAD^
For assay, freshly prepared reaction medium containing 0.15M Tris 
HCl pH 7.4 (2.7ml), lOmM sodium pyruvate (0.1ml) and 2mM NADH (0.1ml) 
was transferred to a 3m1 cuvette and placed in a Pye Unicam SP 8-100 
spectrophotometer equipped with a chart recorder. The reaction was 
initiated by the addition of a sample (0.1ml) of each fraction with 
rapid mixing and the rate of decrease in optical density was monitored 
at 340nm for at least 1 min. Subsequent addition of 10% (v/v) Triton 
X-100 (0.1ml) released any occluded LDH and the reaction was monitored 
for a further 2 min.
The specific activity of LDH was calculated from the relation­
ship :
ymoles pyruvate reduced/min/g protein =
E 10^ . . -1—  X — q- . , X g proteind volume in cuvette (ml) ^
where E = change in absorbance/min
3e = molar extinction coefficient (6.22 x 10 )
d = light path 1cm.
Occluded LDH activity can be calculated from the difference 
between total and free LDH. The proportion of masked activity was used 
as an assessment of the integrity of the synaptosomal plasma membranes.
Succinate dehydrogenate: activity is associated with' the inner membrane
matrix fraction of mitochondria (Schnaitman and Greenwalt, 1968) and was 
accordingly used as a marker for the mitochondrial fraction. The assay 
involves the formation of a formazan dye from p-nitrophenyl phenyl- 
tetrazolium (INT)(From Porteus and Clark, 1965).
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Samples containing sodium phosphate buffer pH 7.6 (0.35ml),
0.3M sucrose (0.1ml), 0.5% (w/v) INT (0.2ml) and 0.2M sodium succinate 
(0.25ml) were placed on ice and the reaction was initiated by the 
addition of tissue fraction (0.1ml). Controls contained buffer in place 
of enzyme. Samples were kept on ice for 30 min. then transferred to a 
water bath at 37°C for a further 15 min. The reaction was terminated by 
the addition of ice cold trichloroacetic acid (1ml) and the tubes placed 
on ice immediately afterwards. The coloured product was extracted with 
ethyl acetate (4ml) and centrifuged at 3000g for 5 min. The ethyl acetate 
phase was removed with a Pasteur pipette and the absorbance at 490nM was 
measured in a Pye Unicam SP 8-100 spectrophotometer.




----------------- X X g protein
d X e X 15 volume in cuvette (ml)
where: OD = The change in optical density in 15 min.
3
e = molar extinction coefficient (20.1 x 10 ) 
d = light path (1cm)
Adenylate cyclase: activity in mammalian brain occurs almost exclusively
in associated with particulate matter, especially subfractions enriched 
with nerve endings (De Robertis et al., 1967, Weiss and Costa, 1968).
Adenylate cyclase activity was measured by the procedure of 
Furman and Shulman (1977) which determines the quantity of cyclic AMP 
(cAMP) produced in 15 min. by the reaction shown below.
Adenylate cyclase ^
-> cAMP + PP. + H
ATP X. 2+ iMg
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cAMP is estimated by the competitive binding of a known quantity of radio­
labelled cyclic AMP to a protein kinase isolated from bovine adrenal 
cortex (supplied as a kit by BDH). Freshly prepared incubation medium con­
taining 30mM Tris buffer pH 7.4, ImM MgCl^ and 8mM theophy 1 line monohydrate 
was heated in a water bath to 30°C. For assay, incubation medium (450yl) 
containing 2mM ATP was transferred to Eppendorf tubes (1.5ml) and the 
reaction was initiated by the addition of tissue fractions (50yl). The 
reaction was terminated at 5, 10 and 15 min. intervals by placing the 
tubes in boiling water for 5 min. Samples were centrifuged in an MSE 
microfuge for 5 min. at ll,500g and the supernatants were retained for the 
estimation of cAMP. Controls contained tissue fractions which had been 
placed in boiling water for 5 min. prior to addition to the incubation 
medium.
cAMP was measured according to the method of Brown et al. (1971), 
For cAMP standards, unlabelled cAMP was dissolved in assay buffer con­
sisting of 50mM Tris buffer pH 7.4, 8mM theophylline monohydrate and
-30.047% (v/v) mercaptoethanol with the addition of 10 M sodium azide.
Standard preparations ranged between 0-15 pmoles per 50yl. Tritiated
-8
cAMP was diluted with assay buffer to a concentration of 5.1 x 10 M.
For assay, Eppendorf tubes (1.5ml) containing assay buffer (150yl) , 
tritiated cAMP (50 1) and unlabelled standards or unknown samples 
(50yl) were mixed well and a sample (50yl) was transferred to a scin­
tillation vial for counting. Binding protein (lOOyl) diluted 1:10 (v/v) 
in assay buffer was added to the remaining 300yl and the samples were 
incubated at 4°C for 90 min. The absorption efficiency control contained 
assay buffer (300yl) and tritiated cAMP (50yl). The zero standard con­
tained assay buffer (200yl), tritiated cAMP (50yl) and diluted binding
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protein (lOOyl). Following the 90 min. incubation period a charcoal 
suspension 10% (w/v) in assay buffer containing 2% (w/v) bovine serum 
albumin was added to each sample, shaken for 2.5 min. and centrifuged 
at 3000g for 10 min. Supernatant fractions (lOOyl) were transferred to 
scintillation vials containing scintillation fluid (5ml) composed of 
toluene (70%), Triton X-100 (30%), PPO (0.5% w/v) and POPOP (0.01% 
w/v). Samples were counted for 5 min. in a Packard scintillation 
spectrophotometer.
For construction of the standard curve, samples containing
unlabelled cAMP were denoted by C and the zero standard by C (see
X o
page 115). Standard curves were reproduced every two weeks in order to 
compensate for any loss of activity of the cAMP binding protein.
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Binding of [ I|-g-Bungarotoxin to Subcellular Fractions
Primary and gradient tissue fractions were assayed for protein 
and diluted if necessary with buffer A (page 7 3) to a concentration not 
exceeding 3mg/ml.
Samples (500yl) corresponding to three different concentrations 
of receptor were assayed for toxin binding activity as described on page 
and toxin receptor complexes were precipitated by ammonium sulphate 
(page 40).
Binding of -QNB to Subcellular Fractions
Assay methods were adapted from Yamamura and Snyder (1974).
The protein concentration of all fractions was adjusted to 0.2mg/ml with 
buffer A. For assay, samples (1ml) corresponding to two concentrations
54.
of receptor were incubated with [^H|-qNB (lOyl) at a final concentration
of 2nM for Ih at 23 C. Non-specific binding was determined in the
-4presence of atropine sulphate (10 M). Bound and free QNB was separated
by vacuum filtration through GF/B glassfibre discs (Whatman). Filters 
were washed with 3 x 5ml ice cold assay buffer, even dried at 70°C and 
placed in scintillation vials. Radioactivity was determined in the 
presence of toluene (5ml) containing 0.5% (w/v) PPO.
Preparation of Subcellular Fractions for Electron Microscopy
Ultrastructural studies were performed on the gradient fractions 
prepared from the brain of a 13 week old foetus obtained within 4h of 
termination. Gradient fractions A, B and C were prepared as described 
on page 4 4. Particulate material in the form of two sharp bands (A and 
B) and the pellet (C) was carefully removed and diluted dropwise with 
0.32M sucrose (10 volumes). The fractions were collected by ultra­
centrifugation at lO^g for Ih and the resulting pellets were fixed
in 2.5% (v/v) glutaraldehyde in O.IM cacodylate buffer (pH 7.0) at 4°C
3 . .for 16h. Samples, approximately 3mm in size were washed (3 x 10 min) 
in the same buffer and postfixed in 1% (v/v) OSO^ in O.IM cacodylate 
buffer (pH 7.2) for Ih at 23°C. Specimens were washed in the same buffer 
as before then transferred to 1% aqueous uranyl acetate for Ih in the 
dark at 4°C followed by three buffer washes. They were then dehydrated 
in a graded series of acetones (50%, 70%, 95%, 100%, 3 x 10 min each) 
and transferred to 50% (v/v) Taab embedding resin in acetone for 16h. 
Specimens were impregnated with resin (two changes) over 48h and embedded 
at 60°C for a following 48h. Ultrathin (gold and silver) sections were 
cut with an LKB ultramicrotome equipped with a diamond knife and collected 
on copper grids. Sections were stained with saturated uranyl acetate in
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70% ethanol followed by Reynolds lead citrate in a Forsdyke stainer 
(Forsdyke,1979) and examined with a Jeol 100 CX electron microscope at 
80 KV.
A parallel investigation was conducted by using gradient 
fractions prepared fran adult rat brain in order for an ultrastructural 
comparison to be made under the conditions used for fractionation 
described in this text.
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QUANTITATIVE STUDIES OF a-BUNGAROTOXIN BINDING
Analysis of the kinetic behavior of toxin was performed using 
the mono-iodinated derivative of labelled a-bungarotoxin.
Materials
Mecamylamine was a gift from Dr. M.P. Caulfield, Glaxo Group 
Research, Greenford, U.S. Benzoquinonium chloride was generously 
provided by Stirling Winthrop Inc., Rensselaer, N.Y., U.S.A. All other 
drugs were obtained from Sigma U.K. Ltd., Kingston-Upon-Thames, Surrey.
Methods
Preparation of a Crude Detergent Extract
A detergent extract was prepared from the crude mitochondrial 
fraction of human foetal brain (page 4 4) by resuspending the pellet in 
5 volumes of buffer A (page 7 3) containing 2% (v/v) Triton X-100 
(scintillation grade). The mixture was stirred gently for Ih at 23°C and 
clarified by centrifugation in a Beckman L5-50B ultracentrifuge equipped 
with a S 35 rotor at lO^g for Ih at 4°C. The supernatant was retained 
and designated "crude detergent extract".
Determination of the Intrinsic Dissociation Constants (K^ )
Membrane Bound Receptor: Samples of the P^ fraction (500yl) were incubated 
with [^^^I|-a-BgTx (0.5-12nM) for Ih at 23°C. Binding was terminated by 
centrifugation (page 40). Non-specific binding was determined in the
-5
presence of 10 M unlabelled toxin.
Solubilized Receptor: Crude detergent extracts were incubated with radio­
labelled toxin as for the membrane bound receptor. Toxin-receptor com­
plexes were precipitated by the addition of saturated ammonium sulphate 
(250yl) and allowed to incubate for 16h at 4°C. Bound and free toxins were
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separated by filtration (page 40).
Determination of the Association Rate Constant (k + 1)
The association rate constant (k + 1) was determined by measuring
the amount of toxin bound specifically to receptor as a function of time.
Independent saturation experiments were performed in order to calculate
the maximal binding capacity B and hence the concentration of receptor
max
ligand complex (RL) assuming a stoichometry of 1:1 (see page 204).
Membrane Bound Receptor: A sample of (10ml, O.lnM) was incubated with
a-BgTx (5nM) at 23°C. Aliquots (500yl) were removed at intervals 
of initially 1 min, up to 60 min. and the reaction was terminated by 
centrifugation (page 40). Non-specific binding was determined in the
-5
presence of 10 M unlabelled toxin.
Solubilized Receptor: Crude detergent extract (10ml, 0.25nM) was in­
cubated with I^^^Ij-a-BgTx at concentrations of 4, 6, 8 and lOnM.
Aliquots (500yl) were removed at time intervals within a 12 min. period 
and the toxin receptor complex was precipitated with saturated ammonium 
sulphate (250yl). Bound and free toxin was separated by filtration 
(page 40) and non-specific binding was determined as above. Specifically 
bound toxin after 1.5h incubation was taken to represent the equilibrium 
binding and designated (B^).
Binding of toxin to receptor was analysed in terms of a bi- 
molecular reaction mechanism using a pseudo first order scheme of analysis. 




FronijR + L -«s:------  RL
k-1
where:- R = The concentration of receptor at equilibrium.
L = The concentration of -u-BgTx at equilibrium.
RL = The concentration of toxin-receptor complex at
equilibrium, 
k t 1 = The on rate constant.
k - 1  = The off rate constant.
The association (k + 1) and dissociation (k - 1) rate constants can be
defined:
dRL (1)
  = k + 1 . R.L-k-l.RL
dt
At equilibrium, the bound concentration (B) at any prior time is related 
to the equilibrium concentration (Be) by:-
In — = (k + 1 . L* + k-l)t = k t (2)
Be-B ^




is plotted with respect to time the slope will be k^^.
From the equation above
k +1 = k ^ - k - 1  (3)
ob________
^T
k-1 is determined by independant experiments in order to calculate the 
value of k + 1.
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A second method was used in order to calculate the value of 
k + 1 .  If the value of k^^ is determined at different ligand concentrations 
and k^^ is plotted with respect to then the slope is k + 1 and the 
intercept is k - 1.
k , = k + 1 . LT + k-1 (4)ob
Determination of the Dissociation Rate Constant (k-1)
Membrane Bound Receptor; A sample of fraction (10ml, O.lnM) was 
incubated with BgTx (5nM) at 23°C for 90 min, after which
unlabelled toxin (10 ^M) was added to the mixture. Aliquots (500yl) 
were removed at successive intervals (up to 4h) and the reaction was 
terminated by centrifugation (page 40). Non-specific binding was deter­
mined by independant experiments and the total binding (samples containing
labelled toxin only) was measured in parallel.
Solubilized Receptor: Crude detergent extract (10ml, 0.25nM) was in­
cubated with [^^^l|-a-BgTx (5nM) and subsequent experimental procedures 
were as described for the particulate fraction. The toxin-receptor com­
plex was precipitated by ammonium sulphate and bound on free toxin was 
separated by filtration.
Using this method, the addition of excess unlabelled toxin 
prevents rebinding of the labelled species, so the term k+l.R.L in
equation (1) (page 58) is essentially zero whence
dB
—  = — k-1. B
dt
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Integration gives in(B/B^ » -k-l.t 
where :
= The amount of toxin bound at equilibrium (t = o)
B = The amount of toxin bound at specified intervals thereafter
The value of k-1 is derived from the slope of B/ plotted as a 
function of time.
Bo
Values for the t^  were calculated from the relationship:- 
k-1 = ^
t^  represents the time at which one half of the total receptor sites are 
occupied.
For detergent solubilized receptor, the value of k-1 was also 
calculated as described on page 140.
Determination of the IC^q values of Various Drugs
The IC^o value of a given drug is the concentration at which 
the specific binding of the labelled ligand investigated is reduced by 
50% in the presence of competitor when determined at equilibrium (iCj) or 
by initial associated rates (Kp). The values of or Kp are shown to 
be equivalent to the true dissociation constant of the competing drug if 
certain conditions are met within the assay (see page 209)
The ability of various drugs to inhibit the binding of 
I-a-BtTx to the particulate fraction of human foetal brain at 
equilibrium was investigated. _ . _ _
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Samples of the ?2 fraction (500yl, O.lnM) were incubated with
in the presence of various drugs which ranged in concentration 
between 10 Si and 10 ^^M. Non-specific binding was determined by pre­
incubating membranes for 20 min. with 10 ^M unlabelled toxin. Bound and 
free toxins were separated by centrifugation (page 40).
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REGIONAL BINDING STUDIES OF BRAIN AND SPINAL CORD 
Autoradiography
Materials
Nuclear emulsion (K5) was obtained from Ilford Ltd., Basildon, 
Essex. Slides and coverslips were obtained from Chance/Propper Ltd., 
O.C.T. compound from Lab. Tek Products, Miles, D.P.X. paraformaldehyde 
and gelatin from BDH Chemicals, photographic materials from Kodak, 
cresyl violet from Sigma and Hypnorm from Crown Chemical Co. Ltd., 




Autoradiographic procedures were adopted from Young and Kuhar
(1979).
Coverslips (22 x 64mm) were cleaned in chromic acid and 
rinsed in water followed by 50% (v/v) ethanol. They were oven dried at 
70°C and stored in airtight boxes. Nuclear K5 emulsion (4ml) contained 
in a narrow vessel (the length of which just exceeded the coverslips) 
was placed in a water bath at 45°C. Upon liquification, water (8ml) at 
45°C containing 0.5% (v/v) glycerol was added to the emulsion and stirred 
for 2 min. The mixture was filtered through muslin and left for a further 
2 min. The temperature was maintained between 40-50°C. All photographic 
procedures were performed under safelight (Ilford, light brown).
Cleaned coverslips (100) were dipped once in emulsion to coat 
up to two thirds of their surface and placed in an upright position in a 
humidified atmosphere for 3h at room temperature to dry. Coverslips were
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stored (when dry) in light-tight boxes until required.
Slides (76 x 26nnn) were cleaned with chromic acid, rinsed 
thoroughly with water and oven dried. Gelatine (1% w/v) and chrome alum 
(0.05% w/v) were dissolved in distilled water, heated to 70°C, filtered 
and maintained at this temperature. Slides (racked) were dipped once, 
allowed to drain and dried at 60°C.
Rat Brain Intraventricular Injections
[^^^I_l-a-Bungarotoxin was injected into the third ventricle 
of rat brain (see Fig.3.38a, page 158) by the method described by Hunt 
and Schmidt (1978 a 1.
Four male Wistar rats were each given an i.p. injection of
Hypnorm (lOOyl/Kg) which resulted in anaesthesia for up to 5h. A mounted
-8Hamilton syringe was used to inject 30yl of labelled (5 x 10 M) and 
-5unlabelled (10 M) a-bungarotoxin in 3mM sodium phosphate, pH 7.4, con­
taining 80mN sodium chloride and 0.2% (w/v) bovine serum albumin. Un­
labelled toxin was administered to two of the animals Ih prior to the 
injection of the labelled species as a control for non-specific binding.
The animals were allowed to survive for 24h before the administration 
of 1ml 5% chloral hydrate (ipt) to evoke anaethesia followed by vascular 
perfusion with O.IM sodium phosphate buffer (200ml), pH 7.2, containing 
4% (w/v) parafomaldehyde. Brains were removed and freeze mounted on to 
cryostat chucks resting on dry ice using OCT compound. Coronal sections 
(6yM) were cut in a cryostat maintained at -18°C and collected on gelatinized 
slides. The sections were allowed to dry for Ih at room temperature 
before applying emulsion-coated coverslips, the uncoated portion being 
fastened to the slide with Superglue (Loctite, U.K.). Each slide was
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wrapped in tissue and a paperclip secured contact between the surfaces. 
Slides were stored in lightproof boxes for seven days at 4°C and then 
developed in Kodax D19 at 17°C (3 min.), transferred to a stop bath 
(30 sec) and fixed in Kodafix (1 + 3, 5 min.). Sections were washed in 
running water for 30 min., postfixed in A.F.A. (90% ethanol, 5% chloro­
form, 5% glacial acetic acid) for Ih. Slides were then transferred to 
70% ethanol, rinsed in water and stained in 1% (w/v) aqueous cresyl violet 
for 5 min. Sections were quickly rinsed in water and taken through 70,
95 and 100% ethanol (2 min. each) then transferred to xylene for 30 min. 
before the application of D.P.X. mounting medium. The D.P.X. was allowed 
to harden for 10 days before examining the slides under a Leitz 
Orthomat light microscope using dark field optics. Photographs were 
taken using Panatomic-x film (Kodak).
Human Foetal Spinal Cord Sections
A human foetus (at 14 weeks gestation) was obtained within 4h of 
termination following prostaglandin induced abortion and placed on ice.
The spinal cord was dissected out and a portion of the lumbar region 
(L4) was frozen on to a cryostat chuck placed on dry ice. Sections 
(16ym) were collected on gelati nized slides and air dried.
-9Slides were incubated with labelled toxin (5 x 10 M) in buffer 
A for Ih at 23°C. Controls pre-incubated with unlabelled toxin (10 ^M) 
for Ih prior to the addition of the labelled species. Sections were 
washed in the same buffer (on ice) for 10 sec,, dipped once in ice cold 
water and dried in an air stream at 4°C. Slides were coverslipped and 
processed as previously described for rat brain.
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Binding of [^^^ij-a-Bungarotoxin to Rat Brain Regions
Male Wistar rats (4) were killed by cervical dislocation and
the brain dissected into various regions on ice. Homogenates were pre­
pared in ice cold sucrose (10 vol) as previously described (page 4 7) 
and centrifuged at 17,000g for 30 min. The pellets were washed twice 
with buffer A and resuspended in the same buffer (50 vol). Toxin 
binding assays were performed as described on page 39.
Binding of [^^^ij-a-Bungarotoxin to Human Foetal Brain Regions
The binding of a-bungarotoxin was investigated in the cerebral 
cortices, cerebellum and spinal cord of two foetuses aged 13 and 14 weeks 
Homogenates were prepared in 5 volumes of ice cold sucrose as described 
on page 4 4 . For binding studies (Methods, page 39 ) the pellets were 
resuspended in buffer A to give a protein concentration of between 2-3mg/ 
ml.
Electron Microscopy
Ultrastructural studies were performed on the brain of a 13
week old foetus obtained within 3h of termination. The brain was
dissected out on ice and the dura mater carefully peeled back with
3
forceps. Samples of tissue of approximately 2mm were taken from the 
surface of areas 1, 7 and 10 as shown in Fig.2.2, page 66.
The blocks of tissue were fixed and processed as described 
on page 54.
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Fig. 2.2. The Human Brain at Approximately Four Months Gestational Age.












BINDING OF ANTI-(nAChR) ANTIBODIES TO HUMAN FOETAL BRAIN 
Purification of anti-(nAChR) antibodies
Materials
Citrated plasma from a myasthenic patient treated by plasma 
exchange was obtained from The Royal United Hospital, Bath, and frozen 
at -20°C until required. Sepharose 4B was obtained from Pharmacia Fine 
Chemicals, Uppsala, Sweden. Freunds adjuvant was obtained from Miles 
Laboratories and a-bungarotoxin from Boeringer Corps., Lewes, Sussex.
Methods
Extraction of nAChR from Muscle
A crude detergent extract of human muscle was prepared by the 
method of Stephenson et al. (1981).
Frozen gastrocnemius muscle (200g) was finely chopped and 
homogenized in ice cold buffer C (4 vols)(see page 7 3) in a Sorvall 
Omnimix for 1 min. at full speed. Homogenate was centrifuged at 
20,000g for 45 min. at 4°C in an M.S.E. 18 centrifuge equipped with a 
6 X 250ml rotor. The supernatant was discarded and the pellet was 
resuspended in buffer D (page 73)(200ml) and homogenized as before.
The mixture was stirred for 4h at room temperature and centrifuged at 
lO^g in a Beckman ultracentrifuge equipped with an S35 rotor. The 




Crude detergent extract of human muscle (lOOyl) was incubated 
with O.Spmol ^ij-a-BgTx (lOyl) for 24h at 4°C. Non-specific binding 
was determined by preincubating the extract in the presence of 0.ImM 
benzoquinonium chloride. The receptor-toxin complex was precipitated 
by the addition of saturated ammonium sulphate (80yl). Samples were 
incubated overnight at 4°C and the precipitate was collected by fil­
tration through GF/C (Whatman) glassfibre discs. Filters were washed 
with 3 X 3ml of 40% (v/v) saturated ammonium sulphate and the radio­
activity determined.
Preparation of Affinity Column
Sepharose 4B was coupled to a-bungarotoxin by the method 
described by March et al. (1974). Sepharase 4B (10ml packed beads) was 
washed in O.IM NaCl (200ml) followed by ice cold distilled water 
(200ml). The beads were resuspended in ice cold water (10ml) to which 
2M sodium carbonate (20ml) was added. Cyanogen bromide (500mg dissolved 
in 250yl of acetonitrile) was added to the beads, stirred for 2 min. 
and the mixture was quickly filtered through a glass scinter. The beads 
were washed rapidly with ice cold water (200ml), a-bungarotoxin (2mg 
dissolved in 10ml 0.2M NaHCO^ pH 9.0) was added to the beads and stirred 
for 21h at 4°C. The mixture was then filtered and the beads washed 
alternately three times with O.IM sodium acetate buffer containing 
l.OM NaCl (pH 4.0) and sodium borate buffer containing l.OM NaCl 
(pH 8.0). The beads were washed in ice cold lOmM potassium phosphate 
buffer containing 0.02% (w/v) sodium oxide, pH 7.4 (100ml) and stored at 
4°C in the same buffer until required.
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Radioimmunoassay for anti-(nAChR) Antibodies
The radioimmunoassay procedure was adapted from Carter et al., 
(1981). Human muscle nAChR in the form of a crude detergent extract 
(O.lpmol, 200yl) was incubated with -a-BgTx (O.Spmol, lOyl) for
2h at 23°C. Non-specific binding was determined by preincubating 
receptor with benzoquinonium chloride (O.lmM). Serial dilutions of 
myasthenic plasma and immunoglobulin fraction were prepared using normal 
human serum. Antibody (5yl) was added to the toxin-receptor complex 
and incubated for 24h at 4°C. Controls were substituted with normal 
human serum. The receptor-antibody complex was precipitated by the 
addition of goat anti-(human IgG) serum (lOOyl) and incubated at 23°C 
for 3h then pelleted at 3000g for 10 min. in a M.S.E. Mistral centrifuge. 
The pellets were washed twice with lOmM potassium phosphate pH 7.4 
containing 0.15N sodium chloride, Triton X-100 )4% w/v) and sodium 
azide (0.1% w/v) and the radioactivity determined.
Purification of Anti-(Receptor) Antibodies
The immunoglobulin fraction of plasma was prepared by the 
method of Habeeb ^nd Francis, (1976).
Ammonium sulphate (4M, 100ml) was added slowly with continuous 
agitation to citrated plasma (100ml) stirred for a further 2.5h at 23°C. 
The suspension was centrifuged at 3000g in a M.S.E. bench centrifuge for 
10 min. and the pellet was redissolved in lOmM potassium phosphate buffer 
(10ml) pH 6.2. The solution was then dialysed against 2 x 1& of the 
same buffer for 16h at 4°C. The antibody titre was determined by radio­
immunoassay employing the f| -a-BgTx-nAChR complex as antigen
as previously described.
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Sepharose-toxin heads (10ml) were mixed with muscle in AChR in the form 
of a crude detergent extract (150ml) and stirred overnight at 4°C. The 
mixture was poured onto a column (2 x 15cm) to retain the beads. The 
extract was collected and designated the "Non-bound fraction" and the 
beads were washed with buffer E (page 73)(100ml) at 4°. The non-bound 
fraction and washings were assayed for toxin binding activity to deter­
mine the amount of nAChR that had bound to the affinity beads. The 
results (page 167) indicated that 57% of the receptor was associated with 
the affinity beads.
Affinity Purification of Anti-(Receptor) Antibodies
The toxin-receptor affinity beads were mixed with the myasthenic 
immunoglobulin fraction (5ml) and stirred for 2Oh at 4°C. The mixture 
was then returned to the column and the non-bound fraction assayed for 
toxin binding activity and antibody activity.
The absence of a detectable titre against the muscle receptor 
(Results, page 168) indicated that the anti-(nAChR) antibodies were re­
tained by the column.
The beads were washed with lOmM potassium phosphate (100ml) 
pH 7.4 and anti-(nAChR) antibodies were eluted from the column with 
2M KI (2ml). Fractions, (10 x 1ml) were collected and measured for 
protein at A^g^. The peak tubes were pooled and dialysed against lOmM 
potassium phosphate (2 x 2 )^ and stored at -20°C until required.
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Binding of Anti-(nAChR) Antibodies to the a-Bungarotoxin Binding Component 
in Human Foetal Brain
A crude detergent extract of human foetal brain was prepared 
as previously described (page 56) . Samples (250yl) were incubated with 
l^^^^-a-BgTx (lOnM) in the presence and absence of 10 nicotine for 
Ih at 23°C. Toxin binding activity was determined by ammonium sulphate 
precipitation (page 40). The toxin labelled antigen (250yl) was 
incubated with increasing dilutions of myasthenic plasma (lOyl) or the 
immunoglobulin fraction (20yl) for 3h at 23°C followed by goat anti- 
(human IgG) serum (120yl) for a further 3h. The precipitates were 
collected by centrifugation as previously described (page 40). Con­
trols contained normal human serum in place of myasthenic plasma or the 
immunoglobulin fraction.
72.
g-BUNGAROTOXIN BINDING PROTEIN PURIFICATION
The procedure described by Moore and Brady (1977) was followed 
with some modifications. The affinity beads were prepared by coupling 
a-bungarotoxin to Sepharose 4B as described on page 68. A P^ fraction 
was prepared from 50g of starting material (see page 44) and resuspended 
in buffer B (page 73). A crude detergent extract was prepared as 
previously described (page 56) mixed with affinity beads (2ml) and 
stirred gently for 2h at 4°C. The beads were separated from the mixture 
by passage through a glass column (1 x 5cm) plugged with glass wool and 
the non-bound fraction was retained for the measurement of toxin binding 
activity. The column was washed with ice cold buffer F (20ml) and the 
washings retained as above. The beads were mixed with IM carbachol 
(10ml) and stirred gently for 2h at 4°C. The suspension was then filtered 
and the filtrate subsequently dialysed against buffer F (2 x 1&) to 
remove the carbachol. All steps in the purification procedure were 
performed at 4°C. Toxin binding activity was measured by ammonium 
sulphate precipitation (page 40).
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Fig. 2.3. List of Buffers
A 50mM sodium phosphate 
ImM EDTA 
O.lmM PMSF




5yg/ml soybean trypsin inhibitor 
2mM benzamidine hydrochloride 
2% (v/v) Triton X-100 
0.02% sodium azide
C lOmM potassium phosphate 
lOOmM sodium chloride 
0.02% (w/v) sodium azide 
ImM EDTA
2mM benzamidine hydrochloride 





2% (v/v) Triton X-100
ImM EDTA 
O.lmM PMSF
0.15M sodium chloride 
0.1% Triton X-100
20mM sodium phosphate 
ImM EDTA 
O.lmM PMSF
5yg/ml soybean trypsin inhibitor 





PREPARATION AND PROPERTIES OF [-LABELLED a-BUNGAROTOXIN FRACTIONS
The specific activity of the radiolabelled a-bungarotoxin 
prepared by the Chloramine T method (page 361 ranged from 350 to 
500Ci/mmol for all preparations. The % incorporation of radioactivity 
into the protein varied between 85 and 90%.
Radiolabelled toxin was separated into the mono and di- 
iodinated derivatives following salt elution from CM-52 cellulose.
The elution profile is shown in Fig. 3.1. The recovery of radio­
activity from the column varied between 75% and 88% over five pre­
parations. A small peak of radioactivity which did not exceed 7% of 
the total was always present in the column wash prior to salt elution.
The concentration of a-bungarotoxin in the iodinated preparation 
was determined by competition studies (Methods, page 41). The concen­
tration of toxin in a single preparation of the mono-iodinated deriv­
ative was calculated as shown in Fig. 3.2. The specific activity of 
the mono-iodinated derivative varied between 240 and 310 Ci/mmol over 
five preparations. Experiments involving the use of mono-iodinated 
a-bungarotoxin were performed within 10 days of preparation.
Biological Activity of Radiolabelled a-Bungarotoxin
The proportion of radioactivity in iodinated toxin preparations 
estimated to be biologically active is shown in Table 3.1. A commercial 
preparation of -a-bungarotoxin was shown to have the highest biolog­
ical activity although values differed according to the method of 
assay. In the case of all radiolabelled preparations, the highest 
apparent biological activities were obtained by using gel filtration 












Frac t i on  number
Fig. 3.1. The Elution Profile of the Radiolabelled Derivatives
of Iodinated g-Bungarotoxin from CM-52 Cellulose
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Figure 3.2. The Quantitation of the Concentration of a-Bungarotoxin 
in the Mono-iodinated Derivative of Radiolabelled Toxin
(a) The binding of mono-iodinated toxin to increasing quantities 
of Torpedo receptor in the presence of various quantities of 
unlabelled toxin:- • - •, 0 pmoles; o - o, 2 pmoles;
A - 4 , 4 pmoles; a - a , 8 pmoles.
The best fit was calculated for each slope from the relation­
ship: 3 (slope) =
ex
allowing zero to remain fixed. Symbols represent the mean 
values of triplicate determinations. S.E. < 10%.
(b) Slopes derived from (a) plotted against the concentration of 
unlabelled toxin. The intercept on the abcissa gives the 
quantity of a-Bungarotoxin present in 5yl of the radiolabelled 
derivative.
A value of O.56pmol/yl was obtained by linear regression analysis


















Table 3.1. The Biological Activity of Radiolabelled a-Bungarotoxin
Radiolabelled Species Biological Activity (%)
Unfractionated a-Bungaro­
toxin
43 - 72^ (14)
66*'h (1)
85 - 93^ (3)
Mono- 1-a-Bungarotoxin 62 - 70^ (5) 
88 - 92^ (3)
-a-Bungarotoxin >96= (3) 




a Bound and free toxin separated by ion exchange using DEAE 
cellulose discs.
b a-Bungarotoxin radiolabelled in this laboratory by the method 
of Vogel et al. (1972)
c Toxin-receptor complex separated from free toxin by gel filtration 
(H. Lotwick, personal cohnnunication) .
d Toxin-receptor complex separated from free toxin by millipore 
filtration (Jones and Thompson, 1980).
e Toxin receptor complex separated from free toxin by density gradient 
centrifugation (Gibson et al., 1976).
f Lukas et al. (1978).
The number of determinations is indicated in parenthesis.
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Table 3.2. The Immunological Activity of lodinated a-Bungarotoxin
Radiolabelled Species Immunological Activity (%)
Unfractionated- |- 
a-bungarotoxin
68 - 89 (12)
M o n o - 1-a-Bungarotoxin 85 - 90 (3)
The number of preparations are indicated in parenthesis.
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The Production of Anti-(a-Bungarotoxin) Antibodies
Fig. 3.3 shows the increase of anti-(a-Bungarotoxin) anti­
bodies in the serum of two New Zealand white rabbits in the course of
10 weeks following weekly injections of antigen. The titres in both 
of the animals reached a maximum level of 3ymoles per litre of serum
at eight weeks. Samples of serum were used for determining the
immunological activity of the iodinated derivatives of a-bungarotoxin,
The Immunological Activity of [^^^iJ-a-Bungarotoxin
The proportion of radioactivity precipitated in several pre­
parations of unfractionated and mono-iodinated toxin preparations by 
anti-(a-bungarotoxin) antibodies is shown in Table 3.2. Immunological 
activity is defined on page 4 2 . Preincubation of the antisera with 
unlabelled toxin or substitution of the immune serum with normal rabbit 
serum reduced the radioactivity to 5% of the total amount added.
g-Bungarotoxin Binding Assays
(i) Separation of Toxin-Receptor Complexes from Free Toxin
Unbound toxin was separated from the membrane fraction 
receptor-toxin complex by either centrifugation, filtration or 
ammonium sulphate precipitation. The results are shown in Table 3.3(a) 
Greatest reproducibility was achieved by using the centrifugation or 
filtration method as reflected by the standard errors. The centri­
fugation procedure was adopted for most experiments.
In the case of crude detergent extract, the ion exchange method 
gave a much lower estimate of the toxin binding activity than ammonium 
sulphate precipitation (Table 3.3(b)).
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(ii) Concentration of Membrane Protein
The relationship between toxin binding and the concentration of 
membrane protein was linear up to 2mg/ml (Fig. 3.4). At concentrations 
lower than 0.6mg/ml the levels of specific binding approached the mag­
nitude of error observed within quadruplicate determinations. For 
subsequent experiments, the concentration of protein in the P^ fraction 
was adjusted to within 2 and 3mg/ml.
The binding of toxin to detergent extracted receptor increased 
linearly with protein up to 5mg/ml (Fig. 3.5). For subsequent kinetic 
experiments the concentration of protein was adjusted to within 4 and 
5mg/ml.
The Stability of g-Bungarotoxin Binding Activity
(i) Human Foetal Brain
Particulate Fraction: No appreciable loss in toxin binding
activity was observed up to 4h after the preparation of the P^ fraction 
(Table 3.5, page 88). After 24h at either 4°C or 23=0 the apparent 
binding activity of the foetal preparations diminished by 48% and 
52% respectively. Frozen and unfrozen foetal brain tissue was found to 
bind similar amounts of -g-BgTx (Table 3.4) and a crude mito­
chondrial fraction (P^ ) stored for up to nine weeks at -80=0 showed 
no apparent loss in activity (Table 3.6). Frozen aliquots of the P^ 
fraction stored for up to two months were therefore employed in some 
experiments.
Orude Detergent Extract: The change in toxin binding activity and
crude detergent extract prepared is shown in Fig. 3.6, (page 90). Since 
the ammonium sulphate assay required 16h for the formation of a pre­
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cipitate, the loss of activity during this period was based on the 
original activity of the fraction measured by centrifugation. 
Although results indicate that less than 10% of the original activity 
is lost during this time, the comparison may not be accurate for the 
reasons stated on page 191.
(ii) Rat Brain
In rat brain P^ no loss in binding activity was observed after 











Fig. 3.3. The Production of Anti-(g-BgTx) Antibodies
The solid and empty circles represent the titre anti- 
(a-BgTx) antibodies present in the serum of two New Zealand 
white rabbits following repeated injections of antigen over 
a period of 10 weeks. Titres were measured one week after 
each injection. Points are the means of triplicate deter­
minations, S.E. <8%.
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Table 3.3. A Comparison of the Assay Methods Used to Determine the 
Binding of [^^^î]-a-Bungarotoxin to Human Foetal Brain
(a) Particulate Fraction (Pg)
Assay Method
j^^^;f|-a-BgTx Bound 
(fmol/mg protein ± S.E.)
Centrifugation 42 ± 2.7 (4)
Ammonium Sulphate 
Precipitation 54 ± 7.0 (4)
Filtration 45 ± 4.5 (4)
(b) Crude Detergent Extract of P^
Assay Method
-a-BgTx Bound 
(fmol/ml extract ± S.E.)
Ammonium Sulphate 
Precipitation
61.0 ± 5.6 (3)
Ion Exchange (DEAE) 7.7 ± 1.0 (2)
The number of determinations is shown in parenthesis.
85.






Foetal Brain as a Function of the Protein Concentration
1 2 3
Protein concentration (mg ml I
Binding is expressed as f moles of toxin specifically 
bound per ml of P^ membrane suspension.
Points are the means of quadruplicate determination ± S.E,
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Fig. 3.5. The Binding of r^^^f|-a-BgTx to the Crude Detergent 
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Protein concentration (mg ml"')
Binding is expressed as f moles of toxin specifically 
bound per ml of extract.
Points are the means of quadruplicate determinations 
± S.E.
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Table 3,4. A Comparison Between the Toxin Binding Activity in 
Frozen and Unfrozen Human Foetal Brain Tissue
Human Foetal Brain 
Tissue
a-BgTx Bound
(f mol/mg protein ± S.E.)
Unfrozen 
(13-17 weeks)
45.3 ± 3.8 (6)
Frozen
(13-15 weeks)
40.5 ± 2.5 (6)
Toxin binding activity was measured by centrifugation. 
The number of foetal brains is indicated in parenthesis
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Table 3,5. The Stability of |-a-Bungarotoxin Binding Sites







35 ± 3.0 
(2)
31 ± 4.6^ 18 ± 1.0^ 
(2) (2)




30 ± 1.2 
(2)
32 ± 3.2 26 ± 0.65 
(2) (2)
The results are expressed as f moles of ]-a-BgTx bound
specifically per mg protein ± S.E. (quadruplicate determin­
ations) .
The times at which toxin binding activity was determined after 
the preparation of the P^ fraction.
Membranes stored at 4°C. All other preparations were kept at 23°C,
The number of experiments is indicated in parenthesis.
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Fig. 3.6. The Stability of Detergent Solubilized a-Bungarotoxin 
Sites in Human Foetal Brain
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a-Bungarotoxin binding activity is expressed as fmol bound/ml of 
extract prepared from the fraction. Day 1 represents the 
initial activity observed 18h after preparation of the P^ fraction,
The extract was stored at 4 C.
Points are the means of quadruplicate determinations ± S.E.
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Table 3.6. The Stability of Human Foetal Brain Fraction
Stored at -80°C
Day Specific Binding (f mol/mg protein ± S.E.)
1 42.0 ± 1.0 ^ (2)
4 41.6 ± 4.0 (3)
9 39.6 ± 5.0 (3)
The P^ fraction was stored as a membrane suspension at a concentration 
of 1.6mg/ml in 50mM sodium phosphate buffer at -80°C.
Experiments were performed using a single neuronal preparation. Toxin 
binding activity was measured by centrifugation.
a Measurement taken before freezing.
The number of determinations (each in triplicate) is shown in parenthesis
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(x-Bungârotoxin Binding Activity During Development
a-Bungarotoxin binding levels were measured in the whole brains 
of foetuses aged between 10 and 28 week postmenstruum. Gestational 
ages of 13 weeks or older were assessed on the basis of brain weight 
(Winick, 1968) as shown in Fig. 3.7(b) on page 93. Younger 
foetuses were aged according to crown rump length (Arey, 1954) as 
shown in Fig. 3.7(a) on page 93.
The concentration of a-bungarotoxin binding sites in the brains 
of 16 human foetuses aged between 10 and 28 weeks is shown in Fig. 3.8(a) 
During the 10 to 25 week period, receptor density varied between 
l-2pmol/g wet weight. No marked change in the receptor density with 
development was observed.
The concentration of toxin binding in the particulate (P^) 
fraction as a function of protein is shown in Fig. 3.8(b). Of a total 
of 33 foetuses, the level of toxin binding varied between 20 and 
60 fmol/mg protein. No obvious trend in toxin binding activity with 
development was seen and binding levels often varied considerably 




(a) The Relationship Between Crown-Rump Length and the 
Gestation Period During the Development of the Human 
Foetus
The data were taken from Arey (1954) •
The crown-rump length is the measurement from the crown of the hemd 
to the rump of the foetus or embryo (England, 1983).
(b) The Relationship Between Brain Weight and Gestational 
Age During the Development of the Human Foetus
The filled circles represent the age of a single 
foetus determined by crown-rump length plotted 
against brain weight.
The open circles represent data obtained from 
Winick (1968).
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Fig. 3.8.
(a) The Concentration of a-Bungarotoxin Binding Sites in 
Human Brain
Binding experiments were performed on brain homogenates 
and toxin binding activity was determined by ammonium 
sulphate precipitation.
Each point represents a single foetus and is the mean 
of triplicate determinations S.E. < 14%.
(b) .The Binding of |-a-Bungarotoxin to the Particulate 
Fraction of Foetal Human Brain During Development
Binding experiments were performed using the membrane 
fraction.
Toxin binding activity was determined by centrifugation. 
Each point represents a single foetus and is the mean 
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Post- mortem Stability of Bungarotoxin Binding in Rat Brain,
Binding studies were performed on rat brains stored at room 
temperature (-=24*C) for Ih, 5h and 18h in polythene bags. One rat 
was used for each time point.
No change in toxin binding levels was observed up to 18h after 
death compared to the value obtained using a freshly killed animal.
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THE SUBCELLULAR FRACTIONATION OF BRAIN
Human foetal and rat brain homogenates were fractionated 
(Methods, page 44) according to the scheme shown on page 4 6. Of 
the primary fractions recovered (P^, P^, S^) the P^ was resolved 
further by density gradient centrifugation (Methods, page 45) and 
particulate material was collected by total or partial recovery 
as shown on pages 104 and 106. Total recovery involved collection of 
particulate material at the gradient interfaces and of the areas 
in between. The partial recovery scheme involved the collection of 
material at the gradient interfaces only.
(i) Rat Brain
Following centrifugation of (page 46) the crude mito­
chondrial fraction was recovered as a creamy-white pellet and the 
supernatant (S^) was almost devoid of particulate material. Fraction­
ation of P^ using a sucrose gradient resulted in the resolution of 
a distinct band at each of the two interfaces and a tan-coloured 
pellet. The bands were designated A,B and C.
(ii) Human Foetal Brain
The nuclear fraction (P^) of foetal brain demonstrated 
markedly different properties from that of rat brain. Difficulty 
in resuspending the foetal P^ pellet in buffer was often experienced 
because of its fibrous consistency. Centrifugation of the fraction 
resulted in a creamy white pellet (P^) and a supernatant (Sg) which, 
unlike rat brain 82» appeared to contain large amounts of particulate 
material. Fractionation of P2 using a sucrose density gradient resulted 
in the resolution of a minor band at the 0.32-0.8 interface and major 
band at the 0.8-1.2 interface. The bands were designated A, B and C.
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Unlike rat brain, fraction B was not sharply defined and sucrose 
below the 0.8-1.2 interface contained large amounts of particulate 
material as judged by its opacity. The mitochondrial fraction (C) 
was recovered as a tan-coloured pellet.
Recovery of Protein
(i) Human Foetal Brain
In foetal brain primary fractions most of the protein pre­
sent in homogenate (H) was found in the soluble fraction (Sg) and the 
lowest recovery was found in the crude mitochondrial fraction (Pg) 
(Table 3.8). Collection of the gradient fractions A B and C, by the 
total and partial recovery schemes resulted in a marked difference in 
the recovery of protein (Fig. 3.9). Collection of the whole gradient 
gave a recovery of 62% compared to 42% in which only discrete bands 
were removed. Significant amounts of protein were found in the super­
natants following centrifugation of the gradient fractions at lO^g 
(Table 3.8).
(ii) Rat Brain
In rat brain, almost equal amounts of protein were recovered 
in the three primary fractions (Table 3.9). The collection of gradient 
fractions A B and C resulted in a recovery of 81% (total recovery 
scheme) or 64% (partial recovery scheme)(Fig. 3.10).
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Recovery of Enzyme Activity
(i) Human Foetal Brain
The highest recovery of choline acetyltransferase activity 
was observed in fractions and the subsequent nerve ending
fraction B (Table 3.10(a)). Enzyme activity was enriched in fractions 
P2, B and the mitochondrial fraction C (Fig. 3.11).
The membrane markers adenylate cyclase and acetylcholin­
esterase were recovered mainly in the soluble fraction (S^) although 
activity was enriched in the P^ fraction (Figs. 3.16, 3.13). In the 
gradient fractions, most of the AChE activity was recovered in 
Fraction B and was enriched by almost two-fold. Adenylate cyclase 
was recovered in equal amounts in fractions A and B and an enrichment 
of the activity was observed in fraction A (Fig. 3.16). cAMP was 
measured from the standard curve shown in Fig. 3.15(a). The activity 
of adenylate cyclase in rat and human foetal brain homogenates over a 
period of 15 min. is shown in Fig. 3.15(b).
The mitochondrial marker, succinate dehydrogenase was 
recovered mainly in fractions P^ and C (Table 3.12(b)) although 
significant quantities were present in fractions and B. Activity 
was enriched by approximately four-fold in fractions P^ and C 
(Fig. 3.18).
The cytoplasmic marker lactate dehydrogenase was recovered 
mainly in the soluble and the subsequent mitochondrial fraction 
(Table 3.14). The highest enrichment of LDH activity was found in 
fractions P^ and C (Fig. 3.22). Rupture of the membranes using 
Triton X-100 showed that the highest proportion of occluded activity
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was associated with fractions and the nerve ending fraction B 
(Fig. 3.20). A significant proportion of occluded activity was also 
observed in fraction C. Of the total volume activity present in 
fractions and A, small amounts were often found to be occluded.
(ii) Rat Brain
Choline acetyltransferase activity was recovered mainly in 
fractions P^ and B (Table 3.11(a)) although the highest enrichment among 
the gradient fractions was observed in fraction C (Fig. 3.12).
The membrane markers adenylate cyclase and acetylcholinesterase 
were recovered mainly in fractions P^ and B (Tables 3.13(a), 3.11(b')) 
and a corresponding enrichment of activity was observed in these two 
fractions (Figs. 3.17, 3.14).
Succinate dehydrogenase exhibited the highest recovery in 
fractions P^ and C (Table 3.13(b)) and showed a corresponding enrich­
ment in these two fractions (Fig. 3.19). A significant quantity of 
enzyme activity was also recovered in fraction B.
The cytoplasmic marker, LDH, was recovered mainly in fractions 
P^ and the subsequent nerve ending fraction (Table 3.15) which also 
exhibited an enrichment in activity (Fig. 3.23). The highest proportion 
of occluded activity was associated with fractions P^ and B (Fig. 3.21).
A significant proportion of occluded activity was also observed in 
fraction C. Occluded activity was absent in fractions and A.
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Recovery of Ligand Binding Sites
(i) Human Foetal Brain
d-Bungarotoxin binding activity was recovered mainly in the 
soluble fraction and the nerve ending fraction (B)(Table 3.16(a)).
An enrichment of activity was found in fractions and B (Fig. 3.24). 
Similarly, the highest recovery of [^ h]-QNB binding activity was found 
in fractions and P^ and was correspondingly enriched in these 
fractions (Fig. 3.26). A slight enrichment was observed in fraction C.
(ii) Rat Brain
The highest recovery of a-bungarotoxin binding activity was 
found in fractions P^ and the subsequent nerve ending fraction B 
(Table 3.17(a)). A significant quantity of activity was also found in 
the soluble fraction, S^. Activity was enriched in fractions P^ and B 
(Fig. 3.25).
Q^ I^ I-QNB binding activity was recovered mainly in fractions 
P^ and B (Table 3.17(b)). An enrichment of activity was observed in 
fractions P^, A and B (Fig. 3.27).
Specific Activity of the Enzymes and Ligand Binding
On the whole, the specific activity of all the enzymes 
investigated in foetal brain was much lower than the corresponding 
activity in rat brain (specific activities are listed in the appropriate 
tables).
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Subcellular Fractionation of Human Foetal and Rat Brain
Figure Legend
1) From Tables 3.8 to 3.17, the % recovery and relative specific 
activities of each fraction are presented as histograms on the 
subsequent pages. The recovery of each fraction is expressed 
as the mean ± S.E. of the recoveries from the total homogenate 
in each individual preparation. Relative specific activity is 
expressed as:
% recovery of activity in each fraction
% recovery of protein in each fraction
thus giving a measure of the enrichment of activity in each 
fraction relative to the homogenate.
2) From Figures 3.9 to 3.27, the number beneath parenthesis enclosing 
P^, P^ and S^ represents the mean % recovery from the original 
homogenate. The numbers beneath parenthesis enclosing fraction A, 
B and C represent mean % recovery from the P^ fraction.
3) In the case of all figures and tables, n denotes the number of 
separate determinations.
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Table 3.7. The Concentration of Protein with Respect to the Wet 
Weight of Tissue in Rat and Human Foetal Brain
Rat Brain Human Foetal Brain
101 ± 8.3(5) 38.2 ± 2.0(14)
The results are expressed as og/g ± S.E.
The number of preparations is indicated in parenthesis
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Table 3.8. The Recovery of Protein from Human Foetal Brain 
Subcellular Fractions
Primary Fractions % Recovery ± S.E.
Homogenate (H) 100
Nuclear (P^) 30 ± 2.2
Crude Mitochondrial (F^) 16 ± 2.0
Cytoplasm, Microsomal (S^) 46 ± 2.2
Gradient % Recovery from
Recovery Scheme Fractions
5 A 17 ± 3.3
Total (1 X 10 g Pellet) B 27 ± 1.3
C 18 ± 2.6
A 10 ± 0.5
Total (Supernatants) B 10 ± 1.0
C 5 ± 1.0
c A 9 ± 2.0
Partial (1 x 10 g Pellet) B 19 ± 2.1
C 14 ± 2.0
A 7 ± 2.0
Partial (Supernatants) B 4 ± 1.3
C 2 ± 0.5
n = 5
The collection of gradient material (total and partial recovery 
schemes) are described on page 45 and is illustrated diagramatically 
in Fig. 3.9.
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Recovery scheme: Total Partial
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Table 3.9. The Recovery of Protein from Rat Brain 
Subcellular Fractions
Primary Fractions % Recovery ± S.E.
Homogenate (H) 100
Nuclear (P^) 30 ± 4
Crude mitochondrial (P^) 31 ± 3
Cytoplasm, Microsomal (S^) 29 ± 2
Gradient Fractions % Recovery from P^ ± S.E.
Total
1 X lO^g Pellet
A 25 ± 0.5
B 43 ± 1.0
C 13 ± 2.0
Partial
1 X lO^g Pellet
A 14 ± 3.0
B 14 ± 3.0
C 13 ± 3.0
n = 5
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Table 3.10. The Recovery and Distribution of Choline Acetyltransferase 
and of Acetylcholinesterase Activity in Human Foetal Brain 
Subcellular Fractions 
(a) Choline Acetyltransferase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 3.4 ± 0.44
24 ± 1.7 0.8 3.3 ± 0.46
39 ± 6.5 2.4 9 ± 3.9
«2
40 ± 0.8 0.9 3 ±0.76
A 15 ± 2.5 0.8 19 ± 5.8
B 39 ± 4.2 2.1 20 ±4.4
C 26 ± 3.2 2.3 15 ± 3.2
a ymoles/h/g protein ± S.E. n = 8 
(b) Acetylcholinesterase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 30 ± 2.6
8 ± 2.8 0.3 10 ± 1.8
^2
27 ± 4.5 1.7 34 ± 3.3
^2
46 ± 1.3 1.0 32 ± 1.0
A 4 ± 0.3 0.4 42 (22->75)
B 33 ± 7.0 1.8 30 ± 2.7
C 11 ± 3.1 0.8 22 ± 3.0
b ymoles/min/g protein ± S.E. Figures in parenthesis indicate the 
limits of a range of values, n = 8
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Table 3.11. Recovery and Distribution of Choline Acetyltransferase 
and of Acetylcholinesterase Activity in Rat Brain 
Subcellular Fractions
(a) Choline Acetyltransferase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity*
H 100 1.0 9 ± 1.3
26 ±5.0 0.8 9 ± 3.6
^2
67 ± 7.3 2.2 16 ± 1.0
«2
30 ± 4.6 1.0 16 ± 2.6
A 11 ± 3.3 0.7 15 ± 6.0
B 44 ± 4.0 1.2
18 ± 2.8
C 25 ± 1.6 1.9
32 ±5.0
a ymoles/h/g protein ± S.E. n = 3
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 95 ± 5.5
?1
23 ± 4.0 0.7 106 ± 19.8
^2
44 ± 5.0 1.4 120 ± 12.9
^2
20 ± 0.8 0.7 4 ± 0.4
A 10 ± 1.0 0.7
114 ± 28.0
B 58 ± 2.0 1.6
406 ± 43.5
C 5 ± 0.6 0.4
44 ± 11.0
b ymoles/min/g protein ± S.E. n - 3
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Fig. 3.12. Choline Acetyltransferase, Rat Brain
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Fig. 3.13. Acetylcholinesterase, Human Foetal Brain
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Table 3.12. The Recovery and Distribution of Adenylate Cyclase and of 
Succinate Dehydrogenase Activity in Human Foetal Brain 
Subcellular Fractions 
(a) Adenylate Cyclase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity*
H 100 1.0 128 ± 18
19 ± 2.6 0.6 51 ± 17
^2
30 ± 5.2 1.9 271 ± 17
«2 53 ± 5.0
1.2 162 ± 42
A 19 ± 3.1 2.1 486 ± 38
B 19 ± 1.5 1.0 191 ± 9
C 11 ± 2.7 0.8 117 ± 26
a pmoles/min/mg protein ± S.E. n = 8
(b) Succinate Dehydrogenase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 1.9 ± 0.10
13 ± 2.7 0.4 1.2 ± 0.12
^2
58 ± 4.0 3.6 7.0 ± 0.62
®2
16 ± 3.3 0.3 0.8 ± 0.21
A 2 ± 0.5 0.1 3.7 ± 0.70
B 13 ± 6.0 0.6 8.2 ± 3.00
C 58 (40 83) 4.1 13.0 ± 1.47
b ymoles min/g protein ± S.E. Figures in parenthesis indicate the 
limits of a range of values. n = 8
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Table 3.13. The Recovery and Distribution of Adenylate Cyclase
and of Succinate Dehydrogenase Activity in Rat Brain 
Subcellular Fractions
(a) Adenylate Cyclase
Fraction‘ % Recovery ± S.E.
Relative Specific 
Activity Specific Activity*
H 100 1.0 332 ± 33
17 ± 2.7 0.6 188 ± 18
46 ± 5.0 1.5 512 ± 50
»2
19 ± 3.2 0.7 243 ± 39
A 5 ± 0.4 0.4 207 ± 22
B 52 ± 2.0 1.4 656 ± 24
C 4 ± 0.5 0.3 178 ± 30
a praol/min/ mg protein ± S.E. n = 6
(b) Succinate Dehydrogenase
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 6.4 ± 0.91
^1
21 ± 1.0 0.7 7.6 ± 0.4
^2
65 ± 5.0 2.0 18.3 ± 3.5
2^ 3 ± 1.0
0.1 1.6 ± 0.26
A 2 ± 1.0 0.1 3.8 ± 1.5
B 34 ± 1.5 0.9 26.5 ± 7.0
C 52 ± 3.5 4.0 95 ± 4.4
b ymol/min/g protein ± S.E. n = 3
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Fig. 3.15.
(a) Cyclic AMP Standard Curve
Cq (zero standard) is the amount of cAMP bound in the 
absence of standard or unknown.
C^ is the amount of radiolabelled cAMP bound in the 
presence of standard. Points are the means of 
triplicates. S.E. < 3%. The slope was calculated as 
shown on page 76. Slope =0.25, S.E. =0.04.
(b) The Activity of Adenylate Cyclase in Brain Homogenates 
The samples of enzyme in both rat (o - o) and human 
foetal • - • brain homogenates contain equivalent amounts
of protein. Activity was measured over a period of 15 mins. 
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Table 3.14. Recovery and Distribution of Lactate Dehydrogenase
Activity in Human Foetal Brain Subcellular Fraction







H 100 1.0 284 ± 35 13 (041)
11 ± 2.7 0.3 111 ± 20 7 (013)
^2 35(12+64)
2.1 257 ± 36 73(52+88)
^2
46 ± 3.6 0.8 357 ± 39 3(0+6)
A 6 ± 1.5 0.6 131 ± 20 1(04)
B 10 ± 1.4 0.5 112 ± 22 89 ± 1.7
C 35(5+55) 2.5 142 ± 29 29(4+85)
a ymol min/g protein ± S.E. Figures in parenthesis indicate limits of 
a range of values, n = 8.
Fig. 3.20. The % of Occluded LDH Activity
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Table 3.15. Recovery and Distribution of Lactate Dehydrogenase 
Activity in Rat Brain Subcellular Fractions







H 100 1.0 541 ± 28 21 (6+38)
17 ± 3.0 0.5 263 ± 29 16 (0+40)
^2 43 ± 3.6 1.4 1138 ± 227 82 (55+95)
®2 28 ± 7.0 1.0 948 ± 135
0
A 10 ± 2.0 0.7 1244 ± 136 0
B 54 ± 2.0 1.5 2032 ± 193 85 (75+93)
C 12 ± 3.7 0.9 806 ± 36 22 (0+45)
a ymoles min/g protein ± S.E. Figures in parenthesis indicate limits 
of a range of values, n = 6.
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Table 3.16. Recovery and Distribution of f^^^f]-a-Bungarotoxin and 
iTj-QNB Binding in Human Foetal Brain Subcellular
Fractions
(a) g-BgTx Binding
Fraction % Recovery ± S.E.
Relative Specific 
Activity Specific Activity^
H 100 1.0 29 ± 5
21 ± 4.7 0.8 26(10+42)
^2 31 ± 1.5 1.9
53 ± 5.2
«2 41 ± 3.4 0.8 34 ± 4.4
A 7 + 0.6 0.8 58(40+97)
B 27 ± 1.7 1.4 80(49+151)
C 7 ± 1.3 0.5 31 ± 6.0
a Specific binding, f moles/mg protein ± S.E. Figures in parenthesis 
indicate limits of a range of values, n = 8
(b) QNB Binding
Relative Specific
Fraction % Recovery ± S.E. Activity Specific Activity
H 100 1.0 130 ± 2
20 ± 3.8 0.7 68(38+98)
32 + 7.0 2.0 247 + 35
2
So 35 + 2.4 0.8 135 + 92
A 9 ± 0.7 1.0 257 ± 61
B 32 ± 3.2 1.7 370 ± 42
C 16 ± 0.7 1.1 179 ± 48
b Specific binding, f moles/mg protein ± S.E. Figures in parenthesis 
indicate limits of a range of values, n = 5
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Table 3.17. Recovery and Distribution of f^^^f^~a~Bungarotoxin
and r^ H~j-QNB Binding in Rat Brain Subcellular Fractions
(a) g-BgTx Binding
Fraction % Recovery ± S.E. Relative Specific Activity Specific Activity^
H 100 1.0 43 ± 5.7
17 ± 1.0 0.6 34 ± 0.5
^2
38 ± 2.2 1.2 52 ± 7.2
®2 32 ± 2.8 1.0 56 ± 7.0
A 15 ± 0.3 1.0 45 ± 8.2
B 58 ± 4.0 1.6 82 ± 6.3
C 11 ± 1.0 1.0 32 ± 1.7
a f moles/mg protein ± S.E. n = 6
(b) QNB Binding




H 100 1.0 840 ± 46
’’i 17 ± 1.0
0.4 394 ± 51
^2
53 ± 0.5 1.7 1353 ± 75
=2 15 ± 4.0
0.5 318 ± 32
A 19 ± 2.5 1.3 2388± 188
B 57 ± 5.0 1.6 1264± 125
C 10 ± 2.2 0.7 328 ± 20
b f moles/mg protein ± S.E. n = 3
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Fig. 3.26. QNB Binding, Human Foetal Brain 
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An Examination of Subfractions A, B and C at the Electron 
Microscope Level
Rat Brain
An examination of fraction A is shown in Plate 1(a). The 
electron dense concentric rings are characteristic of myelin fragments.
An examination of fraction B revealed that the largest 
number of identifiable profiles shown in plate 1(b) consisted of 
membrane bound structures containing vesicles and frequently mitor 
chondria. Greater detail of the synaptic vesicles was perceived at 
higher magnification (Plate 1(d)),
Aa examination of fraction C is shown in Plate 1(c). The 
internal structure, seen clearly in Plate 1(e) was found to be 
reasonably well preserved. Very few membrane profiles other than those 
identifiable as mitochondria were observed.
Human Foetal Brain
An examination of fraction A is shown in Plate 2(a). This
fraction contained numerous membrane sacs, most of which were devoid
of an internal structure or matrix. The characteristic electron dense 
myelin fragments were absent in this fraction.
An examination of fraction B is shown in Plate 2(b-d). Most
of the membrane profiles contained a granular matrix and a few vesicles
At higher magnification the existence of two types of vesicle was 
observed. Spherical agranular vesicles and dense cored vesicles were 
observed in Plate 2(c). Some of the membrane profiles were found to 
contain neurofilaments and large numbers of mitochondria (Plate 2(d).
132.
An examination of fraction C is shown in Plate 3(a-b). Very few 
mitochondria with intact inner membranes were observed and the 
majority of these structures showed signs of swelling (Plate 3(b)). 
Profiles similar to the majority found in fraction B also appeared 
to sediment in fraction C.
133.
PLATES 1 - 5
PLATE 1
Sucrose density gradient subcellular fractions prepared 
from adult rat brain as described on page 44. The processing of 
samples for electron microscopy is described on page 54.
(a) Fraction P\A: The myelin profiles are clearly identifiable
as electron dense concentric rings. Scale bar = 0.5p
(b) Fraction P^B: The numerous synaptosomal profiles (S) contain
synaptic vesicles and often a mitochondrion (M). Scale bar 
= 0.4y
(c) Fraction P^C; This fraction is composed almost exclusively of 
mitochondrial profiles. A small proportion of the structures 
are devoid of the internal membrane structures.
Scale bar = 0.2y
(d) Fraction P B^; A synaptosomal profile packed with synaptic 
vesicles (SV). M = mitochondrion. Scale bar = ly
(e) Fraction P C^; Mitochondrial profiles, showing a reasonable 
preservation of the inner membranes. Scale bar = 0.5y






Sucrose density gradient subcellular fractions from 
human foetal brain.
(a) Fraction P^A; Characteristic nyelin profiles are absent, 
Identifiable membrane profiles either possess a granular 
matrix or are devoid of electron dense material.
Scale bar = 0.5y
(b) Fraction P^B; Numerous synaptosome-like profiles (S) 
are present which possess a granular matrix and often a 
mitochondrion. V = vacuole. Scale bar = 0.6y
(c) Fraction P B^: Few synaptic vesicles (SV) are present
throughout the granular matrix. Two types of vesicles 
are identifiable, those possessing an electron dense core 
(DCV) and those of the round type with an electron-lucent 
core (SV). VP = vesicular profile. Scale bar = 0,35y
(d) Fraction P^B; Synaptosome-like profiles showing the 
presence of ribosomes (R) and neurofilaments (NF).









Sucrose density gradient subcellular fractions from
human foetal brain.
(a) Fraction P C^. The majority of recognizable mitochondrial
profiles (M) are devoid of the inner membranes and show 
signs of swelling. Membrane profiles of non-mitochondrial 
origin and electron dense bodies are also evident.
(b) Fraction P_C. A mitochondrion (M) devoid of the inner
 1—
membrane lies adjacent to another in which the internal 
structures are preserved. Contamination of this fraction 
by synaptosome-like profiles (S) is evident.
Scale bar = 0.2y
Sections of human foetal cortex cut from fixed tissue
blocks.
(c) Frontal cortex: Scale bar = 2y
(d) Frontal cortex; In places, membrane profiles are poorly 
defined and exhibit an irregular, wavy appearance.
Rosettes of ribosomes (R) and numerous filamentous 
structures are present. N = a cell nucleus containing
electron dense chromatin (C). Scale bar = ly
' t ■ w .
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Plate 3
PLATE 4
Sections of human foetal cortex cut from fixed tissue
blocks and processed as described on pages 54 and 65.
(a) Parietal cortex; The membranous profiles are poorly defined
in places and the majority of the structures contain a 
granular matrix and occasionally spherical agranular 
vesicles. Few mitochondria are present. Scale bar = 0.4y
(b) Parietal cortex; Arrow denotes thickened membrane profiles
which may be a synapse. Scale bar = 0.5y
(c) Parietal cortex; Arrow denotes thickened membrane profiles
between which cleft material is evident. Scale bar = O.ly
Plate 4
PLATE 5
Sections of human foetal cerebellar cortex cut from 
fixed tissue blocks.
(a) Cerebellar cortex: Arrow denotes thickened membrane profiles. 
Numerous ribosomes (R) are present in the form of rosettes. 
Scale bar = 0.5y
(b) Cerebellar cortex; Arrow denotes symmetrically thickened 
membranes. N = nucleus. Scale bar = 0.25y
(c) Cerebellar cortex: Upper arrow denotes symmetrically 
thickened membrane profiles in the form of a regular array 
of electron dense structures projecting into the cytoplasm. 
Cleft material is evident. Lower arrow denotes asymmetrically 
thickened membrane profiles. A structure resembling a dense 
cored vesicle (DCV) and numerous ribosomes (R) are present. 
Scale bar = 0.15y
(d) Cerebellar cortex; Cr = centriole, N = nucleus.





QUANTITATIVE STUDIES OF a-BUNGAROTOXIN BINDING
Binding of [^^^i|-a-Bungarotoxin to Human Foetal Brain at Equilibrium
(i) Membrane Bound Receptor
The specific component of [^^^^-u-BgTx binding to the 
fraction was saturable over the concentration range investigated 
(Fig. 3.28).
The linear plot determined by Scatchard analysis in 
Fig. 3.29 was indicative of a single class of a-toxin binding sites
-9
with an apparent of 3.5 x 10 M (mean of five experiments). 
Specific binding constituted between 30 and 45% of the total.
(ii) Detergent Solubilized Receptor
Saturable binding was observed over the concentration range
investigated (Fig. 3.30(a)) using a crude detergent extract of P^ .
Scatchard analysis shown in Fig. 3.30(b) was indicative of a single
class of toxin binding sites and the apparent was calculated to be 
-92.4 X 10 M from a mean of three experiments.
The difference between the mean values of the K^s determined 
for the membrane bound and detergent solubilized preparations were 
considered to be within experimental error. Hill plots constructed 
for membrane bound and solubilized receptor were linear with regression 
coefficients of 0.94 and 0.96 respectively.
135.
Fig. 3.28 Binding of [^^^l|-a-BgTx to the P_ Fraction of Human Foetal
Brain at Equilibrium (23°C)
Receptor concentration, O.lnM 
■ Total binding
0 Non-specific binding estimated in the presence of
"5
unlabelled toxin (10 M)
# Specific binding (Total minus non-specific)
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Fig. 3.30. Binding of a-BgTx to a Crude Detergent Extract
of Foetal Brain Fraction at Equilibrium (23°C)
(a) Specific binding of a-BgTx to crude detergent
extract. Non-specific binding was determined in the 
presence of unlabelled toxin (10 ^M). Points are the 
means of triplicate determinations. S.E. < 10%.
The insert represents a Scatchard plot of the data. 
Kj^ (app) = 3.4nM B^^^ = 0.24 p moles per ml of extract
(b) Hill plot of the specific binding of -a-BgTx to
crude extract = 0.96
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Determination of the Association Rate Constants (k + 1)
(i) Membrane Bound Receptor
The interaction between [^^^l]-a-Bungarotoxin and membrane 
bound receptor is shown in Fig. 3,31. A 50-fold excess in the concen­
tration of toxin over receptor sites fulfilled the conditions necessary 
for data to be analysed by a pseudo-first order method (Bylund, 1981).
A pseudo first order log plot of the data in Fi&. 3.31 is shown in 
Fig. 3.32. The linearity of the slope was indicative of a simple bi-
molecular reaction and the observed on rate (k , ) was calculated to beob
0.14 min The association rate constant (k + 1) was calculated from
the relationship:
k + 1 = k , - k-1 = 2.3 X lO^M ^sec  ^
ob______
4
where k - 1 = dissociation rate constant
= concentration of [^^^î]-a-BgTx.
The value of k - 1 was determined by the method described
on page 59*
(ii) Detergent Solubilized Receptor
Association rates were determined at four different concen­
trations of radiblabelled toxin (Methods, page 57). All pseudo-first 
order plots exhibited monophasic association over the time period
investigated (Fig. 3.33). The value of k + 1 was calculated to be 
5 -1 -12.6 X 10 M sec from the slope of k^^ with respect to the concen­
tration of toxin as shown in Fig. 3.34. From the same plot, the inter­
cept on the ordinate which corresponded to the dissociation constant
"A 1










Time (m in )
The specific binding of -g-Bungarotoxin to human foetal
membranes with respect to time. Receptor concentration 
O.lnîl, toxin 5nM. Non-specific binding was determined in the
-5
presence of 10 M unlabelled toxin. 100% bound was taken as 
toxin binding observed at equilibrium where t = 2h. Points 









Time (m in i
Pseudo first order log plot of the data from
Fig. 3.31. is the toxin binding observed at
equilibrium and B is the amount of toxin bound at
-1
various time points. Slope (k^^) = 0.14min
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Determination of the Dissociation Rate Constant (k - 1)
(i) Membrane Bound Receptor
The dissociation of the toxin receptor complex is shown
“4 “ 1
in Fig. 3.35. The value of k - 1 was calculated to be 9.2 x 10 sec
from the relationship:
In ^^B = ^ k - I't
o
where B = Toxin bound at zero time 
o
B = Toxin bound at time t 
k - 1 = dissociation rate constant
t = Time (sec)
From the relationship:
k - 1 = 0.693 Ti = 12 min.
-----------------  » 5
T.
The T^ is the time taken for 50% of the toxin-receptor complex to
2
dissociate.
(ii) Detergent Solubilized Receptor
Dissociation of the [^^^î]-a-BgTx-receptor complex was biphasic 
(Fig. 3.36). Up to 75% of the complex had dissociated in 20 min. and a 
further 10% in the next 4h. Rate constants were calculated to be
—•A — 1 “ 5
9.8 X 10 sec and 2.9 x 10 sec from the fast and slow phases
respectively. The rate constant determined for the rapid phase closely 
agreed with the value of k - 1 determined from the association rate plots 
(page 146). The T^ was calculated to be 11.2 min.
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Fig. 3.33. Pseudo-First Order Log Plots for the Rate of
Association of [^^^fl-a-BgTx to Detergent Extracted 
Foetal Brain Receptor at Various Radiolabelled Toxin 
Concentrations
B^ is the specific binding of toxin observed at 
equilibrium. B is the amount of toxin specifically bound at a 
particular point in time. Receptor concentration is 0.25nM.
(A) 4nM; (B) 6nM; (C) 8nM; (D) lOnM. Slopes were calculated 
to be: (A) 0.13min  ^ (B) 0.15min  ^ (C) 0.17min  ^ (D) 0.22 min 














Fig. 3.34. The Relationship Between the Values of and the




Each point represents a mean value for from
three separate experiments. S.E. < 3%.
Intercept is the dissociation rate constant,
k - 1 = 0.053 min The slope is the association
-1 , -1







Dissociation of -a-BgTx from Membrane Bound
Receptor in Human Foetal Brain
is the specific binding of -a-BgTx observed
at equilibrium. B is the amount of -ct-BgTx
specifically bound at various times after the addition
_5
of excess unlabelled toxin (10 M). From the slope of
In ^^B V time, k - 1 = 0.061 min ^. Points are the 
o










Dissociation of the -a-BgTx-Detergent Extracted
Receptor Complex in Foetal Brain
Receptor concentration, 0.05nM, toxin 5nM. is the
j 25 -i
specific binding of |_ iJ-n-BgTx observed at equilibrium. B 
is the amount of -a-BgTx specifically bound at various
times following the addition of excess unlabelled toxin
15 -1
(10 M). From the slope of In B/B^ v  time: k - 1 = 0.072min
-3 -1
for the initial phase and 1.74 x 10 sec for the second 
phase. Points are the means of triplicate determinations.
S.E. < 8%.
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Calculation of the Intrinsic Dissociation Constant
The intrinsic dissociation constant (K^) can be derived 
from the on and off rate constants.
[Rl + s w  M
k - 1
Where [r | = Concentration of toxin binding sites
[F| = Concentration of [^^^f|-ci-BgTx
[RL_| = Concentration of Receptor-Ligand Complex 
k + 1 and k - 1 are the association and dissociation rate 
constants respectively.
= k - 1 
k + 1
-9A value of 4.0 x 10 M was calculated for membrane bound 
receptor which closely agrees with the value determined by equilibrium 
studies.
“9A of 3.3 X 10 M was calculated for detergent solubilized
receptor. For comparison, a list of the kinetic constants is presented 
in Fig. 3.18 on page 151.
Determination of the IC^^ Values for the Inhibition of |-g-Bungaro-
toxin Binding-by Various Drugs
rl25 -I
Semi-log plots of the specific binding of |_ iJ-a-BgTx to 
human foetal fraction in the presence of increasing concentration of 
various drugs are shown in Fig. 3.37. A list of IC^^ values of all the 
drugs tested is presented in Table 3.19.
The most effective inhibitors of radiolabelled toxin binding 
were unlabelled toxin and nicotine, d-tubocurarine and gallamine were 
less potent with IC^^ values in the yM range. Carbachol, benzoquinonium.
150.
décaméthonium and atropine only inhibited toxin binding at concen-
-4
trations greater than 10 M. Least effective were the local anaes­
thetics, procaine and lignocaine and hexaméthonium, a ganglionic 
blocker.
151.
Table 3.18, Kinetic Constants for the Binding of -g-Bungaro-




S -1 -1 
(x 10 M sec )
k - 1
-A -1
(x 10 sec ) (x
U
(min)














Binding assays were performed at 23 C. 
a - Determined by equilibrium studies
b - Determined from the on-rate at various concentrations 
of [^^^f|-a-BgTx.
The number of determinations is indicated in parenthesis.
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Fig. 3.37. The effect of various drugs on the binding of -g-BgTx
to foetal fraction at equilibrium
Receptor concentration O.lnM, Toxin 5hm
The % [^^^:Q-a-BgTx bound refers to the specific binding
where 100% was taken as the total. Non-specific binding
, • "A •
was measured in the presence of 10 M toxin or 10 M nico­
tine and zero was taken as the maximum amount of non-specific 
binding.
# a-BgTx 
□  Nicotine 
■  D-Tubocurarine 
A  Carbachol 
0 Atropine 
A  Décaméthonium
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Table 3.19. Values of Various Drugs for the Inhibition of
[^^^ij-Bungarotoxin Binding to Foetal Brain Membranes
DRUG IC^Q (M)
a-Bungaro toxin 4.8 X loT* (3)
Nicotine 2.0 X 10-8 (2)
d-Tubocurarine 1.2 X 10-5 (3)
Gallamine 3.3 X 10-8 (3)
Carbachol 6.6 X 10-4 (2)
Benzoquinonium 1.7 X 10-4 (3)
Décaméthonium 6.3 X 10-4 (2)
Atropine 2.6 X 10-4 (3)
Eserine 8.5 X 10-4 (2)
Hexame thonium > 10
3 (2)




Mecamylamina 7.4 X 10”‘* (3)
The number of experiments is indicated in parenthesis.
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The Regional Distribution of [^^^î]-a-Bungarotoxin in Rat Brain 
(i ) Autoradiographic Analysis
The structural organization of the sections shown in Plate 6 
is illustrated in Fig. 3.38 on page 158. Injections of o-Bungaro- 
toxin were delivered into the ventricle marked in Fig. 3.38 (a).
Evidence for toxin binding was investigated in the hippocampus, 
hypothalamus, cerebellum and the spinal cord. Plate 6 (a) shows the 
distribution of -a-BgTx in the hippocampal formation. The
density of the silver grains photographed using dark field optics 
reflects the density of toxin binding sites in the areas examined.
Heavy labelling was observed in the outer portion of the stratum 
oriens (gO) and a more diffuse patch of labelling was present in the 
dentate gyrus (DG). Plate 6 (b) shows the labelling of the supra- 
chiasmatic nuclei in the hypothalamic area of rat brain. In the 
cerebellum and spinal cord, only background levels of silver grains 
were observed. Sections taken from animals which had received injections 
of unlabelled toxin prior to the labelled species, exhibited background 
levels of labelling only.
ii ) Toxin Binding Activity
The levels of f]-a-BgTx bound specifically to various 
regions in rat brain is shown in Table 3.20 on page 156. The highest 
density was observed in the superior colliculus and the lowest in the 
striatum and cerebellum.
156.
Table 3.20. Regional Distribution of -a-Bungarotoxin
Binding Sites in Rat Brain
Region Concentration of Sites 
(fmol/mg protein ± S.E.)
Cerebral Cortex 16.0 ± 1.3 (3)
Hippocampus 28.0 ± 5.0 (3)
Striatum 10.5 ± 1.5 (5)
Spinal Cord 11.6 ± 0.4 (2)
Hypothalamus 19.0 ± 1.9 (2)
Cerebellum 7.3 ± 0.7 (2)
Superior Colliculus 45.0 ± 1.0 (2)
Values represent the amount of toxin bound specifically to the 
particulate fraction.
The number of determinations is indicated in parenthesis.
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Fig. 3.38. The Appearance of Adult Rat Brain Sectioned Coronally
at Two Different Levels. (Reproduced from Pelligrino et al.,1979)




pvg Periventricular grey substance
mm Mammillary bodies
mp Posterior mammillary nucleus
(b) cc Corpus callosum
cpu Caudate putamen
mpo Mid preoptic area
ca Anterior commisure
V Ventricle
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rl25 -|The Regional Distribution of [_ I_|-a-Bungarotoxin Binding in Human
Foetal Brain
Autoradiographic Analysis
The distribution of a-toxin binding in the L4 region from 
the spinal cord of a 14 week old foetus is shown in Plate 7(a).
For reference purposes, the central canal (c) is marked on the auto­
radiographs. The heaviest labelling was observed in the vicinity of 
the dorsal horn (Plate 7 (a)). With reference to the structural 
organization of the spinal cord at 13 weeks (Fig. 3.39), the silver 
grains appeared to overly the dorsal horn and possibly the deeper 
layers. A small cluster of silver grains, bilaterally distributed, 
was observed in the ventral horns. Sections pre-treated and co­
incubated with unlabelled toxin exhibited background levels of 
labelling (Plate 7 (b)).
Toxin Binding Activity
The concentration of toxin binding sites measured in the 
cerebral cortex, cerebellum and spinal cord is shown in Table 3.21 
on page 160. The cortex exhibited the highest density of toxin 
binding sites and appreciable levels were found in the spinal cord.
160.
Table 3.21. Regional Distribution of -g-Bungarotoxin
Binding Sites in Human Foetal Brain (15 weeks)
Region
Concentration of Sites 
(fmol mg/pmol)
Cortex 27.2 ± 2.3 (2)
Cerebellum 8.0 ± 1.0 (2)
Spinal Cord 21 ± 1.5 (2)
Values represent the amount of toxin bound specifically to the 
particulate fraction.
Results are the means of triplicate determinations S.E. < 8%. 
The number of preparations is indicated in parenthesis.
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Fig. 3.39. The Organization of the Human Spinal Cord at 13 weeks 
Gestational Age; A Coronal Section.
(Reproduced from Craigmyle and Presley, 1975)
Dorsal raphe 
Dorsal grey column 
Lateral grey column 
Ventral grey column 
Central canal 





PLATES 6 - 7
PLATE 6
Frozen sections cut from rat brain treated with 
-a-BgTx. Sections were processed as described on page 63 
and viewed using darkfield optics.
(a) Hippocampus sectioned coronally at the level shown in 
Fig. 3.38 (a), page 158. V = ventricle, AL = alveus,
DG = dentate gyrus, P = pyramidal cell layer, SO = stratum 
oriens, V = ventricle. Scale bar = 0.18mm
(b) Hypothalamic region sectioned coronally at the level shown 
in Fig. 3.38 (b) page 158. OC = optic chiasm, SC = supra­
chiasmatic nuclei, V = ventricle. Scale bar = 0.18mm
Plate 6
PLATE 7
Frozen sections cut from the spinal cord of a 14 week 
old human foetus and treated with -a-BgTx, Sections were
processed as described on page 64 and viewed using dark field 
optics.
(a) Spinal cord sectioned at the level of L4. The appearance of 
the section is diagramatically represented in Fig. 3.39 
page 161, C= central canal, DH = dorsal horn. Arrows 
emphasise the clusters of silver grains present in the ventral 
horn. Scale bar = 0.2mm.
(b) Spinal cord sectioned at the level of L4 treated with 
unlabelled a-BgTx prior to the labelled species.
C « central canal. The broken line denotes the edge of the 




An Examination of Human Foetal Brain at The Electron Microscope Level 
The samples removed for study were taken from areas 1, 7 
and 10 shown in Fig, 2.2 on page 66, Plates 3-5 are found on page 133.
Area 1 (Frontal Lobe)
An examination of a sample of frontal cortex is shown in 
Plates 3 (c-d). Nuclei (N) containing the electron dense cromatin 
are very clearly defined. Rosettes of ribosomes (R) and numerous 
filamentous structures were observed in Plate 3 (d). Large membranous 
profiles almost devoid of electron dense material can be seen in 
Plate 3 (c). There was no evidence for synaptic contacts in any of 
the sections examined.
Area 7 (Parietal Cortex)
The majority of structures observed in Plate 4 (a) possessed 
a granular matrix and a small number contained mitochondria and 
spherical, agranular vesicles. Thickened profiles were observed in 
Plates 4 (a) and 4 (b) as indicated by the arrows. The structures 
of which the thickenings form an integral part were devoid of synaptic 
vesicles and other subcellular organelles thus preventing elucidation 
of pre- and post-synaptic elements.
Area 10 (Cerebellar Cortex)
The ultrastructure of a sample of cerebellar cortex is shown 
in Plate 5 (a-d). Plate 5 (a-b) show symmetrically thickened membrane 
profiles (arrows) separated by a cleft containing dense material.
The symmetrical thickening in Plate 5 (c) consisted of a regular 
array of electron dense structures projecting into the cytoplasm 
(upper arrow). Structures resembling dense cored vesicles (DCV) were 
observed in the vicinity of the projections. An assymétrie junction
164.
is indicated by the lower arrow. Plate 5 (d) shows a cell body 
and nucleus (N). A centriole (Cr), which is often associated with 
contractile mechanisms was also observed.
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BINDING OF ANTI-(nAChR) ANTIBODIES TO HUMAN FOETAL BRAIN 
The Isolation of Anti-(nAChR) Antibodies from Myasthenic Plasma
The purification steps are described on page 70.
(i) Binding of AChR to a-Bungarotoxin Affinity Beads
The toxin binding activity of the crude detergent extract of 
human muscle before and after incubation with the affinity beads is 
shown in Table 3.22, page 167. The proportion of activity which 
remained in the non-bound fraction indicated that 54% of the receptor 
present is the crude detergent extract bound to the affinity beads.
(ii) Binding of anti-(nAChR) Antibodies to Toxin-Receptor Affinity Beads
Antibodies present in myasthenic plasma, the immunoglobulin 
fraction and the affinity purified fraction capable of binding to the 
nAChR from human muscle was measured by radioimmunoassay (page 69).
A 6% recovery of anti-(nAChR) antibodies from the plasma was found in 
the crude immunoglobulin fraction (Table 3.23). The recovery of protein 
was found to be 2.3% (Table 3.24) thus giving an enrichment of 2.5.
Following the incubation of the crude immunoglobulin fraction 
with the affinity beads the presence of anti-(nAChR) antibodies could 
not be detected in the non-bound fraction (Table 3.23). The elution 
of antibodies from the beads with potassium iodide resulted in the 
recovery of 38% of anti-(nAChR) antibodies applied to the column 
(Table 3.23). The recovery of protein indicated that a 95-fold enrich­
ment of anti-(nAChR) antibodies was achieved in the affinity puri­
fication step.
The proportion of toxin binding activity in the non-bound 
fraction indicated that less than 0.5% of the receptor bound to the
166.
column had dissociated following the addition of the crude immuno­
globulin fraction. A 247-fold enrichment of anti-(nAChR) antibodies 
from citrated plasma was achieved using the toxin-receptor affinity 
beads.
Recognition of the Human Neuronal a-Bungarotoxin Receptor by anti- 
(nAChR) Antibodies from Myasthenic Plasma
The antibody titre in Table 3.25 was obtained using a crude 
detergent extract of human foetal brain fraction (Methods, page 67). 
Citrated plasma and the crude immunoglobulin fraction exhibited low 
but detectable cross reactivity with the a-toxin receptor compared 
with two samples of normal human serum. Activity was not detected in the 
fraction prepared by affinity chromatography. The corresponding titres 
for a crude extract of human muscles are shown for comparison.
167.







Crude Extract 150 1.6 ± 0.2 (4) 240
Non-Bound
Fraction
150 0.7 ± 0.08 (4) 105
Salt Wash 100 <0.05 (4) <5
The non-bound fraction represents extract collected following 
separation from the affinity beads after incubation. Subsequent 
washing of the beads was designated the "salt wash".
The number of determinations is indicated in parenthesis.
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Thble 3.23. The Recovery of Antibody Activity Throughout the
























Not Detectable 0 0.03 ± 0.005^(3)
Antibody titre was measured employing the [^^^ij-a-BgTx-muscle nAChR 
complex as the antigen.
The non-bound fraction represents the C.I.F. collected following 
incubation with the affinity beads.
a Measured by ion exchange using DEAE cellulose discs.
The number of determinations is indicated in parenthesis.
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Table 3.24. The Recovery of Protein. Throughout the Isolation of 






























25 55 2.2 84
(from C.I.F.)
The figures in parenthesis indicate proportion used in the subsequent 
purification step.
The enrichment of anti-(nAChR) antibodies was used as an indication 
purity and could be calculated at each step from;-
% recovery of anti-(nAChR) antibodies
% recovery of protein
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Table 3.25. Radioimmunoassay of Myasthenic Plasma and the Subsequent 
Immunoglobulin Fraction, Employing the Human Neuronal 




























32.0 ± 2.5 18.0 ± 1.2 3.4 ± 0.24 <0.5%
The titres obtained for human foetal brain are the means of results 
obtained from three separate neuronal preparations.
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Attempted Purification of the a-Bungarotoxin Binding Component
Treatment of the P^ fraction with Triton X-100 (Methods, 
page 56 ) resulted in the extraction of 87% of the toxin binding 
activity associated with P^ (Table 3.26). The pellet recovered 
after clarification of the crude detergent extract by centrifugation 
retained only 3% of the activity originally present in the P^ 
fraction.
Attempts to purify the a-Bungarotoxin receptor using an 
affinity column (Methods, page 72) resulted in an extensive loss 
in toxin binding activity (Table 3.26). The maximum recovery of 
activity by carbachol elution in the course of four preparations was 
0.5% of the value determined for P^. The non-bound fraction and 
column washes retained in all preparations contained no detectable 
binding activity.
172.
Table 3.26. Recovery of a-Bungarotoxin Binding Activity from the




Crude Detergent Extract 87 (78-4-93) (4)
lO^g Pellet 3 ± 1.0 (2)
Carbachol Eluate 0.04-0.5 (3)
Non-Bound Fraction Not Detectable (3)
Affinity Column Wash Not Detectable (3)
a The binding activity determined for each preparation of P^
by ammonium sulphate precipitation. Subsequent recovery values 
are expressed as a percentage of the activity associated with 
each separate preparation of P^. Arrows indicate the limits of 
a range of values. Toxin binding activity in the detergent 
extracts was measured by ammonium sulphate precipitation.
In the case of the affinity purification studies the recovery 
values are a collective representation of the result (1) obtained 
in this study and results (2) obtained by S. Wonnacott (unpublished 





THE PREPARATION AND CHARACTERIZATION OF g-BUNGAROTOXIN 
Radiolabelling of a-Bungarotoxin
For the purposes of the kinetic experiments the mono- 
iodinated derivative of [^^^l]-a-bungarotoxin was employed in preference 
to the unfractionated preparation since it has been shown that progressive 
iodination of the protein results in a modification of the kinetic 
behaviour towards the nAChR (James et al., 1980). Significant differ­
ences in the affinities of the mono and di-iodinated forms for receptor 
have also been reported in rat brain (Lukas et al., 1981), chick brain 
(Wang and Schmidt, 1980) and chick muscle cultures (Vogel et al., 1972).
The biological activity of each radiolabelled preparation was 
estimated by measuring the amount of radioactivity capable of binding to 
an excess of nAChR from Torpedo. Gel filtration was used in preference 
to ion exchange as a means of separating unbound toxin from the toxin 
receptor complex because a higher recovery of the complex was achieved 
by this method (Results, page 78).
The lower recovery obtained by ion exchange may be due to in­
complete retention of the toxin-receptor complex by the DEAE cellulose 
discs even when the disc capactiy was doubled.
The biological activity of all the iodinated toxin preparations 
were lower than the values obtained for a commercial preparation of - 
a-BgTx. This may be due in part to the presence of coupled
to protein which can be separated from the radiolabelled toxin prior to 
the salt elution step on a CM cellulose column. A small peak of radio­
activity (see Fig. 3.1) constituting up to 7% of the total radioactivity 
applied to the column was observed in every preparation of the radio­
labelled derivatives . This observation could not wholly account for
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the differences in the activities between tritiated and freshly 
prepared mono-iodinated a-bungarotoxin assuming that all the free 
was washed from the ion-exchange column. Lower recoveries 
in the iodinated preparation may be due to a small degree of protein 
damage during the iodination procedure (Eterovic and Bennet, 1974) 
caused by chloramine T which is a strong oxidant. A progressive loss 
in the activity with storage of several iodinated preparations was 
observed if binding studies were performed using rat or human foetal 
neuronal membranes. Such observations could be a result of the 
increasing radiation damage to the toxin molecule. Eterovic and 
Bennet (1974) have reported that the nAChR from diaphragm muscle did 
not exhibit a similar ability to discriminate between different iodinated 
toxin preparations. These observations suggest that the neuronal toxin 
binding site in the preparations investigated may be particularly sen­
sitive to alterations in the toxin molecule brought about by radio­
labelling procedures or by radiation damage. For these reasons, binding 
assays were performed within 10 days of iodination of a-bungarotoxin.
The Toxin Binding Assay
The binding of -a-BgTx to particulate neural prepar­
ations in the majority of experiments was determined by centrifugation 
(Methods, page 40) because this procedure offered both a rapid and 
reproducible means by which bound and free toxin could be separated. 
Although vacuum filtration through glassfibre discs gave comparable 
results (page 84) it was found that the efficiency of the assay was 
reduced as membrane protein increased due to the limited capacity of 
the filters which resulted in a prolongation in the buffer wash. Pre­
liminary experiments have shown that the rate of dissociation of the 
toxin-receptor complex is rapid (Fig. 3.35, page 147), thus the time
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taken between the removal of free toxin and washing of the particulate 
matter was kept to a minimum. The period of time in which dissociation 
can take place during the centrifugation procedure did not exceed 
1.5 min so it was estimated that under these conditions, not more than 
10% of the toxin specifically bound was likely to have dissociated 
from the receptor.
Ammonium sulphate precipitation has been used to determine 
the toxin binding activity in soluble (Moore and Brady, 1977) and 
particulate (Ben-Barak and Dudai, 197 9) brain fractions. Poor 
reproducibility was frequently encountered using this method in samples 
containing particulate material (Table 3.3, page 84). Despite such 
variability, this method was chosen for measuring the density of a-toxin 
binding sites in human foetal brain because ammonium sulphate will 
precipitate receptor-toxin complexes present in the soluble fraction 
of a homogenate.
Soluble complexes cannot be recovered by centrifugation or 
filtration and subcellular fractionation studies have shown that the 
soluble (S^ ) fraction accounted for 46% of the toxin binding activity 
in the homogenate (Table 3.8, page 103).
The DEAE cellulose assay (page 40) has been used for measuring 
the toxin binding activity in detergent extracts prepared from rat brain, 
a procedure based on the findings of isoelectric focussing studies which 
have demonstrated that the neuronal toxin receptor is an acidic macro­
molecule (Lowy et al., 1976; Seto et al., 1977; Oswald and Freeman, 
1979). Measurement of the toxin binding activity in a crude detergent 
extract of foetal brain by this method resulted in very poor recovery of
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the toxin receptor complex compared with parallel determinations using 
the ammonium sulphate assay. The low activities are likely to result 
from competition by the non-receptor protein present in the extract 
for the DEAE cellulose. A similar problem was encountered in studies 
on the nAChR from human skeletal muscle (Stephenson, 1980) . For this 
reason, subsequent determinations of toxin binding activity in crude 
detergent extracts were measured by ammonium sulphate precipitation.
This procedure was found to be suitable for the determination of the 
kinetic properties of solubilized receptor since the reproducibility 
was comparable to that of the centrifugation method. An important 
consideration, however, had to be taken into account. Stephenson 
(1980) reported that in crude extracts of human muscle, a 40% saturated 
solution of ammonium sulphate did not prevent receptor from remaining 
in equilibrium with the unbound toxin. In human foetal extracts however, 
the addition of ammonium sulphate was found to inhibit the binding of 
toxin to receptor thereafter. The ammonium sulphate assay was thus 
employed in the course of determining the on and off rate constants.
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Stability of a-Bungarotoxin Binding Activity Post-Mortem
In human foetal brain, the toxin binding activity appears 
fairly constant in tissue obtained between 5h and lOh post-mortem 
although it is not known whether activity is lost in the period 
between death and 5h post-mortem. In rat brain, binding levels 
remained unchanged during storage at room temperature up to at least 
18h (this study). In mouse brain, activity remained stable up to at 
least 24h under conditions which simulated the cooling of human cortex 
after death at 4°C (Davis and Feisullln, 1981). It therefore seems 
unlikely that a substantial loss of activity occurs immediately after 
death in human foetal brain. It is preferable, in a more extensive 
study of the post-mortem stability to restrict the study to a single 
preparation in an attempt to eliminate some of the factors which may 
increase the variability of toxin binding activity. Although activity 
appears fairly constant between 10-20 weeks gestational age (Fig. 3.8, 
page 95) differences are apparent among individual preparations of the 
same age (Fig. 3.8(b)) which may be due in part to the variability of 
the biological activity of each iodinated toxin preparation used 
(see page 174).
The toxin binding activity of foetal brain appears to be 
unaffected by freezing at -80° for a.t least 9 weeks. The differ­
ence between the mean activities (page 90) is not considered significant 
as the binding levels in all 12 foetuses varied between 32 and 50 fmol/ 
mg protein.
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Ontogenesis of a-Bungarotoxin Binding Sites in Human Brain
The results show the presence of specific a-bungarotoxin 
binding sites with a distinctly nicotinic pharmacological profile 
(page 154). The concentration of a-BgTx sites in whole brain over 
the foetal age range 10-24 weeks varies between 1.1 and 1.5pmol/g 
wet weight which is comparable to the values reported for adult rat 
brain (Schmidt et al., 1980), chick brain (Norman, 1981) and mouse 
brain (Seto et al., 1977). If the concentration of sites are 
expressed per mg protein, the levels of binding found in foetal 
homogenates (Results, page 87 ) are approximately five-fold greater 
than the value reported for adult tissue (Volpe et al., 1979)
(Davis and Feisullln, 1981). The protein concentration per g wet 
weight of tissue in adult brain is almost twice that of foetal brain 
(Brooksbank et al., 1978). If therefore the concentration of binding 
sites is expressed per unit protein, an apparent two-fold enrichment 
is observed in foetal brain compared with the adult tissue. For 
this reason, in order to validate further comparisons between adult 
and foetal tissue, receptor site concentration is probably better 
expressed per unit wet weight.
The lower concentrations found in adult brain may be a direct 
consequence of maturation, however, it is notable that Davis and 
Feisullln (1981) performed most binding experiments at a concentration 
of 0.2nM -a-BgTx and the tissue wash exceeded 6 min. following
termination of the binding assay. The results obtained in this study 
have shown that a concentration of at least lOnM is required to achieve 
saturation and that owing to a rapid rate of dissociation, it was 
necessary to minimise the time taken to wash the pellets. If the 
adult toxin receptor has kinetic properties similar to its foetal
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counterpart, failure to take into account the assay conditions may 
result in an underestimation of the concentration of receptor sites. 
The density of receptor sites remained remarkably constant from 
10-24 weeks in whole brain homogenates (Fig. 3.8 (d), page 94) and 
in the fraction (Fig. 3.8 (b)) despite variability in the binding 
levels of foetuses of similar gestational age, for example, at 19 
weeks (Fig. 3.8 (b)).
Owing to the scarcity of material aged below 12 weeks and 
above 20 weeks, the period at which toxin binding sites first appear 
and the pattern of ontogenesis up to the adult stage could not be 
established. Appreciable levels of toxin binding were detected at 
10 weeks, and they remained fairly constant up to 20 weeks. The 
density of sites found in whole foetal brain is higher than the 
binding levels found in several areas of adult brain (Volpe et al., 
1979).
In rat brain toxin binding activity is detectable in the 
hippocampus four days before birth (Ben-Barak and Dudai, 1979). The 
receptor concentration reached a peak around birth followed by a 
decline to a third of this value after one month. The proliferation 
of receptors around birth in this brain region was confirmed auto- 
radiographically by Hunt and Schmidt (1979). In chick optic lobe,
Wang and Schmidt (1976) observed a steep increase in the concentration 
of receptor during the latter period of incubation which was followed 
by a decline after hatching. A similar pattern was noticed in the 
retina and other brain areas although it was less pronounced. In 
order to make a comparison between the ontogenic patterns found in 
human brain and other species it is necessary to limit the investi-
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gâtions to discrete brain areas. The results of the analysis of 
toxin binding to regions of rat brain (Morley and Kemp, 1978) 
indicated that development progressed in a caudal to rostral 
direction. Also, in chick brain, Kouvalas and Greene (1976) found 
that the ontogenic pattern of toxin binding followed a characteristic 
time course for each area examined.
The appearance of a-bungarotoxin binding has been shown to 
precede synapse formation in the rat hippocampus (Hunt and Schmidt, 
1979 ; Ben Barak and Dudai, 1979) and chick retina (Vogel and 
Nirenberg, 1976). Although poorly documented, the formation of 
synapses in human brain has been reported to first occur at 7-8 weeks 
(Molliver et al., 1973; Ivanshina, 1978). In contrast to these obser­
vations, Soloveva et al. (1972) reported contacts of the puncta 
adherentia type only in the brain of 9-10 week old embryos. These are 
junctional zones with a symmetrical disposition of dense material 
devoid of vesicles in close association (see Peters et al., 1976) •
The synapse, by comparison, is often polarized (Peters et al.,
1976) consequently, junctions of this type are considered to
be purely adhesive and not concerned with neurotransmission. Of the 
three areas studied in the brain of a 13 week old foetus, the presence 
of contacts is clearly observed in the cerebellum. The contacts 
shown in Plate 5 (c) denoted by the upper and lower arrows are 
similar to the type (II) and (III) contacts respectively, reported by 
Ivanshina (1978). The contacts are thought to be of a synaptic 
origin as judged by the degree of modification of the junctional 
membranes and the presence of vesicles and cleft material (Jones and 
Revell, 1970). The contact in Plate 5 (c) denoted by the upper arrow, 
appears to be symmetrical with evidence of the formation of focal
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densities (Jones, 1969). Cleft material was found to be distributed 
in parallel. The presynaptic element is distinguished by the presence 
of a membrane profile reminiscent of a dense cored vesicle 
(Akert et al., 1969). Indeed, the occurrence of dense cord vesicles 
in developing rat brain have been described by Jones and Revell 
(1970) at seven days post-natally. The authors also describe the 
presence of ribosomes as a dominant feature of the postsynaptic 
component. This was clearly observed in Plate 5 (c) which shows 
an assymetrically thickened synaptic contact with prominant post­
synaptic focal densities. The presence of ribosomal clusters in 
Plate 5 (a) may denote the postsynaptic component since vesicles are 
not evident in the vicinity of the contact.
No evidence for synaptic contacts was observed in the 
sample of frontal cortex. An absence of contacts in this region 
probably reflects chronological differences in development of 
individual brain areas (Dobbing and Sands, 1973) but it may also be 
a consequence of the cortical layer investigated. Huttenlocher et al. 
(1982) found that the density of contacts in the cerebral cortex 
of a 28 week old embryo varied depending on the cortical layer 
examined. In the parietal cortex (Plate 4), very few contacts are 
observed. In Plate 4 (c), the area between the contact appears to 
contain cleft material but the absence of vesicles or lack of any 
membrane modification would tend to suggest that either the contacts 
are immature or of a non-synaptic origin.
Selective staining of the paramembranous components of 
synaptic junctions with phosphotungstic acid (Aganjanian and 
Bloom, 19 67) is likely to be of value in further investi-
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gâtions of the maturation of synaptic connections in foetal brain. 
As phosphotungstic acid does not produce the general staining of 
cellular components seen with osmium textroxide, the quantitation 
of synaptic contacts and fine structural detail could be observed 
with greater clarity.
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Regional Distribution of a-Bungarotoxin Binding Sites
A preliminary investigation of the density of toxin binding 
sites in three brain areas of a 15 week old foetus revealed marked 
regional differences. The relatively low levels of toxin binding 
in the cerebellum is consistent with the findings of Salvaterra and 
Foders (1979) in a variety of different species. At present, only 
one report of the regional distribution of toxin binding sites in 
adult human brain is known (Volpe et al., 1979). The authors found 
that the highest levels of binding were associated with the colliculi 
and mamilliary bodies and that few a-toxin sites were associated with 
the cerebellum and caudate nucleus. In the areas examined in rat 
brain (page 156) the highest levels of toxin binding were found in the 
superior colliculus and the hippocampus. The lowest densities were 
observed in the striatum and the cerebellum. These results are in 
accordance with the findings of Schechter et al. (1978) and 
Segal et al. (1978). A more comprehensive investigation of the toxin 
binding levels in human foetal brain areas may reveal a distribution 
profile which is fairly similar to rat brain, however, it is apparent 
that inter-species differences do exist. Rat striatum for example 
contains very few toxin binding sites but in mouse this area is 
moderately labelled (Marchand et al., 1979) . In the retina, toxin 
binding was observed in the inner and outer plexiform layers in 
chick (Vogel and Nirenberg, 1976); goldfish and turtle (Yazulla and 
Schmidt, 1976) and pigeon (Yazulla and Schmidt, 1977) but in rat only 
the inner plexiform layer was found to be labelled (Vogel and 
Nirenberg, 1976). It is anticipated that the distribution profile of 
toxin binding sites in some areas of foetal brain might bear little 
relationship to the binding pattern observed at maturity. Hunt and
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Schmidt (1979) for example have shown that a population of a-toxin 
receptors in the rat hippocampus exhibits a transient proliferation 
around birth. This phenomenon was also observed in chick optic lobe 
(Kouvalas and Greene, 1976). Future attenq>ts to correlate the 
pattern of toxin binding sites with the distribution of choline 
acetyltransferase and acetylcholinesieiase in the developing brain 
must be approached with caution because components of the cholinergic 
system have been known to appear transiently during development. It 
has been shown that choline acetyl transferase and acetylcholine 
esterase occur in many neuroblasts that subsequently develop into non- 
cholinergic neurones (Filogamo and Marchisio, 1971).
Comprehensive autoradiographic analysis of a-bungarotoxin 
binding patterns in rat (Hunt and Schmidt, 1975) and mouse (Arimatsu 
et al., 1981) brain led to the conclusion that a-toxin sites are 
associated primarily with the limbic system and areas receiving sensory 
input (see Oswald and Freeman, 1981). Preliminary studies were 
restricted to the spinal cord in human foetal brain as the areas 
which are known to receive sensory afferent terminations could be 
easily identified at 14 weeks of development. Appreciable levels of 
toxin binding were observed in the spinal cord at 15 weeks (page 160) 
which, if expressed in terms of tissue wet weight (Table 3.7, page 
102) is comparable to the density observed in rat spinal cord. The 
accumulation of silver grains observed in the dorsal horn of human 
foetal spinal cord (Plate 6) is remarkably similar to the distribution 
found in the rat (Hunt and Schmidt, 1978a) and mouse (Arimatsu et al., 
1981). In mouse cervical spinal cord, diffuse labelling was found 
to overly lamina© I (marginal cell layer), II (substantia gelatinosa)
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and III (nucleus propius) but in rat brain layers I and II exhibited 
the highest density of toxin binding sites. The relatively even 
distribution of silver grains in the dorsal laminae of foetal brain 
may reflect a species difference althought it would be necessary to 
perform parallel incubations using adult tissue in order to exclude 
the possibility of developmental changes. The dorsal horn is an area 
which receives sensory afferent terminations (Ninkovic and Hunt, 1983). 
Many sensory afferent fibres are sensitive to the application of acetyl­
choline (Paintal, 1964), the effect of which can be reversed by the 
nicotinic receptor antagonists tubocurarine and hexaméthonium but not 
by atropine. The presence of high densities of a-bungarotoxin binding 
sites has been demonstrated in the sensory ganglia of rat, monkey, cat 
and human spinal cord (Ninkovic and Hunt, 1983). Axonal fibres of the 
dorsal root ganglion cells project both peripherally (to the skin) and 
centrally (to the spinal cord) and the authors have demonstrated that 
dorsal root section leads to a depletion of toxin binding sites in 
lamina III in the dorsal horn of the rat. Observations following 
ligation of the dorsal roots suggested that the a-toxin receptors 
were transported axonally in a bidirectional fashion. It seems likely, 
therefore, from the evidence of toxin binding in human adult dorsal 
root ganglia (Ninkovic and Hunt, 1983) and the preliminary findings 
in this study that putative nicotinic receptors are concentrated in 
the dorsal horn at maturity with a distribution perhaps not unlike that 
of foetal brain. The enzymes choline acetyl transferase (Kimura et al., 
1981) and acetylcholinesterase (Lewis and Shute, 1978) have been 
found to exhibit highest activity in the substantia gelatinosa 
(layer II) and in rat, the muscarinic cholinergic receptor was found 
in high concentrations in layer III (Wamsley et al., 1981).
186.
The bilateral distribution of the clusters of silver
grains in the ventral horn (Plate 7 (a), arrows) is reminiscent of
the labelling found in the ventral horn of the rat cervical cord
(Hunt and Schmidt, 1978a). The authors were able to observe a number
of small labelled cell bodies lying between and ventral to motor
neuron perikarya. It was proposed that they may be Renshaw cells,
which receive a well-defined nicotinic cholinergic input (Willis,
1971). Radiolabelled a-bungarotoxin, delivered by micropipettes
in the vicinity of Renshaw cells in rat spinal cord failed to label
these neurones (Duggan et al., 1976b)^ Absence of specifically bound
toxin may reflect a species difference, however it is notable that a
combination of a low specific activity of radiolabelled toxin and the
high background levels generated by local delivery may have obscured
any specific labelling. In the ventral horn of mouse spinal cord,
silver grains were observed to be concentrated around small cells
(Arimatsu et al., 1981) although it is not known if these structures
are Renshaw cells. In foetal brain, it was difficult to establish
whether the dense accumulations of silver grains in the ventral
horn was associated with cell bodies since labelling was not
particularly intense (Plate 7 (a)). The elimination of the dense
accumulations of silver grains in the ventral and dorsal horns by the
-5pretreatment of sections with 10 M unlabelled toxin suggests that 
the binding in these areas is specific. Earlier studies (page 154) 
have shown that foetal neuronal receptor exhibits a nicotinic 
pharmacological profile so the toxin labelling observed in the spinal 
cord may reflect the early distribution of putative nicotinic receptors 
In a parallel study, intraventricular injections of labelled toxin 
into the lateral ventricle of rat brain failed to produce the labelling
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patterns in the spinal cord and cerebellum observed by Hunt and 
Schmidt (1978a) By comparing cryostat sectioned material with the 
intraventricular method, the authors concluded that the latter pro­
cedure was adequate for the complete labelling of structures and 
that significantly lower levels of background labelling could be 
achieved. It is not clear why the spinal cord was not labelled 
in either of the two animals which received labelled toxin only. 
Judging from the injection marks observed on cryostat sections, the 
toxin appeared to reach the target area. A possible explanation 
is that inadequate quantities of toxin were delivered into the third 
ventricle since a noticable leakage of fluid occurred from the site 
of injection following withdrawal of the Hamilton syringe.
The distribution of toxin binding in the hippocampus 
(Plate 6 (a)) is in accordance with the results obtained by Hunt 
and Schmidt, (1978a) and Segal et al. (1978). In human adult brain,
an attempt to label the hippocampus using -o-BgTx (Lang and
Henke, 1983) proved inconclusive since the high levels of non­
specific binding may have obscured the specific sites. The labelling 
of the suprachiasmatic nuclei illustrated in Plate 6 (b) has been 
reported by Silver and Billiar (1976), Segal et al. (1978) and Block 
and Billiar (1981) but not by Hunt and Schmidt (1978a), The supra­
chiasmatic nucleus one of the few brain areas in which the local 
application of toxin has been shown to produce quantitative changes. 
Zatz and Brownstein (1981) have shown that intrahypothalamic 
injections of a-BgTx near the suprachiasmatic nuclei resulted in an 
inhibition of the light induced nocturnal decrease in pineal N-acetyl- 
transferase activity. It is also known that the suprachiasmatic 
nucleus is involved with genadotropin release (Barraclough, 1973)
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and Miller et al. (1982) have shown that in female ovariectomised 
rats, there is a marked reduction in the number of a-toxin binding 
sites.
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ATTEMPTED PURIFICATION OF THE a-BUNGAROTOXIN BINDING COMPONENT
With regard to the isolation and characterization of 
putative neuronal nicotinic receptors, progress has been hindered 
in part due to the low concentration of a-toxin binding sites in 
vertebrate brain (Schmidt et al., 1980). Although similarly low 
densities are encountered in human foetal brain (l-2pmol/g) the 
availability of large amounts of material offers the possibility 
of purifying fairly large quantities of receptor. Purification of 
receptor in foetal brain was attempted with a view to investigating 
the molecular properties of the binding component and obtaining 
sufficient quantities of purified protein for the production of 
antisera.
Treatment of the crude mitochondrial fraction (P^) from 
foetal brain with 2% Triton X-100 for Ih at 23°C was found to be 
sufficient for the solubilization of > 95% of the toxin binding 
activity (S. Wonnacott, personal communication). Under these con­
ditions, the activity extracted from the P^ fraction in four separate 
preparations was slightly lower (93% <) but on the whole was consistent 
with findings for rat brain (Wonnacott et al., 1982).
Incubation of the crude detergent extract with Sepharose- 
toxin beads results in an almost total loss of soluble toxin binding 
activity. The absence of activity in the non-bound fraction and sub­
sequent washings suggested that in spite of the rapid dissociation 
of the toxin receptor complex (page 151) the toxin binding component 
has been retained by the affinity beads. Treatment with IM carbachol 
failed in the course of three preparations to elute toxin binding 
activity from the beads. In a single preparation, however, 0.5% of the
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activity originally present in the fraction was recovered. Failure
to recover activity from affinity beads has not been encountered in
rat (Salvaterra and Mahler, 1976); mouse (Seto et al., 1981) or
chick brain (Norman et al., 1982). It is unclear why activity cannot
be recovered to the same extent in human foetal brain. If the
dissociation of receptor from the affinity beads occurred prior to
elution with carbachol then the non-bound fraction and subsequent
washings would be expected to show evidence of activity. In all
experiments however, no detectable activity is observed. It is
unlikely that the IM carbachol was unable to elute activity from the
beads. Previous experiments have shown that it displays a measurable
-4
affinity for the toxin binding site (IC^^ = 6.6 x 10 M). That the 
substantial loss in toxin binding activity is solely the result of 
proteolytic attack is doubtful since, even after eight days, activity 
was still present in the crude extract (page 89) in the presence of 
the anti-proteases EDTA and PMSF. In the purification procedure,the 
buffers were supplemented with additional inhibitors (page 73). In 
foetal brain washing of the bulk of non-receptor protein may have 
increased the susceptibility of the receptor to proteolytic enzymes, 
particularly if such enzymes j were present as contaminants. Norman 
(1981) has shown that solubilization of the nAChR from chick optic 
lobe using Triton X-100 gave an apparent increase in the sedimentation 
coefficient compared with Lubrol due to the association of additional 
non-receptor protein in the extracted oligomer.
In the presence of EDTA and PMSF, the toxin binding activity 
in the particulate fraction remains stable for up to at least Ah 
following the preparation of . Since the ammonium sulphate pre­
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cipitation assay required an incubation period of 16h, the measure­
ments of binding activities in crude extracts up to 16h after pre­
paration could not be performed. Preliminary assessments of the 
activity of the P^ fraction by centrifugation indicates that only a 
small loss in activity (< 10%) occurs in 16h. Experiments have shown 
however, that this assay method gives an underestimation of the 
activity in the P^ fraction (see page 84). Thus, a greater loss may 
have in fact occurred. In addition, an estimation of the loss of 
activity in crude extracts after 18h on the basis of measurements 
performed using the freshly prepared P^ fraction is dependent on the 
% of activity extracted by detergent. The % extraction was calculated 
from the activities of the P^ and crude extracts measured by ammonium 
sulphate precipitation and in most experiments was found to range 
between 78% and 95%, hence the estimated loss in activity may be 
subject to error.
In rat brain, it has been reported that extracts remain 
active for a week and after partial purification, several weeks 
(Salvaterra and Mahler, 1976). Clearly, in particulate fractions, 
activity is more stable in rat brain (page 88). The greater 
instability in human foetal tissue may be attributable to the activity 
of proteolytic enzymes involved in the breakdown and turnover of 
proteins during development (Marks and Lajtha, 1963). In rat brain, 
the rate of breakdown was highest during periods of rapid growth and 
the decline of activity at a later stage was similar to the decrease in 
proteinase and peptidase content (Marks et al., 1975). It would be of 
interest to perform similar experiments using human adult brain since 
the rapid loss in activity may be attributed to an inherent instability 
of a-toxin binding sites in immature brain. A rapid loss of binding
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activity in the detergent extracted and affinity purified nAChR 
from foetal tissue compared with the adult counterpart was 
encountered in human muscle (Tumbull et al., 1985). If this is the 
case then evidence of greater instability may reflect inherent 
structural differences between the developing and mature forms 
since stabilization does not occur until after synaptogenesis is 
completed (Changeux and Danchin, 1976).
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THE SUBCELLULAR FRACTIONATION OF BRAIN
Adult rat brain was selected for comparison with human foetal 
brain with the aim of establishing some of the fundamental character­
istics of the morphology and the distribution of biochemical markers 
unique to the immature tissue. The subcellular fractionation of rat 
brain is well documented (see Gibson and Blass,1982) and some of the 
complications associated with human adult tissue (see Section 1, page 25) 
are avoided (Gottfries et al., 1981; Hardy and Dodd, 1983). Dodd et al. 
(1981) have shown that subcellular fractionation of fresh human biopsy 
samples has produced fractions with morphological and metabolic proper­
ties very similar to those exhibited by rat brain. Species differences, 
however, may well affect some aspects of the study.
In foetal brain, the most distinctive difference in the dis­
tribution of protein, enzyme markers and ligand binding activities is 
their increased recovery in the S^ fraction at the expense of the 
heavier (P^ ) fraction. The apparent shift of activity to the lighter 
fraction is considered to be a reflection of the higher ratio of soluble 
to insoluble proteins at the earlier stages of gestation; post-natal 
proportions are reached at 26 weeks (Sinha et al., 1980). The crude 
mitochondrial fraction (P^) of foetal brain also appears to exhibit a 
greater fragility than its rat counterpart since additional suspension 
and recentrifugation of the pellet facilitated the loss of protein into 
the supernatants. In rat brain, the protein recovered in the pellet 
from fractions P2A, P^B and P^C by the total recovery scheme (Fig. 3.10, 
page 106) amounts to 81% compared to 62% for foetal brain. The loss of 
protein from P^ following disruption of the pellet may explain the dis­
crepancy between the toxin binding activity in this fraction measured by 
ammonium sulphate precipitation and centrifugation. The latter consist-
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ently gave lower activities (page 84). Since the ammonium sulphate 
method measures activity in the soluble and particulate fractions, it 
is possible that some of the protein which exhibits toxin binding 
activity became "solubilized" following the pellet wash in the 
centrifugation method. Despite the loss'; of activity, the centri­
fugation assay was nevertheless adopted for most experiments as poor 
reproducibility was often encountered using ammonium sulphate pre­
cipitation.
A morphological examination of subfractions A, B and C at 
the electron microscope level revealed marked differences between rat and 
human foetal brain. In foetal brain, the characteristic myelin whorls 
are absent from fraction P^A and there is no evidence of myelinated 
axons in the tissue (Plate 3 (c), (d); Plate 4 (a); Plate 5 (a)).
Absence of myelin was anticipated as in human brain, myelination occurs 
late in development and proceeds through the early post-natal years 
(Dobbing and Sands, 1973; Sarma and Subba Rao, 1976).
The origin of the membranous profiles in P^A is unclear 
although a certain proportion may represent early forms of myelin 
since very small quantities have been recovered from foetuses of this 
age (Savolainen et al., 1972). The majority of profiles in the foetal 
P^A fraction are thought to be plasma membrane fragments. Indeed, a 
greater recovery of adenylate cyclase activity is evident in foetal P^A 
compared to rat brain. In neonatal rat brain, synaptosomes occupy the 
lightest fraction in a density gradient and subsequently migrate to a 
denser fraction as the brain matures (see Jones, 1975). In human foetal 
brain few synaptosomes were evident in fraction P^A and the presence of 
intact structures is reflected by the very small amounts of occluded LDH
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activity associated with this fraction.
The nerve ending (PgB) fractions from rat and foetal brain 
show marked differences in morphology (Plates 1 (b), (d); 2 (b), (c),
(d). In rat brain, synaptosomal membrane profiles could be recognised 
by their content of synaptic vesicles and occasionally, mitochondria 
(Plate 1 (b)). In contrast, very few vesicles were present in the 
foetal structures and unlike rat brain, the majority of profiles possess 
a granular matrix with numerous ribosomes and frequently neurofil aments 
(Plate 2 (c)). These structures closely resemble synaptosomes prepared 
from neonatal rat brain (Jones and Revell, 1970). In immature rat 
brain, it has been proposed that the amorphous granular matrix may be the 
result of the poor preservation of synaptic vesicles and microtubules 
(Gonatas et al., 1971) since the latter are easily damaged by agitation 
(Behnke, 1967). In synaptosomes prepared from human adult brain, the 
amorphous matrix is absent and the profiles contain numerous vesicles 
(Van Kempen and Vrensen, 1974; Dodd et al., 1981; Hardy et al., 1982) 
thus it appears that the structures in immature brain exhibit a greater 
fragility. The granular appearance of the foetal profiles may also be 
attributed to the activity of proteolytic enzymes (see page 191). In 
rat cortex, the synaptosomal matrix developed a distinctly granulur 
appearance following treatment with a variety of proteolytic enzymes 
(Barrantes and Lunt, 1970).
The high proportion of occluded LDH activity in fraction 
and the intact appearance of the membrane profiles in Plate 2 (b) suggest 
that the foetal synaptosomes are relatively stable structures, following 
resuspension in 50mM phosphate buffer. Their susceptibility to osmotic 
rupture however is not known. Spence and Wolfe (1967) have shown that 
newborn rat synaptosomes are less easily ruptured than their adult
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counterparts. In view of this, synaptosomes from human foetal brain 
clearly demonstrate their potential in further experiments involving 
metabolic studies and the release of neurotransmitter substances.
Such studies have been performed using synaptosomes prepared from 
human adult brain (Dodd et al., 1981; Hardy et al., 1982).
In adult rat brain, the nerve ending fraction (P^B) sediments 
as a sharp band at the 0.8M-1.2M sucrose interface, but in human foetal 
brain, its distribution is diffuse and projects well below the inter­
face. The particulate material present in the denser part of the 
gradient may represent populations of synaptosomes with a buoyant 
density equivalent to or greater than 1.2M sucrose. In a study by 
Van Kempen and Vrensen (1974), synaptosomes from human adult frontal 
lobe sedimented at densities ranging from IM to 1.6M sucrose on a 
discontinuous gradient. Similarly, Hickey et al. (1976) found that 
large numbers of synaptosomes prepared from the substantia nigra and 
the caudate nucleus of human adult brain sedimented in the mitochondrial 
fraction. In foetal brain, fraction P^C exhibits moderate synaptosomal 
contamination as judged by electronmicrographs (Plate 3 (a)) and the 
proportion of occluded LDH activity found associated with this fraction.
The mitochondria recovered in the rat P^C fraction exhibit a 
reasonably well preserved inner structure (Plate 1 (e)) but in foetal 
brain, the majority of structures are devoid of the internal membranes 
(Plate 3 (a)). It was proposed that loss of structural integrity of 
mitochondrial membranes in human adult brain (Hickey et al., 1976) 
is a result of a long post-mortem delay (Rees, 1977). Swanson et al. 
(1973) have shown that in guinea pig brain, subfraction C was most pro­
foundly affected by long periods of storage, the result of which mi to-
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chondria became increasingly swollen and fragmented. In foetal brain, 
the post-mortem delay of up to 8h may have caused some ultrastructural 
degeneration although it is notable that mitochondria present in 
fraction are reasonably well preserved (Plate 2 (d)). In this case 
it is possible that the synaptosomal membrane offers some degree of pro­
tection to the osmotic changes arising from the transfer of the 
gradient fractions back to 0.32M sucrose; compared to the profiles in 
PgC, no obvious sign of swelling is apparent in mitochondria from this 
fraction (Plate 2 (d)). The recovery of mitochondria in foetal subcellular 
fractions closely parallels the distribution found in adult rat brain as 
judged by the marker enzyme, succinate dehydrogenase. Unlike rat brain 
however, the highest proportion of SDH activity in the foetal primary 
fractions is recovered in the fraction. This does not appear to 
arise from species difference since in human adult tissue, very small 
amounts of activity are associated with the fraction (Stahl and Swanson, 
1975; Hickey et al., 1976). Membrane damage accelerated by post-mortem 
delay (Rees, 1977) may have resulted in the contamination of this 
fraction by mitochondrial fragments, however in guinea pig brain,
Swanson et al (1973) did not observe a shift in the recovery of SDH 
from fraction P^ to S^ after 20h post-mortem. It is unlikely that 
the SDH activity is associated with synaptosomes in this fraction since 
the proportion of LDH activity occluded in this fraction is only 3%.
It appears therefore that the presence of SDH activity in the Sg 
fraction is a feature of immature brain since these structures may 
exhibit a greater fragility than the adult counterpart particularly 
after long post-mortem delays.
198.
Distribution of the Cholinergic Binding Sites and Enzyme Markers
In both rat and foetal subcellular fractions, acetylcholine 
esterase and choline acetylt ra nsferase are enriched in the fractions 
which contain the bulk of nerve ending particles. In the foetal 
primary fractions, AChE activity is recovered primarily in the 
lighter S^  fraction compared to the in rat. Since AChE from 
mammalian brain is found associated with neuronal membranes (see 
Gibson and Blass, 1982) these observations are in accordance with the 
similar distribution profile exhibited by the plasma membrane marker 
adenylate cyclase (Fig. 3.16, page 117) and the protein content 
(Fig. 3.9).
In guinea pig and human adult brain, the highest recovery of 
AChE activity is observed in the microsomal fraction (Stahl and Swanson, 
1975). It is notable however that this fraction was prepared at 17,000g 
which is comparable to the conditions used to prepare the P^ in this 
study, thus it is difficult to establish whether a species difference 
does exist. In rat brain the S^ fraction comprises the bulk of 
ribosomes, cell cytoplasm, large numbers of vesicles and occasionally 
a few small nerve endings (Gray and Whittaker, 1962). The fraction 
of foetal brain may contain in addition to these entities a population 
of synaptosomes capable of expressing toxin binding activity. Com­
pared to rat brain, the higher recovery of protein, AChE,adenylate 
cyclase and to a lesser extent CAT, suggests that this may indeed be 
the case. If synaptosomes are present, it is unlikely that they are 
intact as the proportion of occluded LDH activity is extremely low 
when compared to the p^ fraction. In rat brain. De Bias and Mahler 
(1978), have shown that the toxin binding activity in the fraction 
is associated with a particulate subfraction thought to be derived from
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Grays’ type II synapses (Gray, 1975). In foetal brain, toxin binding 
activity may be similarly associated with particulate material which 
consists mainly of small membrane fragments, perhaps of synaptosomal 
origin.
In rat and foetal gradient fractions, the highest enrich­
ment of toxin and QNB binding activity is observed in fraction PgB 
which contains the bulk of the synaptosomes, as judged by occluded 
LDH (Figs. 3.20 and 3.21) and electron microscopy (see Plates 1 (b) 
and 2 (b)). The largest proportion of AChE is recovered in this 
fraction in both tissues although the presence of this enzyme is not 
sufficient for the identification of purely cholinergic neurones 
since it is also associated with non-cholinergic structures (Parent 
and Butcher, 1967). The bulk of CAT activity in both tissues is 
recovered in fraction P^B although the highest enrichment is observed 
in the mitochondrial fraction (PgC). The cytoplasmic marker enzyme 
LDH, exhibits a similar enrichment in the P^C fraction from foetal 
brain but not rat brain. The enrichment of the two cytoplasmic 
enzymes in foetal P^C is not likely to be the result of extensive 
synaptosomal contamination since the majority of synaptosomes are 
located in fraction P^B and the recovery profiles are not super­
imp o sable with the other cholinergic markers. A probable explanation 
resides in the tendency for both enzymes to bind to membranes under 
certain conditions of pH and ionic strength (Fonnum, 1966; Wong and 
Prince, 1979). This phenomenon is also species dependent (Fonnum, 
1970) and in the case of LDH, a difference clearly exists between rat 
and human tissue. The predominant recoveries of AChE, CAT, LDH and 
protein in association with synaptosomal profiles in immature tissue 
is reported in neonatal rat brain (Gonatas et al., 1971) although at
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one day after birth, the synaptosomes are recovered in the lighter 
fraction.
In foetal brain, a poor recovery of a-BgTx and QNB binding 
from the fraction is observed following collection of the gradient 
fractions. The low recoveries are attributed to the collection of 
only the discreet bands from the gradient interfaces. In foetal 
brain the visual difference of the gradient and measurement of the 
protein content revealed that significant quantities of particulate 
material is discarded if material present at the interfaces only is 
collected. Omission of such material is likely to explain the low 
recoveries of the membrane markers and the cholinergic receptor 
binding sites. The higher recovery of CAT however from the foetal 
gradient fractions is likely to be the result of the enzyme binding 
to membranes for reasons mentioned previously.
The P^ fraction which is employed in the majority of receptor 
binding experiments exhibits a greater enrichment of toxin binding 
activity in foetal brain than in its rat counterpart. The apparently 
higher enrichment in foetal tissue is a consequence of the lower 
recovery of protein in this fraction compared to rat brain.
It is evident that at 13 weeks, elements of the cholinergic 
system are associated with the fraction enriched with nerve endings.
The capacity of the human brain to synthesize acetylcholine as judged 
by the activity of CAT has been reported at eight weeks gestation by 
Bull et al. (1970). In view of further studies, it would be of inter­
est to investigate some of the functional aspects of cholinergic 
receptors associated with the synaptosomal fraction during development.
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In rat brain, nicotinic facilitation of dopamine release from the 
striatum is documented by Giorguieff et al (1977), De Belleroche and 
Bradford (1978),De Belleroche and Bradford,(1980); Futerman et al., 
(1981); Takano et al. (1983) and Mills and Wonnacott (1984). The 
presence of nicotinic receptors in the caudate nucleus of human adult 
brain as implicated by the low but measurable toxin binding activity 
(Volpe et al., 1979) demonstrated the potential of this approach to 
the study of the cholinergic receptors in selected brain areas.
Garey and Heath (1974) have shown that synaptosomes derived from the 
dorsal caudate nucleus of human brain up to 7h after death actively 
accumulate noradrenaline and dopamine. Coupled with histological 
studies, this approach may prove useful for investigating the role of 
the cholinergic system \r. the modulation of other neurotransmitter. 
during development with an insight to neurological disorders.
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QUANTITATIVE STUDIES OF a-BUNGAROTOXIN BINDING
The specificity of -a-BgTx binding to foetal brain was
-5determined by incubating samples in the presence and absence of 10 M
-4unlabelled toxin or 10 M nicotine. In the presence of competitor, 
the binding of -a-BgTx increased, linearly with concentration
(Fig. 3.28, page 136). Since preincubation of the samples with 
unlabelled toxin or nicotine was assumed to protect the toxin receptor 
sites, the binding of labelled toxin in the presence of competitor is 
designated as "non-specific". Non-specific binding may be the result 
of one or more of the following:-
a) Binding of toxin to non-biological materials used 
in the assay procedure.
b) Insufficient washing of the tissue sample following
the separation of bound and free toxin.
c) Binding of toxin to non-receptor material present in 
the particulate fraction or crude detergent extract.
The labelled toxin specifically bound was determined from the total 
binding (toxin bound in the absence of competitor) minus the non­
specific binding and it is found in most preparations to constitute 
between 24% and 45% of the total. By comparison, specific binding in
rat brain is found to vary between 55 and 65% of the total under the
same conditions. The binding of toxin to assay materials contributes 
significantly to the non-specific binding component, particularly if 
glassfibre filters are used for separating bound and free toxin.
Levels could be reduced however, if the filters were pre-soaked in 1% 
BSA.
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It was anticipated that a certain amount of the unbound 
toxin may be "trapped" by the particulate matter as a result of 
insufficient washing when employing the centrifugation procedure 
(Methods, page 40). Although the rapid rate of dissociation of 
toxin from foetal receptor (Results, page 151) permitted only a 
single wash, it was found that up to three washes of particulate matter 
from rat brain, of which the dissociation rate of the specifically 
bound toxin is much slower, (see Section 1, page 16) resulted in a very 
small decrease in the non-specific binding. Repeated washing of the 
particulate fraction prior to incubation with toxin was reported to 
have reduced the high levels of toxin bound non-specifically in human 
adult brain (Davis and Feisullin, 1981). Similar treatment did not, 
however, reduce the non-specific binding levels in human foetal brain.
The proportion of non-specific binding remaining in a toxin 
binding assay is likely to be attributable to the binding of toxin to 
non-receptor material. The highly postive charge carried by the a- 
bungarotoxin molecule (Hanley, 1978) may be a contributing factor. 
Although the levels of non-specific binding were often considerably 
higher in foetal brain than in rat brain, subsequent kinetic and drug 
competition studies were not in any way hindered.
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Determination of the Intrinsic Dissociation Constant
The relatively low K^s determined by equilibrium studies 
indicates that the receptor displays a high affinity for mono- 
iodinated a-bungarotoxin and the linear plots obtained by Scatchard 
analysis were indicative of a homogenous population of receptor sites. 
These observations are consistent with studies performed with chick optic 
lobe (Barnard et al., 1979) and in rat brain (Schmidt et al., 1980).
The difference in the mean values of the obtained
for the membrane bound and solubilized forms of receptor (3.5nM and 
2.4nM respectively) were not considered to be significant since the 
range of values obtained for both forms varied considerably (1.9nM->
6.8nM, total of eight experiments).
Hill plots of the binding data were found to be linear with 
2good correlation; (r = 0.93 and 0.97 for membrane bound and solubilized 
forms respectively). The Hill numbers (Tly) are close to unity (>0.93) 
indicating that no co-operativity was taking place.
Determination of the Association Constant (k + 1)
For the purposes of determining the concentration of foetal
brain receptor (B ) the number of toxin molecules binding to each max
oligomer is assumed to be 1:1 although the actual ratio in brain is 
not known. Calculations of the specific activity of toxin binding 
activity of purified chick optic lobe receptor has tentatively indicated 
that each oligomer binds only one toxin molecule (Norman, 1981).
Maximum binding of [^^^I |-a-BgTx to human foetal membranes i 
achieved in 12 min and pseudo first-order treatment of the data
I S
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resulted in a linear plot characteristic of a simple bimolecular 
interaction. The first order method of analysis was chosen in order 
to correct for dissociation estimated to be very rapid from preliminary 
studies.
The binding of ligand to receptor with respect to time can 
be expressed as:
dB
—  = k + l.L_. (B -B) -k-l.B 
dt ^
When the total ligand concentration (L^) is at least 10 times in excess 
of the total receptor population (B^^^) then L can be approximated to
^T
where
= concentration of -a-BgTx at time zero.
L = concentration of ^^if|-a-BgTx at time t.
B = concentration of receptor at time zeromax ^
(determined from Scatchard analysis)
B = concentration of [^^^iJ-a-BgTx-receptor
complex at time t. 
k-1 = dissociation rate constant (determined from
separate experiments. 
k+1 = association rate constant.
For all studies involving the determination of the association rate 
constant, the concentration of toxin was fifty times in excess of the 
total receptor concentration thus fulfilling conditions necessary for 
this kind of approximation. The second method used to calculate the 
value of k+1 involved the determination of the on rate at various
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ligand concentrations. Although circumventing the necessity to cal­
culate k-1 by a separate set of experiments, this method is prone to 
greater inaccuracy (Bylund, 1981) particularly if a small number of 
concentrations is used or if there is a poor correlation between 
points. The value of k-1 is obtained directly from the ordinate 
(see Fig. 3.34) and a small shift in the slope (k+1) would tend to
magnify the shift in the k-1. The association constants determined
5 -1 -1for membrane bound receptor (2.3 x 10 M sec ) and crude extract 
5 -1 -1 .
(2.6 X 10 M sec ) are in good agreement with data reported for 
chick and rat brain although greater diversity exists among data 
reported for the latter (see pages 16 and 17).
Determination of the Dissociation Constant
The dissociation constants calculated for toxin-receptor
complexes from membrane bound receptor (9.4 x 10 ^sec )^ and crude 
—4 —1
extract (9.8 x 10 sec ) were determined by diluting the radiolabelled 
toxin with over a thousand-fold excess of native a-bungarotoxin so 
that rebinding of the radio labelled species is prevented. A second 
method often used in receptor binding studies involves dilution of 
receptor to such an extent that the rate of reassociation approximates 
to zero (Bylund, 1981). Under some experimental conditions this method 
is subject to error, thus when ( X I i s  high the retention effect may 
give rise to a deviation from first-order kinetics (Cuatrecasas and 
Hollenberg, 1976). Dilution of receptors integrated in particulate 
fractions may not necessarily modify their local density (Boeynaems 
and Dumont, 1975). An estimation therefore of the dissociation rate 
constant by diluting receptor is probably more reliable if a detergent 
solubilized form of receptor is employed. The "excess ligand" method 
was selected for determining the off rate constants in foetal brain
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in view of these considerations and of the practical implications 
involved in duluting assay volumes of 500pl by at least 50 times.
Dissociation of toxin receptor complexes in foetal brain 
proceeds rapidly following the addition of native toxin and the 
values of k-1 obtained for the solubilized form of receptor by the 
two different methods were found to agree closely (see Table 3.18 
for comparison). The time taken for 50% of the complex to dissociate 
(t|) is approximately 12 min which is several orders of magnitude 
lower than the values reported for the majority of a-toxin binding 
sites from a variety of different species (pages 16-17). Comparable 
rates of dissociation have been reported for locust ganglia (Filbin, 
1981) and lobster axonal membranes (Jumblatt et al., 1981) but not in 
the central nervous systems of other mammalian species investigated.
It is not known whether the rapid dissociation rate is unique to 
immature brain; experiments using foetal rat brain or adult human 
tissue may clarify this issue.
The close agreement of the intrinsic dissociation constants 
(K^s) determined for membrane bound and crude detergent extract 
(Table 3.18) indicates that treatment of the receptor with Triton 
X-100 did not alter its affinity for -a-bungarotoxin. In chick
optic lobe, Barnard (1979) demonstrated a similarity in toxin binding 
affinities between the membrane bound, detergent extracted and puri­
fied forms which suggests that solubilization does not significantly 
alter a-toxin binding properties of the receptor. Affinity constants 
calculated for the membrane bound and soluble forms of a-toxin binding 
site in rat brain are in close agreement when determined from rate 
constants (Salvaterra and Mahler, 1976; Lowy et al., 1976; Schmidt,
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1977) although greater diversity exists among values derived by 
equilibrium studies. This may be a consequence of this method of 
determination of the Kg being subject to experimental constraints and 
an explanation is offered by the following derivations (Cuatrecasas 
and Hollenberg, 1976). At equilibrium the dissociation constant is 
given by the relationship:
•s - tg a
IXI
which is more accurately expressed as:
Where B = The maximum binding of labelled ligand determined
max
by Scatchard analysis (equivalent to the total 
receptor population (R))
B = The various concentrations of radioligand bound to
receptor at equilibrium (equivalent to RL)
= Total radioligand concentration 
L = Concentration of radioligand at equilibrium
combining the above expressions:
B IC +
max D





L = - B and B = a.B
T max
then, = Kjj. _ a _  ^
. max1 - a
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Under the circumstances where the receptor concentration (B ) «  IC
max D
then at half maximal saturation (a = 0.5) approximates to the
value of Kjj. When B^^ becomes very large with respect to then
L_ -+ a.B . This relationship serves to indicate that the concen- T max
tration of radiolabelled ligand at which 50% of the sites are occupied 
represents the true only if the total receptor concentration is 
numerically much smaller than the K^. This phenomenon can be pre­
dicted to occur in re cep tor-ligand systems of very high affinity but 
for human foetal brain receptor-toxin complexes the ratio of 
was 40:1 thus can be approximated to K^.
B
max
The Effect of Various Drugs on the Binding of |-g-BgTx Binding
to Foetal Brain
The affinity of various compounds for the a-toxin binding 
site expressed as the (see page 60 for derivation) accurately
reflects the dissociation constant of the competing drug provided 
certain conditions are met within the assay. The relationship 
between and the can be expressed in the form of this
equation (Jacobs et al., 1975).
I C 5 0  “  "  -  3/2B)
IC50 = K. + n (L^ + «max ' ^/2B)
where, = The dissociation constant of the competing drug
= The dissociation constant of the labelled ligand 
IC^Q = The concentration of drug which reduce the
binding of the labelled ligand by 50%
^max ^ are defined on page 20 8.
It can be seen from the equation that when L_ + B «  K_ then theT max D
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IC^Q can be approximated to the K^. If on the other hand (K^ +
<< L or K + L << B then the IC_^ will be greater than K. i D T max 50 i
so it is only under conditions where the concentrations of binding 
sites and radiolabel are below the of the labelled ligand that com­
petitive displacement curves accurately reflect the affinity of a 
ligand.
The conditions under which competition studies were per­
formed on human foetal brain could not meet the ideal requirements 
due to the low concentration of receptor present in membrane 
preparations. Higher concentrations of membrane protein in receptor 
assays appeared to inhibit toxin binding (page 85) and when toxin 
concentrations below the were employed, the low levels of specific 
binding was subject to greater error and therefore unreliable. A 
compromise was made where toxin concentration was kept at 5nM and 
receptor, O.lnM; under these conditions the value of IC^^ was 
approximately twice that of K^.
Among the cholinergic compounds surveyed the IC^^ values 
presented in Table 3.19 show that only the classical nicotinic drugs 
display a high affinity for the receptor, a property which it 
evidently shares with neuronal toxin binding sites reported in 
several species (see Table 1.2 on page 19). Nicotine appears to have 
a greater affinity for the human foetal receptor than for the rat or 
chick a-BgTx binding site although similar affinities are reported 
for goldfish brain. All experiments were performed by preincubating 
receptor with the competing drug prior to the addition of toxin.
If co-incubation conditions are used however a lower affinity might 
be observed. Lukas and Bennet (1979a) have shown that preincubation of
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the rat toxin binding site with nicotinic agonists produce up to 
12-fold difference in affinity if compared with coincubation (see 
also Lukas and Bennet, 1978). d-Tubocurarine and gallamine both 
exhibited affinities in the yM range although the latter is 
reported to have a similar affinity for the toxin and QNB binding 
sites in rat brain (Ben-Barak and Dudai, 1978). The authors suggest 
that the appreciable affinity for the muscarinic site is attributed 
to the flexibility of the gallamine molecule. Décaméthonium, a potent 
competitor for toxin binding sites at the neuromuscular junction 
(Barnard et al., 1980), is considerably less effective at the a-toxin 
binding sites in human foetal brain. The low affinity of décaméthonium 
for neuronal toxin receptor is noted by several authors, (Seto et al., 
1977; Wang et al., 1978; Moore and Brady, 1977). Carbamylcholine, 
a strong cholinergic agonist, is effective at concentrations of 
O.lmM, a finding similar to that reported for rat and chick neuronal 
preparations. Hexaméthonium, a ganglionic blocking agent, is in­
effective at inhibiting the binding of toxin even at mM concentrations, 
an observation similar to that in rat (Schmidt, 1977) and it was noted 
by the author that the ganglionic stimulating agents exhibited a con­
siderably higher affinity for the a-toxin site than the ganglionic 
blocking agents. The muscarinic blocker atropine sulphate and the 
acetylcholinesterase inhibitor physostigmine (eserine) partially 
inhibit toxin binding only at concentrations greater than O.lmM.
These observations reveal further similarities between rat and chick 
brain receptors. The local anaesthetics lignocaine and procaine which 
act as non-competitive antagonists of the physiological response of 
postsynaptic nAChRs (Heidemann and Changeux, 1978) have practically no 
inhibitory action on toxin binding. The compounds tetracaine and
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dimethisoquin do however inhibit toxin binding in rat brain (Lukas 
and Bennet, 1979b)
The classical nicotinic pharmacology exhibited by the 
foetal toxin binding site implicates a role in cholinergic trans­
mission although in the immature brain, this role may not yet be 
fulfilled since it is known that receptors have appeared prior to 
the synthesis of neurotransmitter (Coyle and Yamamura, 1976;
Hunt and Schmidt, 1979).
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BINDING OF ANTI-(nAChR) ANTIBODIES TO HUMAN FOETAL BRAIN 
Purification of Anti-(nAChR) Antibodies
Preliminary investigations show that a population of 
antibodies that recognizes the antigenic determinants exhibited by 
the nAChR from human muscle can be removed selectively from myasthenic 
plasma by the use of immobilized toxin receptor complexes followed 
by elution with a chaotropic agent (Methods, page 70). Following 
the first purification step, only 6% of the antibody activity 
exhibited by the plasma is recovered by ammonium sulphate precip­
itation in the crude Ig fraction. Subsequent analysis of the protein 
concentration suggests that the low recovery is primarily the result 
of the incomplete precipitation of the immunoglobulin fraction. The 
range of published values of the concentration of Y-globulin in adult 
serum varies from 7.9g/& to 23.5g/& (see Keyser, 1979) but in this 
preparation, the concentration of protein recovered is much lower 
(1.3g/£.) The precipitation of y-globulins using ammonium sulphate 
is well established (see Williams and Chase, 1967) and Habeeb and 
Francis (1976) report that Ig fraction can be totally removed from a 
sample of human plasma by this method. Since the same procedure 
described by these authors is employed in this study, the reason for 
an incomplete recovery is unclear.
Following the incubation of the crude immunoglobulin 
fraction with the affinity beads, no detectable activity could be 
measured in the non-bound fraction and the buffer employing radio­
immunoassay procedures. This observation indicates that the antibodies 
directed towards the [^^^l]-a-BgTx-receptor complex are retained by 
the affinity beads. The presence of small amounts of receptor in the 
non-bound fraction probably reflects the degree of dissociation from
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the immobilized toxin during the 20h period of the incubation of 
affinity beads with the crude immunoglobulin fraction. Dissociation 
of the receptor from the toxin is expected during this step since the
complex no longer exists under equilibrium conditions, but the loss
of receptor from the column was not considered sufficient to 
necessitate a reduction in the incubation time.
Treatment of the affinity beads with 2M KI results in a 
38% recovery of the anti-(nAChR) antibodies applied to the toxin- 
receptor beads (see Table 3.23, page 168. ) Since the non-bound fraction 
shows no evidence of antibody activity it is possible that the in­
complete recovery may be accounted for by one or more of the following
a) Although prolonged contact of the KI with all proteins was
avoided, some dénaturation of the immunoglobulins may have
occurred.
b) The masking of antibody activity by the presence of receptor
originating from complexes disrupted by the KI. In this
case, the high concentration of KI may also render the 
receptor incapable of binding to toxin thus binding activity 
could be undetectable.
c) Treatment with KI may not be sufficient for the complete
disruption of some of the antibody-receptor complexes since
a heterogenous population is likely to exist, each of which 
could differ in affinity for the antigenic determinants 
present on the receptor. Conditions which prove sufficiently 
effective for the elution of molecules from the column may 
irreversibly denature both described substances and ligand 
(see Hoffman-Ostenhof, 1978). KI was chosen since extremes 
in pH could be avoided thus minimising dénaturation of both
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the receptor and the antibodies. It is possible that prolonged 
contact with 2M KI causes disruption of the toxin receptor 
complex and some dénaturation of antibody so in view of 
future experiments it would be better to separate the salt 
from the protein by gel filtration. The purity of the eluted 
fraction could also be assessed by gel electrophoresis, since 
receptor protein is likely to be present. Such proteins may no 
longer be capable of binding toxins following treatment with 
KI even after extensive dialysis. Clarification of these 
points is necessary in order to optimise the conditions required 
for the maximum recovery of active populations of anti-(nAChR) 
antibodies.
Recognition of the Human Neuronal a-BgTx Binding Component by anti- 
(nAChR) Antibodies from Myasthenic Plasma
The myasthenic plasma and the crude immunoglobulin fraction 
is able to precipitate low but detectable amounts of the a-bungaro- 
toxin binding component in a crude extract of human foetal brain.
The failure of the affinity purified fraction to demonstrate similar 
cross-reactivity is attributed to the lower concentration of anti- 
(nAChR) antibodies present compared to the crude immunoglobulin 
fraction. Since 5ml of the crude fraction is recovered as 10ml of 
the affinity purified fraction following dialysis and the recovery 
of activity is only 38% then a five-fold difference in the concentration of 
anti-(nAChR) antibodies is evident. In view of further experiments, 
the immunoglobulin in the affinity purified fraction could be concen­
trated by ion exchange (Habeeb and Francis, 1976) which would enable 
smaller volumes to be used in a radioimmunoassay.
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The endplate nAChR is established as the autoantigen in 
the disease Myasthenia gravis (Lindstrom, 1981). There is some 
evidence for central dysfunctions in patients with this disease 
(see Wonnacott, 1980) which may suggest an interaction between 
circulating auto-antibodies known to be present in the CSF of such 
patients (Lefvert and Pirakanen, 1977; Kam Hansen et al., 1982) 
and nAChR’s in the brain. In rat brain Weidenfeld et al. (1983) 
have shown that intraventricular injections of myasthenic sera 
inhibited the stress induced elevation of prolactin, corticosterone 
and ACTH. By comparison, control animals, injected with normal sera 
and saline exhibited normal responses. Immunological cross­
reactivity between the partially purified a-bungarotoxin binding com­
ponent from rat brain and nAChR from rat skeletal muscle and Torpedo 
marmorata of 5% and 0.5% respectively, has been demonstrated by 
Wonnacott et al. (1982) employing radioimmunoassay procedures. Com­
parable levels of crossreactivity between the toxin binding component 
from chick brain and the nAChR from skeletal muscle are reported by 
Norman et al. (1982). These observations clearly implicate a 
structural but not necessarily a functional relationship between 
central and peripheral nAChRs although the proportion of shared 
determinants appears to be small. The proportion of specific a- 
bungarotoxin binding sites in human foetal brain precipitated by 
myasthenic plasma and the immunoglobulin fraction constitute less 
than 5% of the sites precipitated in human skeletal muscle. By 
comparison, three samples of normal human serum failed to precip­
itate specific toxin binding sites in the crude extract of foetal 
brain. It is probable that the titre exhibited by the myasthenic 
antibodies for the foetal toxin binding sites doesnot represent the
217.
true value. Higher quantities of receptor were not employed 
because the linear relationship between toxin binding and receptor 
concentration is no longer apparent at a concentration of protein 
exceeding 12mg/ml extract (see Fig. 3.5, page 86). The amount of 
receptor used in each assay was 0.025 pmol compared to 0.1 pmol in 
the case of the peripheral receptor. Amounts of receptor below 
0.01 pmol exhibited toxin binding activity which generated specific 
counts too low to measure accurately. Ideally, a purified preparation 
of the toxin binding component is desirable for such studies, the 
advantages being that the antigen could be concentrated and the 
preparation would essentially be free of non-receptor protein.
Earlier studies however, have shown that the foetal toxin binding 
component has resisted initial attempts at purification (Results, 
page 171).
Purified anti-(nAChR)ab from myasthenic sera demonstrate 
the potential for investigation of nicotinic involvement in the 
release of dopamine from striatal synaptosomes ( Giorguieff et al., 
1977, de Belleroche and Bradford, 1980). Release of [^ I^ |- dopamine 
from striatal synaptosomes could be elicited by nicotine (Futerman 
et al., 1981) in a dose dependant manner (Mills and Wonnacott, 1984) 
and the response could be blocked by mecamylamine, a ganglionic 
blocker. Preincubation of the synaptosomes with a sample of rabbit 
anti-(rat muscle nAChR) resulted in a statistically significant 
decrease of [^H|-dopamine release to nicotine at all agonist con­
centrations tested (Mills and Wonnacott, 1984) which implies that 
the mediation of dopamine release occurs in part by nAChR*s. Similar 
experiments using synaptosomal preparations prepared from the striatum 
of human adult or foetal brain may provide information relating to the
218.
involvement of auto-antibodies in central responses and the degree 
to which the cholinergic system is involved.
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